

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 2016347471 B2**

(54) Title  
**Methods of treatment using anti-IL-17A/F antibodies**

(51) International Patent Classification(s)  
**C07K 16/24** (2006.01)

(21) Application No: **2016347471** (22) Date of Filing: **2016.10.26**

(87) WIPO No: **WO17/072183**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>62/303,230</b>	<b>2016.03.03</b>	<b>US</b>
<b>62/246,989</b>	<b>2015.10.27</b>	<b>US</b>
<b>62/405,546</b>	<b>2016.10.07</b>	<b>US</b>
<b>62/346,826</b>	<b>2016.06.07</b>	<b>US</b>

(43) Publication Date: **2017.05.04**  
(44) Accepted Journal Date: **2023.08.03**

(71) Applicant(s)  
**UCB Biopharma Sprl**

(72) Inventor(s)  
**Glatt, Sophie;Ionescu, Lucian;Jones, Margaret;Oliver, Ruth;Shaw, Stevan  
Graham;Strimenopoulou, Foteini;Vajjah, Venkata Pavan Kumar**

(74) Agent / Attorney  
**Griffith Hack, Level 15, 376-390 Collins Street, Melbourne, VIC, 3000, AU**

(56) Related Art  
**WO 2012/095662 A1**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2017/072183 A1

(43) International Publication Date

4 May 2017 (04.05.2017)

(51) International Patent Classification:

C07K 16/24 (2006.01)

(21) International Application Number:

PCT/EP2016/075821

(22) International Filing Date:

26 October 2016 (26.10.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/246,989	27 October 2015 (27.10.2015)	US
62/303,230	3 March 2016 (03.03.2016)	US
62/346,826	7 June 2016 (07.06.2016)	US
62/405,546	7 October 2016 (07.10.2016)	US

(71) Applicant: UCB BIOPHARMA SPRL [BE/BE]; 60, Allée de la Recherche, 1070 Brussels (BE).

(72) Inventors: **GLATT, Sophie**; IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **IONESCU, Lucian**; IPD, UCB Biopharma SPRL, 60 Allée de la Recherche, 1070 Brussels (BE). **JONES, Margaret**; IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **OLIVER, Ruth**; IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **SHAW, Stevan Graham**; IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **STRIMENOPOLOU, Fotini**; IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **VAJJAH, Venkata Pavan Kumar**; IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(74) Agent: UCB INTELLECTUAL PROPERTY; c/o UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))



WO 2017/072183 A1

(54) Title: METHODS OF TREATMENT USING ANTI-IL-17A/F ANTIBODIES

(57) Abstract: The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.

**METHODS OF TREATMENT USING ANTI-IL-17A/F ANTIBODIES****FIELD OF THE INVENTION**

The application relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, as well as therapeutic uses of the antibody molecules.

5

**BACKGROUND**

Interleukin 17 (IL-17), also known as CTLA-8 or IL-17A, is a pro-inflammatory cytokine which stimulates the secretion of a wide range of other cytokines from various non-immune cells. IL-17A is capable of inducing the secretion of IL-6, IL-8, PGE2, MCP-1 and G-CSF by adherent cells like fibroblasts, keratinocytes, epithelial and endothelial cells and is also able to induce 10 ICAM-1 surface expression, proliferation of T cells, and growth and differentiation of CD34+ human progenitors into neutrophils when cocultured in the presence of irradiated fibroblasts (Fossiez et al., 1998, *Int. Rev. Immunol.* 16, 541-551). IL-17A is predominantly produced by activated memory T cells and acts by binding to a ubiquitously distributed cell surface receptor (IL-17R) (Yao et al., 1997, *Cytokine*, 9, 794-800). It may also act through binding to a complex 15 of IL-17RA and IL-17RC (Toy et al., 2006, *J. Immunol.* 177(11); 36-39). IL-17 producing T cells called 'TH17 cells' have been implicated in the pathogenesis of certain cancers (Weaver et al., 2006, *Immunity*, 24, 677-688; Langowski et al., 2006, 442, 461-465; Iwakura and Ishigame, 2006, *J. Clin. Invest.* 116, 5, 1218-1222).

A number of homologues of IL-17 have been identified which have both similar and distinct 20 roles in regulating inflammatory responses. For a review of IL-17 cytokine/receptor families see Dumont, 2003, *Expert Opin. Ther. Patents*, 13, 287-303. One such homologue is IL-17F, also known as IL-24 and ML-1, which has been reported as around 55% identical to IL-17A and is thought to share the same receptors as IL-17A (Kolls and Linden 2004, *Immunity*, 21, 467-476; Hymowitz, et al., 2001, *EMBO J.* 20(19), 5332-5341; Kuestner et al., 2007, *Journal of 25 Immunology*, 179, 5462-5473). While individual signalling molecules of IL-17A are more potent than those of IL-17F, IL-17F has a greater impact in cooperation with other molecules. For example, when IL-17F is added with TNF $\alpha$  to RA synoviocytes, the induction of the potent

inflammatory pathway is similar to the response observed with IL-17A and TNF $\alpha$ . (Hot et al., 2011, *Ann. Rheumatic Dis.*, 70,341–348.)

IL-17A and IL-17F are expressed as homodimers, but may also be expressed as the IL-17A/F heterodimer (Wright et al. 2008, *J. Immunol.* 181: 2799-2805). IL-17A and F signal through the receptors IL-17R, IL-17RC or an IL-17RA/RC receptor complex (Gaffen 2008, *Cytokine*. 43: 402-407).

IL-17A and IL-17F have been associated with dermatological and rheumatological conditions. Such dermatological conditions include, but are not limited to, psoriasis, atopic dermatitis, discoid lupus erythematosus, alopecia areata, autoimmune urticaria, bullous pemphigoid,

10 dermatitis herpetiformis, hidradenitis suppurativa, linear IgA dermatosis, morphea, pemphigus vulgaris, and pyoderma gangrenosum. Such rheumatological conditions include psoriatic arthritis, axial spondyloarthritis including ankylosing spondylitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, vasculitis, Sjogren's syndrome (extraglandular), juvenile idiopathic arthritis, granulomatosis, Behçet's disease (mucocutaneous), antiphospholipid syndrome, giant 15 cell arteritis, scleroderma, polyarteritis nodosa, Behçet's disease (thrombosis), and Takayasu disease.

Psoriatic arthritis is an inflammatory condition which affects both the joints and the skin. It can lead to significant joint damage and disability over time and can involve both skin and nail abnormalities seen in psoriasis. (Schett et al., 2011, *Arthritis Research and Therapy*, 13 Suppl. 1: S4.)

20 Psoriatic arthritis may be difficult to distinguish from other forms of arthritis, particularly when skin changes are minimal or absent. Psoriatic arthritis patients often experience a number of other diseases at a higher frequency than the general population including autoimmune conditions such as iritis/uveitis (swelling and irritation of the eye) and inflammatory bowel disease (IBD), as well as cardiovascular disease and osteoporosis.

25 Psoriatic arthritis can negatively affect many aspects of a patient's life, imposing burdens of pain, physical functioning and fatigue, as well as reductions in psychological, emotional and social well-being and overall health-related quality of life. (Husted et al., 2001, *Arthritis Care and Research*, 45:151-8; Picchianti-Diamanti et al., 2010, *Qual. Life Res.*, 19:821-6.) Studies suggest many aspects of health-related quality of life (HRQol) are affected to a similar degree in 30 patients with psoriatic arthritis and rheumatoid arthritis. (Husted et al., 2001, *Arthritis Care and*

Research, 45:151-8). Psoriatic arthritis is associated with a considerable economic burden, both in terms of direct costs (money spent on medication, hospital care, informal care and over-the-counter medication) and indirect costs (those associated with a loss of productivity at work). (Ackermann & Kavanaugh, 2008, *Pharmacoeconomics*, 26 (2):121-9).

5 Psoriatic arthritis can develop in individuals with psoriasis, an inflammatory disorder of the skin (Shbeeb et al., 2000, *J Rheumatol.*, 27: 1247-50). Psoriatic arthritis typically develops in patients after the onset of psoriasis. (Gladman et al., 2006, *Annuals of the Rheumatic Diseases*, 65 (Suppl. III): iii12-iii24). The mean age at which patients with psoriatic arthritis are diagnosed is 41 years, with men often diagnosed at a younger age (20 – 39 years) than women (40 – 59

10 years). (Shbeeb et al., 2000, *J Rheumatol.*, 27:1247-50.) Between 3 and 8 people per 100,000 are newly diagnosed with psoriatic arthritis each year. (Gladman et al., 2005, *Annuals of the Rheumatic Diseases*, 64(Suppl II): ii14-ii17.)

15 Certain genes have been associated with psoriatic arthritis, particularly the HLA-B27 (human leukocyte antigen) gene, which is present in approximately 50% of psoriatic arthritis patients, compared to just 3-18% of the Western European general population. (Gladman et al., 2005, *Annuals of the Rheumatic Diseases*, 64(Suppl II): ii14-ii17; Salvarani & Fries, 2009, *World J. Gastroenterol.*, 15 (20): 2449-55.)

20 However, environmental factors may induce disease onset as well. Risk factors associated with psoriatic arthritis include: psoriasis involving the scalp, intergluteal areas, more than 3 affected sites, nail dystrophy, recent oral ulceration, and trauma leading to medical care. (Ogdie & Gelfand, 2010, *Arch. Dermatol.* 146(7):785-8; Pattison et al., 2008, *Ann. Rheum. Dis.*, 67(5):672-6.)

25 There is a strong association between psoriasis, psoriatic arthritis and obesity. (Russolillo et al., 2013, *J. Rheumatol.*, 52:62-67). In 80% of psoriatic arthritis cases, arthritis develops after the appearance of psoriasis.

30 Symptoms of psoriatic arthritis include, but are not limited, to: stiffness, pain, tenderness, swelling and throbbing in one or more joints, usually in the hands or feet, but sometimes in the wrists, ankles, knee or lower back; swollen fingers or toes that may result in a “sausage-like” appearance (dactylitis); reduced ability to move; nail changes, such as pitting or separation from the nail bed causing functional impairment, pain and emotional distress; eye redness and pain

(uveitis); fatigue and morning stiffness (in affected joints); tenderness, pain and swelling over tendons (enthesis); psoriatic arthritis may affect a small number of joints (oligoarthritis) or many joints (polyarthritis) and/ or spine.

People with psoriatic arthritis symptoms, especially those with psoriasis or a family history of

5 psoriatic arthritis, need to see a specialist (e.g. a rheumatologist), as their joint problems may be similar to those seen in other forms of arthritis (e.g. rheumatoid arthritis, gout and reactive arthritis). (Conaghan & Coates, 2009, *The Practitioner*, 253(1724):15-18.) Diagnosis is based on symptoms, medical history, physical examination, results of blood tests and X rays. (Conaghan & Coates, 2009, *The Practitioner*, 253(1724);15-18.)

10 Mild cases of psoriatic arthritis are usually treated with non-steroidal anti-inflammatory drugs (NSAIDs), low doses of oral steroids or steroid injections into painful joints. (Mease, 2011, *Ann. Rheum. Dis.*, 70(Suppl 1):i77-i84.) More severe psoriatic arthritis is often treated with disease-modifying anti-rheumatic drugs (DMARDs). (Weger, 2010, *British Journal of Pharmacology*, 160:810-20.) More recently, biological agents including anti-tumour necrosis

15 factor alpha antibodies (TNF $\alpha$  blockers) have become available. (Weger, 2010, *British Journal of Pharmacology*, 160:810-20.) Clinical evidence has demonstrated that minimal disease activity was achieved in 64% of patients treated with TNF-inhibitors, which means that a considerable portion of patients (36%) did not achieve even this target. (Haddad A et al, *Arthritis Care Res.* 2015; 67, 842-7).

20 Some subjects are not responsive to previously known treatments, do not maintain a clinical response (defined as achieving American College of Rheumatology 20% response criteria ("ACR20"), or have contraindications or intolerance to these agents. The availability of effective medicines for psoriatic arthritis that have an alternative mechanism of action will improve the treatment of patients, especially those patients who have not gained benefit from,

25 lost effectiveness to, or could not use TNF-inhibitor medications for safety or tolerability reasons. (Mease P, *Curr Opin Rheumatol*. 2015, 27: 127-33). Because ACR score is a scale that measures symptoms such as joint effects associated with psoriatic arthritis and rheumatoid arthritis, improvements in ACR score are associated with the treatment of both psoriatic arthritis and rheumatoid arthritis.

Breakthroughs in the understanding of immunopathogenesis of psoriatic arthritis have led to novel therapies beyond TNF-inhibitors. These therapies are reviewed in Sritharan and Ying Leung, Ther. Adv. Musculoskel. Dis., 2015, 7(5), 173-186). Table 1 of this paper sets out the ACR and PASI scores for the various therapies.

5 Drugs that inhibit IL-17 and IL-23 have demonstrated significant benefit in psoriasis and emerging studies are also showing benefit in psoriatic arthritis and ankylosing spondylitis. (Mease P, Curr Opin Rheumatol 2015, 27: 127-33). Biological therapies are being developed which target IL-17A, including the anti-IL-17A antibodies secukinumab and ixekizumab which are currently in Phase III clinical trials for psoriatic arthritis. The results of a Phase II clinical 0 study of secukinumab in psoriatic arthritis are described in Mease *et al.*, 2015, N Engl J Med, 373,14, 1329-1339 and in ankylosing spondylitis in Baeten *et al.*, N. Engl. J. Med, 2015, 373 (26), 2534-48. The results of a Phase III clinical study of ixekizumab in psoriatic arthritis are described in Mease *et al.*, 2015, ACR Abstract number 977. Brodalumab is an anti IL-17RA monoclonal antibody which, by targeting IL-17RA, blocks IL-17A, IL-17F and IL-17E (IL-25) 5 activity. The results of a Phase II clinical study of brodalumab in psoriatic arthritis are described in Mease *et al.*, 2015, N Engl J Med, 370, 24, 2295-2306. The efficacy of current therapies at week 24 is around 60%, 40% and 20% for ACR20, ACR50 and ACR70 respectively, along with a PASI 75 of around 65% (Table 1 in Sritharan and Ying Leung, Ther. Adv. Musculoskel. Dis., 2015, 7(5), 173-186).

0 It is to be understood that if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art in Australia or any other country.

## SUMMARY OF THE INVENTION

25 The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules in the treatment of dermatological and rheumatological diseases, such as psoriatic arthritis, and methods for producing said antibody molecules.

A first aspect provides a method of treating psoriatic arthritis in a human comprising administering to the human a neutralizing antibody which binds human IL-17A and human IL-

17F, wherein the antibody comprises a light chain and a heavy chain, wherein the light chain variable domain comprises SEQ ID NO:10 and the heavy chain variable domain comprises SEQ ID NO:11, and wherein the human is administered 160mg of antibody every four weeks or 320mg of antibody every four weeks.

5 A second aspect provides use of a neutralizing antibody which binds human IL-17A and human IL-17F in the manufacture of a medicament for treating psoriatic arthritis in a human, wherein the antibody comprises a light chain and a heavy chain, wherein the light chain variable domain comprises SEQ ID NO:10 and the heavy chain variable domain comprises SEQ ID NO:11, and wherein the human is administered 160mg of antibody every four weeks or 320mg of antibody every four weeks.

In one example, the antibody of the disclosure may be used in the treatment of dermatological conditions (such as, but not limited to, psoriasis, atopic dermatitis, discoid lupus erythematosus, alopecia areata, autoimmune urticaria, bullous pemphigoid, dermatitis herpetiformis, hidradenitis suppurativa, linear IgA dermatosis, morphea, pemphigus vulgaris, and pyoderma gangrenosum)

5 and/or rheumatological conditions (such as, but not limited to psoriatic arthritis, axial spondyloarthritis including non-radiographic axial and ankylosing spondylitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, vasculitis, Sjogren's syndrome (extraglandular), juvenile idiopathic arthritis, granulomatosis, Behçet's disease (mucocutaneous), antiphospholipid syndrome, giant cell arteritis, scleroderma, polyarteritis nodosa, Behçet's disease (thrombosis), 0 and Takayasu disease). In one example, the antibody of the disclosure may be used in the treatment of psoriatic arthritis. Neutralising antibodies which bind both IL-17A and IL-17F, such as bimekizumab, may provide a significant improvement over existing psoriatic arthritis therapies, both in the speed and magnitude of clinical effect. For example, they may mediate equivalent or even improved clinical scores by week 8. Suitable clinical scores include American 25 College of Rheumatology ("ACR") 20/50/70 response for joints and, for skin, the clinical features of psoriasis, Psoriasis Area and Severity Index ("PASI") 50/75/90 response. For example, these antibodies may increase the number of patients achieving ACR20, ACR50, ACR70 and PASI75 at week 8 or week 12 to greater than 60%, 40%, 20% and 65% respectively (average response rate). They may even have the potential to increase the number of patients 30 achieving ACR20, ACR50, ACR70 and PASI75 at week 8 or week 12 to 60-95%, 40-60%, 20-40% and 80-100% respectively. For example these may be 80%, 60%, 40% and close to 90% or

close to 100% respectively. The speed to achieving a beneficial response in subjects administered an antibody as described herein also is remarkable. For example, in various embodiments, the subject achieves ACR20 or ACR50 (or PASI 20 or PASI50) within four weeks (e.g., within three weeks or within two weeks) of a first administration. Additionally, in various embodiments, the beneficial response to the methods described herein may be sustained for a remarkable period of time. For instance, subjects administered three doses of anti-IL-17A/F antibody described herein (e.g., at days 0, 21, and 42) enjoyed near maximal-response to week 20. Thus, the methods described herein may achieve a biological response in a subject at week 8 or week 12 that diminishes no more than 10%, no more than 20%, no more than 30%, no more than 40%, or no more than 50% at week 20. In one example, the antibody of the disclosure may be used in the treatment of any of the symptoms of psoriatic arthritis listed herein below, including but not limited to dactylitis, enthesitis, nail dystrophy, skin manifestations; signs and symptoms of peripheral arthritis; axial disease and structural progression of the disease. In one example, the antibody of the disclosure may be used to prevent the development of psoriatic arthritis or other conditions in psoriasis patients.

Also disclosed is use of an antibody molecule according to the disclosure in the manufacture of a medicament for the treatment or prophylaxis of a pathological disorder that is mediated by IL-17A and/or IL-17F or associated with an increased level of IL-17A and/or IL-17F. Preferably the pathological disorder may be one of the medical indications described herein. In one

embodiment, the pathological disorder may comprise psoriatic arthritis. In other embodiments, the pathological disorder may comprise psoriasis, rheumatoid arthritis, and/or arthritis. In various embodiments, the pathological disorder is ankylosing spondylitis. In various embodiments, the pathological disorder is axial spondyloarthritis or non-radiographic axial spondyloarthritis.

25 An antibody molecule of the disclosure may be utilised in any therapy where it is desired to reduce the effects of IL-17A and/or IL-17F in the human or animal body. IL-17A and/or IL-17F may be circulating in the body or may be present in an undesirably high level localised at a particular site in the body, for example a site of inflammation.

Also disclosed is a method of treating human or animal subjects suffering from or at risk of a disorder mediated by IL-17A and/or IL-17F, the method comprising administering to the subject an effective amount of an antibody molecule of the disclosure.

Also disclosed is an antibody molecule of the disclosure, in particular a neutralising antibody which binds human IL-17A and human IL-17F, for use in the treatment of human or animal subjects suffering from or at risk of a disorder mediated by IL-17A and/or IL-17F. Preferably the pathological disorder may be one of the medical indications described herein. In one embodiment, the pathological disorder may comprise psoriatic arthritis. In other embodiments, the pathological disorder may comprise psoriasis, rheumatoid arthritis, and/or arthritis. In one embodiment the pathological disorder may comprise ankylosing spondylitis. In one embodiment the pathological disorder may comprise axial spondyloarthritis or non-radiographic axial spondyloarthritis.

Also disclosed is an antibody molecule of the disclosure, in particular a neutralising antibody which binds human IL-17A and human IL-17F, for use in the treatment of psoriatic arthritis, psoriasis, rheumatoid arthritis, arthritis, axial spondyloarthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis.

“Psoriasis” encompasses disorders or skin-related components (i.e., symptoms) of disorders such as, but not limited to, plaque psoriasis, pustular psoriasis, generalised pustular psoriasis, palmo-plantar psoriasis, scalp psoriasis, guttate psoriasis, erythrodermic psoriasis, inverse psoriasis, acrodermatitis continua, SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis) syndrome, hidradenitis suppurativa, and DITRA (deficiency of the IL-36 receptor [IL-36R] antagonist) / DIRA (deficiency of the interleukin 1 (IL-1) receptor antagonist). The severity of psoriasis may vary and may be selected, for example, from mild, mild to moderate, moderate, severe and moderate to severe psoriasis.

An antibody molecule according to the disclosure may also be used in diagnosis, for example in the *in vivo* diagnosis and imaging of disease states involving IL-17A and/or IL-17F.

Also disclosed is a method of treating psoriatic arthritis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F. In an embodiment, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. In the same or a different embodiment, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the

antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. Optionally, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in

5 SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human IL-17F. In various embodiments, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10. In one embodiment, the antibody is bimekizumab. Optionally, the antibody is administered as a pharmaceutical composition. In 0 various embodiments, the antibody is administered subcutaneously or intravenously.

In any of the embodiments of the method of treating psoriatic arthritis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F, the human optionally has a diagnosis of adult-onset psoriatic arthritis.

Optionally, the human is at least 18 years of age and/or was diagnosed at least six months prior

5 to administration of the antibody. Also optionally, the human was diagnosed based on the CASPAR criteria. In any of the embodiments described above, the human has active arthritis. This is typically defined as  $\geq 3$  tender and  $\geq 3$  swollen joints. The patients may have coexistent or concomitant psoriasis and/or a history of psoriasis. For example, the human optionally has active psoriatic lesions or a history of psoriatic lesions.

0 In any of the embodiments of the method of treating psoriatic arthritis, psoriasis, rheumatoid arthritis or axial spondylitis, including ankylosing spondylitis and non-radiographic spondylitis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F described herein, the antibody may be administered as a monotherapy.

25 In any of the embodiments of the method of treating psoriatic arthritis, psoriasis, rheumatoid arthritis or axial spondylitis, including ankylosing spondylitis and non-radiographic spondylitis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F described herein, the human optionally is biologic-naïve i.e. has not been previously treated with a biological agent, such as a TNF alpha inhibitor such as 30 an anti-TNF antibody.

In any of the embodiments of the method of treating psoriatic arthritis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F described herein, the human optionally is an inadequate responder to at least one non-biologic disease-modifying antirheumatic drug (“DMARD”) and/or one or more approved 5 biologic DMARD (e.g., a TNF inhibitor such as an anti-TNF antibody, examples including infliximab or adalimumab, or a soluble TNF receptor, such as etanercept). Examples of non- biologic DMARDs include sulfasalazine, methotrexate, cyclosporine, hydroxychloroquine, azathioprine and leflunomide. Optionally the human is an inadequate responder to at least one 0 non-steroidal anti-inflammatory drug (NSAID). Examples of suitable NSAIDs include but are not limited to, propionic acid derivative, acetic acid derivative, enolic acid derivatives, fenamic acid derivatives, cox inhibitors, ibuprofen, fenoprofen and aspirin.

Also disclosed is a method of treating psoriatic arthritis in a human concurrently treated with

methotrexate or other non-biologic DMARD (such as leflunomide) or non-steroidal anti-

inflammatory drug (NSAID) and/or steroid comprising the step of administering to the human a

5 neutralizing antibody which binds human IL-17A and human IL-17F. In various embodiments, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. In the same or different embodiments, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52,

0 HIS54 and ASP84 of SEQ ID NO: 28. Optionally, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. Also optionally, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light

25 chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human IL-17F. In various embodiments of the method, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10. In a preferred embodiment, the antibody is bimekizumab. The antibody may be administered as a pharmaceutical composition. The 30 antibody is optionally administered subcutaneously or intravenously.

Also disclosed is a method of treating psoriatic arthritis in a human comprising the step of administering to the human a therapeutically effective amount of a neutralizing antibody which binds human IL-17A and human IL-17F. In various aspects, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, 5 ARG73, LEU75 and ILE86 of SEQ ID NO: 27. In the same or different embodiments, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. Optionally, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the 0 sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. In various embodiments, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human IL-17F. The antibody, in various embodiments, comprises a light chain variable domain and a heavy chain variable 5 domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10. In a preferred embodiment, the antibody is bimekizumab. The antibody is optionally administered as a pharmaceutical composition. The antibody may be administered subcutaneously or intravenously.

Also disclosed is a method of treating psoriatic arthritis in a human patient comprising the step 0 of administering to the patient a neutralizing antibody which binds human IL-17A and human IL-17F in an amount that is effective to provide an ACR20 response at week 8 or week 12, an ACR50 response at week 8 or week 12, or an ACR70 response at week 8 or week 12 in a population of patients in need of treatment. For example, the administered amount is effective to provide an ACR50 response at week 8 or week 12, or an ACR70 response at week 8 or week 12 25 in the population of patients. In a preferred embodiment, the amount is effective to provide an ACR70 response at week 8 or week 12 in the population of patients. Alternatively or in addition, the neutralizing antibody is administered in an amount that is effective to provide a PASI50 response at week 8 or week 12, PASI75 response at week 8 or week 12, or a PASI90 response at week 8 or week 12, such as an amount that is effective to provide a PASI75 response at week 8 30 or week 12, or a PASI90 response at week 8 or week 12 in the population of patients. In a preferred embodiment, the neutralizing antibody is administered in an amount that is effective to

provide a PASI90 response or a PASI100 response at week 8 or week 12 in the population of patients. Typically the response is sustained such that ACR50, ACR70 and/or PASI responses may be maintained to week 16, 20, 24 or later. In various embodiments, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27 and/or specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. In various embodiments, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human IL-17F. Optionally, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO: 10. In a preferred embodiment, the antibody is bimekizumab. The antibody is optionally administered as a pharmaceutical composition. The antibody may be administered subcutaneously or intravenously.

Also disclosed is a method of reducing psoriasis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F. In various embodiments, the psoriasis is plaque psoriasis. In various embodiments the psoriasis is mild to moderate plaque psoriasis. In various embodiments the psoriasis is moderate to severe plaque psoriasis. The reduction of plaque psoriasis is optionally measured by PASI criteria. In various embodiments, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. Alternatively or in addition, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. Optionally, the antibody

cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human IL-17F. In various embodiments, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the

5 light chain comprises the sequence given in SEQ ID NO:10. In a preferred embodiment, the antibody is bimekizumab. The antibody may be administered as a pharmaceutical composition. The antibody is optionally administered subcutaneously or intravenously. In one or more embodiments, the psoriasis treated using the method of the present disclosure may be selected from plaque psoriasis, pustular psoriasis, generalised pustular psoriasis, palmo-plantar psoriasis,

0 nail psoriasis, scalp psoriasis, guttate psoriasis, erythrodermic psoriasis, inversive psoriasis.

Also disclosed is a method of treating psoriasis in a human comprising the step of administering to the human a therapeutically effective amount of a neutralizing antibody which binds human IL-17A and human IL-17F.

Also disclosed is a method of treating psoriasis in a human patient comprising the step of

5 administering to the patient a neutralizing antibody which binds human IL-17A and human IL-17F in an amount that is effective to provide a PASI75 response at week 8 or week 12, or a PASI90 response at week 8 or week 12. In a preferred embodiment, the neutralizing antibody is administered in an amount that is effective to provide a PASI75 response or a PASI90 response at week 8 or week 12 in the population of patients. In various embodiments, the antibody

0 specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27 and/or specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17

25 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. In various embodiments, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human IL-17F. Optionally, the antibody

30 comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10. In a preferred

embodiment, the antibody is bimekizumab. The antibody is optionally administered as a pharmaceutical composition. The antibody may be administered subcutaneously or intravenously.

The method of treating psoriasis optionally comprises administering to the human a loading dose of the neutralizing antibody followed by at least one maintenance dose of the antibody. In various embodiments, the loading dose is between 80 and 560 mg and the at least one maintenance dose is between 40 and 320 mg. In one embodiment of the method, the loading dose is 80 mg and the at least one maintenance dose is 40 mg. In another embodiment of the method, the loading dose is 160 mg and the at least one maintenance dose is 80 mg. In a further embodiment, the loading dose is 240 mg and the at least one maintenance dose is 160 mg. In a further embodiment, the loading dose is 320 mg and the at least one maintenance dose is 160 mg. In another embodiment, the loading dose is 560 mg and the at least one maintenance dose is 320 mg. In various embodiments, the loading dose is administered followed by two maintenance doses. Optionally, the loading dose is administered followed by at least one maintenance dose at a three week interval or a four week interval.

In any of the embodiments of the method of treating psoriasis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F described herein, the human optionally is an inadequate responder to at least one non-biologic disease-modifying antirheumatic drug (“DMARD”) and/or one or more approved biologic DMARD (e.g., a TNF inhibitor such as an anti-TNF antibody, examples including infliximab or adalimumab, or a soluble TNF receptor, such as etanercept). Examples of non-biologic DMARDs include sulfasalazine, methotrexate, cyclosporine, hydroxychloroquine, azathioprine and leflunomide. Optionally the human is an inadequate responder to at least one non-steroidal anti-inflammatory drug (NSAID). Examples of suitable NSAIDs include but are not limited to, propionic acid derivative, acetic acid derivative, enolic acid derivatives, fenamic acid derivatives, cox inhibitors, ibuprofen, fenoprofen and aspirin.

Also disclosed is a method of treating psoriasis in a human concurrently treated with methotrexate or other non-biologic DMARD (such as leflunomide) or non-steroidal anti-inflammatory drug (NSAID) and/or steroid comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F.

Also disclosed is a method of reducing joint effects in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F. The reduction of joint effects is optionally measured by ACR criteria. In various embodiments, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. Alternatively or in addition, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. In various embodiments, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human IL-17F. Optionally, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO: 10. In a preferred embodiment, the antibody is bimekizumab. The antibody may be administered as a pharmaceutical composition. The antibody is optionally administered subcutaneously or intravenously. Such joint effects may also include peripheral joint involvement, including synovitis, enthesitis and/or dactylitis.

Also disclosed is a method of reducing psoriasis and reducing joint effects in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F. In various embodiments, the psoriasis is plaque psoriasis. The reduction of plaque psoriasis is optionally measured by PASI criteria and/or the reduction of joint effects is optionally measured by ACR criteria. Alternatively or in addition, the reduction of joint effects, such as structural progression, may be measured by modified total sharp score (mTSS). Where measured, a reduction in enthesitis or dactylitis may be measured by a reduction in Leeds enthesitis index (LEI) and Leeds dactylitis index (LDI) scores respectively. In various embodiments, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. Alternatively or in addition, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46,

TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. In various embodiments, 5 the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human IL-17F. Optionally, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO: 10. In a preferred embodiment, the antibody 0 is bimekizumab. The antibody may be administered as a pharmaceutical composition. The antibody is optionally administered subcutaneously or intravenously.

Also disclosed is a method of treating psoriatic arthritis in a human, comprising the step of administering to the human a loading dose of a neutralizing antibody which binds human IL-17A and human IL-17F followed by at least one maintenance dose of the antibody. Optionally, the

5 loading dose is between 80 and 560 mg and the at least one maintenance dose is between 40 and 320 mg. In one embodiment of the method, the loading dose is 80 mg and the at least one maintenance dose is 40 mg. In another embodiment of the method, the loading dose is 160 mg and the at least one maintenance dose is 80 mg. In a further embodiment, the loading dose is 240 mg and the at least one maintenance dose is 160 mg. In a further embodiment, the loading dose 0 is 320 mg and the at least one maintenance dose is 160 mg. In another embodiment, the loading dose is 560 mg and the at least one maintenance dose is 320 mg. In various embodiments, the loading dose is administered followed by two maintenance doses. Optionally, the loading dose is administered followed by at least one maintenance dose at a three week interval or a four week interval. The antibody, in various embodiments, specifically binds an epitope of human IL-17F, 25 the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. Alternatively or in addition, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer 30 as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. In various embodiments,

the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-1 7A and human IL-1 7F. In various embodiments, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10. In a preferred embodiment, the antibody is bimekizumab. The antibody may be administered as a pharmaceutical composition. The antibody is optionally administered subcutaneously or intravenously.

An embodiment may include a method of treating psoriatic arthritis in a human, comprising the step of administering to the human at least one dose of a neutralizing antibody which binds

human IL-17A and human IL-17F. In various embodiments, at least one dose is between 40 and 640 mg of the antibody. For example, in various embodiments, at least one dose is 40 mg of the antibody. In various embodiments, at least one dose is 80 mg of the antibody. In various embodiments, at least one dose is 160 mg of the antibody. In various embodiments, at least one dose is 240 mg of the antibody. In various embodiments, at least one dose is 320 mg of the

antibody. In various embodiments, at least one dose is 480 mg of the antibody. In various embodiments, at least one dose is 560 mg of the antibody. In various embodiments, at least one dose is 640 mg of the antibody. In any of the embodiments, the doses are optionally administered at a three week interval or a four week interval. In any of the embodiments, the doses are optionally administered at an eight week interval or a twelve week interval. In any of

the embodiments, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. Alternatively or in addition, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the antibody

binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. In various embodiments, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-1 7A and human IL-1 7F. Optionally, the antibody comprises a light chain

variable domain and a heavy chain variable domain, wherein the variable domain of the light

chain comprises the sequence given in SEQ ID NO:10. In a preferred embodiment, the antibody is bimekizumab. The antibody may be administered as a pharmaceutical composition. The antibody is optionally administered subcutaneously or intravenously.

Also disclosed is a method of treating rheumatoid arthritis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F. In various embodiments, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. Alternatively or in addition, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45,

0 ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. Optionally, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in

5 SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human IL-17F. In various embodiments, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10. In a preferred embodiment, the antibody is bimekizumab. The antibody may be administered as a pharmaceutical composition.

0 The antibody is optionally administered subcutaneously or intravenously.

In various embodiments of the method of treating rheumatoid arthritis in a human, the human has a diagnosis of adult-onset rheumatoid arthritis; optionally, the human is at least 18 years of age. Also optionally, the human was diagnosed at least six months prior to administration of the antibody. In various embodiments, the human was classified based on the ACR/EULAR 2010 criteria. In various embodiments of the method of treating rheumatoid arthritis in a human, the human has active arthritis. In various embodiments of the method of treating rheumatoid arthritis in a human, the human is an inadequate responder to at least one non-biologic disease-modifying antirheumatic drug (“DMARD”) and/or at least one approved biologic DMARD. Alternatively, or in addition, the human may be an inadequate responder to at least one non-steroidal anti-inflammatory drug (NSAID).

Also disclosed is a method of treating rheumatoid arthritis in a human concurrently treated with methotrexate or other non-biologic DMARD (such as leflunomide) or non-steroidal anti-inflammatory drug (NSAID) and/or steroid comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F. In various embodiments, 5 the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. Alternatively or in addition, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. Optionally, the antibody binds to the same epitope on human IL- 0 17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. In various embodiments, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human 5 IL-17F. In various embodiments, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10. In a preferred embodiment, the antibody is bimekizumab. The antibody may be administered as a pharmaceutical composition. The antibody is optionally administered subcutaneously or intravenously.

0 Also disclosed is a method of treating rheumatoid arthritis in a human comprising the step of administering to the human a therapeutically effective amount of a neutralizing antibody which binds human IL-17A and human IL-17F. In various embodiments, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. Alternatively or in addition, the 25 antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence 30 given in SEQ ID NO: 10. In various embodiments, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light

chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-1 7A and human IL-1 7F. Optionally, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10. In a preferred embodiment, the antibody is bimekizumab. The antibody may be administered as a pharmaceutical composition. The antibody is optionally administered subcutaneously or intravenously.

Also disclosed is a method of treating rheumatoid arthritis in a human patient comprising the

step of administering to the patient a neutralizing antibody which binds human IL-17A and human IL-17F in an amount that is effective to provide an ACR20 response at week 8 or week

12, an ACR50 response at week 8 or week 12, or an ACR70 response at week 8 or week 12 in a population of patients in need of treatment. For example, in various embodiments, the amount administered is effective to provide an ACR50 response at week 8 or week 12, or an ACR70 response at week 8 or week 12 in the population of patients. In a preferred embodiment, the amount is effective to provide an ACR70 response at week 8 or week 12 in a population of

patients in need of treatment. In various embodiments, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. Alternatively or in addition, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various

embodiments, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. In various embodiments, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence

given in SEQ ID NO: 10 and binds human IL-1 7A and human IL-1 7F. Optionally, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10. In a preferred embodiment of the disclosure, the antibody is bimekizumab. The antibody may be administered as a pharmaceutical composition. The antibody is optionally administered subcutaneously or intravenously.

Also disclosed is a method of treating rheumatoid arthritis in a human, comprising the step of administering to the human a loading dose of a neutralizing antibody which binds human IL-17A and human IL-17F followed by at least one maintenance dose of the antibody. In various embodiments, the loading dose is between 80 and 560 mg and the at least one maintenance dose is between 40 and 320 mg. For example, in various embodiments, the loading dose is 80 mg and the at least one maintenance dose is 40 mg, the loading dose is 160 mg and the at least one maintenance dose is 80 mg, the loading dose is 240 mg and the at least one maintenance dose is 160 mg, the loading dose is 320 mg and the at least one maintenance dose is 160 mg, or the loading dose is 560 mg and the at least one maintenance dose is 320 mg. Optionally, the loading dose is administered followed by two maintenance doses. Also optionally, the loading dose is administered followed by at least one maintenance dose at a three week interval or a four week interval. In various embodiments, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. Alternatively or in addition, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. In various embodiments, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human IL-17F. Optionally, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10. In a preferred embodiment, the antibody is bimekizumab. The antibody may be administered as a pharmaceutical composition. The antibody is optionally administered subcutaneously or intravenously.

Also disclosed is a method of treating rheumatoid arthritis in a human, comprising the step of administering to the human at least one dose of a neutralizing antibody which binds human IL-17A and human IL-17F. Optionally, the at least one dose is between 40 and 640 mg of the antibody. For example, at least one dose is 40 mg of the antibody or 80 mg of the antibody or 160 mg of the antibody or 240 mg of the antibody or 320 mg of the antibody or 480 mg of the antibody.

antibody or 560 mg of the antibody or 640 mg of the antibody. Also optionally, the doses are administered at a three week interval or a four week interval. In various embodiments, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. Alternatively or 5 in addition, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the 0 sequence given in SEQ ID NO: 10. In various embodiments, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human IL-17F. Optionally, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the 5 sequence given in SEQ ID NO:10. In a preferred embodiment, the antibody is bimekizumab. The antibody may be administered as a pharmaceutical composition. The antibody is optionally administered subcutaneously or intravenously.

Also disclosed is a method of treating axial spondyloarthritis (e.g., ankylosing spondylosis) comprising the step of administering to the human a neutralizing antibody which binds human 0 IL-17A and human IL-17F. Axial spondyloarthritis refers to a group of inflammatory arthritis diseases which primarily affects the spine and other joints, causing inflammation and chronic pain in the spine and sacroliliac joints which may eventually result in syndemophyte formation and which includes both ankylosing spondylitis and nonradiographic spondylitis. Thus, also disclosed is a method for treating (e.g., ameliorating the symptoms of, reducing the progression 25 of) ankylosing spondylosis and/or nonradiographic axial spondyloarthritis (nr-axSpA). In various embodiments, the antibody specifically binds an epitope of human IL-17F, the epitope comprising one or more residues selected from ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO: 27. Alternatively or in addition, the antibody specifically binds an epitope of human IL-17A, the epitope comprising one or more residues selected from TYR44, ASN45, ARG46, 30 TRP51, ASN52, HIS54 and ASP84 of SEQ ID NO: 28. In various embodiments, the antibody binds to the same epitope on human IL-17A, human IL-17F, or IL-17 A/F heterodimer as a

neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10. In various embodiments, the antibody cross-blocks a neutralising antibody that has a heavy chain comprising the sequence given in SEQ ID NO: 11 and a light chain comprising the sequence given in SEQ ID NO: 10 and binds human IL-17A and human IL-17F. Optionally, the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10. In a preferred embodiment, the antibody is bimekizumab. The antibody may be administered as a pharmaceutical composition. The antibody is optionally administered subcutaneously or intravenously. Preferably the antibody is administered in a therapeutically effective amount. Any of the dosing regimens described herein are suitable for use in the context of this method. For example, in various embodiments, the method comprises administering to a subject a 16 mg, 64 mg, 160 mg, or 320 mg of antibody every four weeks, optionally for a treatment period of 12 weeks, 36 weeks, 48 weeks, or 52 weeks. The amount and timing of administration is preferably sufficient to achieve at least an ASAS20 response (e.g., ASAS40,) at week 2, week 4, week 8, or week 12 of treatment. ASAS scoring and methods of evaluating the severity of axial spondylitis are further described in Ann Rheum Dis 2009;68;ii1-ii44. In one example the amount and timing of administration is preferably sufficient to achieve an ASAS40 at week 12 of treatment. In one example the amount and timing of administration is preferably sufficient to provide at least 30% or at least 40% or at least 45% or at least 50% of subjects achieving an ASAS40 response at week 12 of treatment. Also disclosed is a method of inhibiting (e.g., slowing the progression of) periosteal bone formation in a human, such as a human suffering from spondyloarthritis (e.g., ankylosing spondylosis), by administering a neutralizing antibody which binds human IL-17A and human IL-17F as described herein. Periosteal bone formation is evaluated via, e.g., radiography

In any of the embodiments of the method of treating axial spondyloarthritis including ankylosing spondylitis and nr-axSpA in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F, the human optionally has a diagnosis of adult-onset ankylosing spondylitis or nr-axSpA. Optionally, the human is at least 18 years of age and/or was diagnosed at least six months prior to administration of the antibody. Also optionally, the human has been classified based on the modified New York or ASAS criteria. In any of the embodiments described above, the human has active axial arthritis.

In any of the embodiments of the method of treating axial spondyloarthritis including ankylosing spondylitis and/or nr-axSpA in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F described herein, the human optionally is an inadequate responder to at least one nonsteroidal anti-inflammatory drug (“NSAID”) and/or one or more approved biologic DMARD (e.g., a TNF inhibitor such as an anti-TNF antibody, examples including infliximab or adalimumab, or a soluble TNF receptor, such as etanercept).

Also disclosed is a method of treating axial spondyloarthritis including ankylosing spondylitis and/or nr-axSpA in a human concurrently treated with a non-steroidal anti-inflammatory drug (NSAID) comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F.

Also disclosed is a method of treating psoriatic arthritis comprising the step of administering a neutralizing antibody which binds human IL-17A and human IL-17F in an amount that is effective to provide at least 50% of subjects achieving an ACR20 response at week 8 or week 12.

For example, the amount is effective to provide at least 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 or 65% of subjects achieving an ACR20 response at week 8 or week 12. In one example, the amount is effective to provide at least 50-90% or 60-90% or 63-91% of subjects achieving an ACR20 response at week 8 or week 12. In one example, the amount is effective to provide at least 40%, at least 45%, at least 50% or at least 55% of subjects achieving an ACR50 response at week 8 or week 12 or week 20. Alternatively or in addition, the amount of neutralizing antibody is effective to provide at least 80% of subjects achieving a PASI75 response at week 8 or week 12. For example, the amount is effective to provide 80-100% of subjects achieving a PASI75 response at week 8 or week 12, such as an amount effective to provide at least 80, 85, 90, 95 or 99% of subjects achieving a PASI75 response at week 8 or week 12. In various embodiments, the amount of neutralizing antibody is effective to provide at least 60% of subjects achieving a PASI90 response or a PASI100 response at week 8 or week 12, e.g., an amount effective to provide 60-100% or 62-96% of subjects achieving a PASI90 response at week 8 or week 12 (such as an amount effective to provide at least 60, 65, 70, 75, 80, 85, 90, 95 or 96% of subjects achieving a PASI90 response at week 8 or week 12).

## BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Nucleotide and Amino Acid Sequences

Figure 2: CASPAR criteria

Figure 3a: PASI 50/75/90 response at week 8 for cohorts 1-4 described in Example 1.

5 Figure 3b: Time course of PASI 90-response (PA0007) from first dose(day 0) to day 140 (week 20) in Example 1.

Figure 4: Secukinumab Future 1 Results: PASI

Figure 5a: ACR20/50/70 response at week 8 for cohorts 1-4 described in Example 1.

0 Figures 5(b)-5(d): Summary Plots of the ACR20/50/70 response rates from PA0007 from start of study (day 0) to day 140 (week 20) (Example 1).

Figure 6: Secukinumab Future 1 Results and Cimzia RAPID PSA results: ACR20

Figure 7: Summary Table of Bayesian Analysis

Figure 8: Summary Table of ACR20 response at week 8 in psoriatic arthritis for registered anti-TNFs or Phase III results. References 1. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to

5 severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis and rheumatism. 2005;52(10):3279-89. 2. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

10 Arthritis and rheumatism. 2009;60(4):976-86. 3. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Annals of the rheumatic diseases. 2014;73(1):48-55.

4. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al.

15 Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137-46. 5. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

20 Lancet. 2013;382(9894):780-9.

Figure 9: Targeted CA028\_0496.g3 PK concentrations

Figure 10: Summary PK plot of predicted SC dosing, illustrating that a dose of 320 loading followed by 160 mg Q4W or 160 mg Q4W and higher, are able to achieve the plasma 25 concentrations studied in PA0007 at the top 3 doses.

Figure 11: Percent change from baseline in lesional severity score in study UP0008

Figure 12: Percent Change for baseline in PASI in study UP0008

Figure 13: Summary Table of PASI 90 response in study UP0008

Figures 14A-14C: Mean percentage change from baseline in (A) LSS, (B) PASI and (C) PGA in the placebo and bimekizumab cohorts. Closed circles=placebo; diamonds=8 mg bimekizumab; closed squares=40 mg bimekizumab; open squares=160 mg bimekizumab; open diamonds=480 mg bimekizumab; open triangles=640 mg bimekizumab.

5 Figures 15A-15G: Figures 15A-15E are bar graphs illustrating osteogenic gene expression in hPDSCs following treatment with GFC (growth factor cocktail; first bar from left), GFC (-IL-6) (growth factor cocktail without IL-6; second bar), TH-17SN (TH-17 supernatant in (GFC-IL-6), third bar), TH-17SN + IL-17A mAb ((TH-17 supernatant in (GFC-IL-6) with IL-17A monoclonal antibody treatment; fourth bar), or IL-17F mAb ((TH-17 supernatant in (GFC-IL-6) with IL-17F monoclonal antibody treatment; fifth bar), or IL-17A/F mAb ((TH-17 supernatant in (GFC-IL-6) with IL-17A/F monoclonal antibody treatment; sixth bar). Figure 15F is a bar graph 10 illustrating in vitro mineralisation (y-axis=Absorbance at 595 nm; bars from left to right: Control, GFC, GFC-IL-6, TH-17SN, IL-17A mAb, IL-17F mAb, IL-17A/F mAb). Figure 15G is a bar graph illustrating IL-6 gene expression following treatment with GFC (growth factor 15 cocktail; first bar from left), GFC (-IL-6) (growth factor cocktail without IL-6; second bar), TH-17SN (TH-17 supernatant in (GFC-IL-6), third bar), TH-17SN + IL-17A mAb ((TH-17 supernatant in (GFC-IL-6) with IL-17A monoclonal antibody treatment; fourth bar), or IL-17F mAb ((TH-17 supernatant in (GFC-IL-6) with IL-17F monoclonal antibody treatment; fifth bar), or IL-17A/F mAb ((TH-17 supernatant in (GFC-IL-6) with IL-17A/F monoclonal antibody 20 treatment; sixth bar). Results are expressed as the mean fold change in expression compared to GM ± SEM. \*\*\*p<0.001; \*\*p<0.01; \*p<0.05 as compared by one-way ANOVA (n=3) between all treatment groups.

Figures 16A-16B: Bar graphs illustrating reduction in expression of IL-6 (Figure 16A) and RUNX2 (Figure 16B) in three patient samples (SRSC04, SRSCO6, and SRSCO7). hPDSCs 25 treated with 10% AS patient serum (CTRL, first bar from left), or AS patient sera with IgG mAb control (second bar), IL-17A mAb (third bar), IL-17F mAb (fourth bar), IL-17A/F mAb (fifth bar) preincubation. Results are expressed as the mean relative expression ± SEM. (\*\*p<0.001; \*\*p<0.01; \*p<0.05) §§§ p<0.01 (comparisons between neutralisation groups as compared by one-way ANOVA (n=3) in all cases).

## DETAILED DESCRIPTION OF THE INVENTION

### Antibodies

In one embodiment, the antibodies of the invention specifically bind to IL-17A. Specifically binding means that the antibodies have a greater affinity for IL-17A polypeptides than for other polypeptides.

In one embodiment, the antibodies of the invention specifically bind to IL-17F. Specifically binding means that the antibodies have a greater affinity for IL-17F polypeptides than for other polypeptides.

In a preferred embodiment, the antibodies of the invention specifically bind to IL-17A and IL-17F. Specifically binding means that the antibodies have a greater affinity for IL-17A and IL-17F polypeptides (including the IL-17A/IL-17F heterodimer) than for other polypeptides.

Preferably, the IL-17A and IL-17F polypeptides are human. In one embodiment, the antibody also binds cynomolgus IL-17A and/or IL-17F.

It will be appreciated that an antibody of the invention that neutralizes both IL-17A and IL-17F may be generated as a cross-reactive antibody as described herein below or by combining both an IL-17A binding domain with an IL-17F binding domain in a bispecific antibody.

In one embodiment, an antibody of the invention which is capable of binding to both IL-17A and IL-17F is capable of neutralising the activity of both isoforms of IL-17. Preferably, an antibody of the invention neutralises the activity of both IL-17A and IL-17F. In one embodiment, an antibody of the invention also neutralises the activity of the IL-17A/IL-17F heterodimer. The antibodies provided by this aspect of the invention therefore have the advantageous property that they can inhibit the biological activity of both IL-17A and IL-17F. Accordingly, the invention also provides the use of such antibodies in the treatment of and/or prophylaxis of a disease mediated by either or both of IL-17A or IL-17F such as autoimmune or inflammatory disease .

As used herein, the term “neutralising antibody” describes an antibody that is capable of neutralising the biological signalling activity of IL-17A and/or IL-17F and/or IL-17A/F heterodimer, for example by blocking binding of IL-17A and/or IL-17F to one or more of their receptors and by blocking binding of the IL-17A/IL-17F heterodimer to one or more of its receptors. It will be appreciated that the term “neutralizing” as used herein refers to a reduction

in biological signalling activity which may be partial or complete. Further, it will be appreciated that the extent of neutralisation of IL-17A and IL-17F activity by an antibody which binds both IL-17A and IL-17F may be the same or different. In one embodiment, the extent of neutralisation of the activity of the IL-17A/IL-17F heterodimer may be the same or different as 5 the extent of neutralisation of IL-17A or IL-17F activity.

IL-17A or IL-17F polypeptides, or a mixture of the two, or cells expressing one or both of said polypeptides, can be used to produce antibodies which specifically recognise one or both polypeptides. The IL-17 polypeptides (IL-17A and IL-17F) may be “mature” polypeptides or biologically active fragments or derivatives thereof which preferably include the receptor 10 binding site. Preferably the IL-17 polypeptides are the mature polypeptides provided in SEQ ID NOS: 27 and 28 for IL-17A and IL-17F respectively. IL-17 polypeptides may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems or they may be recovered from natural biological sources.

In the application, the term “polypeptides” includes peptides, polypeptides and proteins. These 15 are used interchangeably unless otherwise specified.

The IL-17 polypeptide may in some instances be part of a larger protein such as a fusion protein for example fused to an affinity tag. Antibodies generated against these polypeptides may be obtained, where immunisation of an animal is necessary, by administering the polypeptides to an animal, preferably a non-human animal, using well-known and routine protocols, see for 20 example Handbook of Experimental Immunology, D. M. Weir (ed.), Vol 4, Blackwell Scientific Publishers, Oxford, England, 1986). Many warm-blooded animals, such as rabbits, mice, rats, sheep, cows or pigs may be immunized. Mice, rabbits, pigs and rats may be preferred.

Antibodies for use in the invention include whole antibodies and functionally active fragments or derivatives thereof and may be, but are not limited to, monoclonal, multi-valent, multi-specific, 25 bispecific, fully human, humanized or chimeric antibodies, domain antibodies e.g. VH, VL, VHH, single chain antibodies, Fab fragments, Fab' and F(ab')<sub>2</sub> fragments and epitope-binding fragments of any of the above. Other antibody fragments include those described in International patent applications WO2005003169, WO2005003170, WO2005003171, WO2009040562 and WO2010035012. Antibody fragments and methods of producing them are 30 well known in the art, see for example Verma et al., 1998, Journal of Immunological Methods,

216, 165-181; Adair and Lawson, 2005. Therapeutic antibodies. *Drug Design Reviews—Online* 2(3):209-217.

Antibodies for use in the invention include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site 5 that specifically binds an antigen. The immunoglobulin molecules of the invention can be of any class (e.g. IgG, IgE, IgM, IgD and IgA) or subclass of immunoglobulin molecule.

Monoclonal antibodies may be prepared by any method known in the art such as the hybridoma technique (Kohler & Milstein, 1975, *Nature*, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, *Immunology Today*, 4:72) and the EBV-10 hybridoma technique (Cole et al., *Monoclonal Antibodies and Cancer Therapy*, pp 77-96, Alan R Liss, Inc., 1985).

Antibodies for use in the invention may also be generated using single lymphocyte antibody methods by cloning and expressing immunoglobulin variable region cDNAs generated from 15 single lymphocytes selected for the production of specific antibodies by for example the methods described by Babcock, J. et al., 1996, *Proc. Natl. Acad. Sci. USA* 93(15):7843-78481; WO92/02551; WO2004/051268 and International Patent Application number WO2004/106377.

Humanized antibodies are antibody molecules from non-human species having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule (see, e.g. U.S. Pat. No. 5,585,089; 20 WO91/09967).

Chimeric antibodies are those antibodies encoded by immunoglobulin genes that have been genetically engineered so that the light and heavy chain genes are composed of immunoglobulin gene segments belonging to different species. These chimeric antibodies are likely to be less antigenic. Bivalent antibodies may be made by methods known in the art (Milstein et al., 1983, 25 *Nature* 305:537-539; WO 93/08829, Traunecker et al., 1991, *EMBO J.* 10:3655-3659). Multi-valent antibodies may comprise multiple specificities or may be monospecific (see for example WO 92/22853 and WO05/113605).

In one embodiment, the antibody provided by the invention is a monoclonal antibody. In one embodiment, the antibody provided by the invention is a humanized antibody. In one

embodiment, the antibody provided by the invention is a chimeric antibody. The antibody molecules of the invention preferably comprise a complementary light chain or a complementary heavy chain, respectively.

The antibodies for use in the invention can also be generated using various phage display methods known in the art and include those disclosed by Brinkman et al. (in *J. Immunol. Methods*, 1995, 182: 41-50), Ames et al. (*J. Immunol. Methods*, 1995, 184:177-186), Kettleborough et al. (*Eur. J. Immunol.* 1994, 24:952-958), Persic et al. (*Gene*, 1997 187 9-18), Burton et al. (*Advances in Immunology*, 1994, 57:191-280) and WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Pat. Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108. Techniques for the production of single chain antibodies, such as those described in U.S. Pat. No. 4,946,778 can also be adapted to produce single chain antibodies which bind to IL-17A and IL-17F. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies, including those within the scope of the invention.

In one embodiment, the antibody provided by the invention is a CDR-grafted antibody molecule. As used herein, the term 'CDR-grafted antibody molecule' refers to an antibody molecule wherein the heavy and/or light chain contains one or more CDRs (including, if desired, one or more modified CDRs) from a donor antibody (e.g. a murine monoclonal antibody) grafted into a heavy and/or light chain variable region framework of an acceptor antibody (e.g. a human antibody). For a review, *see* Vaughan et al, *Nature Biotechnology*, 16, 535-539, 1998. In one embodiment, rather than the entire CDR being transferred, only one or more of the specificity determining residues from any one of the CDRs described herein above are transferred to the human antibody framework (*see*, for example, Kashmiri et al., 2005, *Methods*, 36, 25-34). In one embodiment, only the specificity determining residues from one or more of the CDRs described herein above are transferred to the human antibody framework. In another embodiment, only the specificity determining residues from each of the CDRs described herein above are transferred to the human antibody framework.

When the CDRs or specificity determining residues are grafted, any appropriate acceptor variable region framework sequence may be used having regard to the class/type of the donor

antibody from which the CDRs are derived, including mouse, primate and human framework regions. Preferably, the CDR-grafted antibody according to the invention has a variable domain comprising human acceptor framework regions as well as one or more of the CDRs or specificity determining residues described above. Thus, provided in one embodiment is a neutralising

5 CDR-grafted antibody wherein the variable domain comprises human acceptor framework regions and non-human donor CDRs.

Examples of human frameworks which can be used in the invention are KOL, NEWM, REI, EU, TUR, TEI, LAY and POM (Kabat et al., *supra*). For example, KOL and NEWM can be used for the heavy chain, REI can be used for the light chain and EU, LAY and POM can be used for both 10 the heavy chain and the light chain. Alternatively, human germline sequences may be used; these are available at, for example: <http://vbase.mrc-cpe.cam.ac.uk/>. In a CDR-grafted antibody of the invention, the acceptor heavy and light chains do not necessarily need to be derived from the same antibody and may, if desired, comprise composite chains having framework regions derived from different chains.

15 As described herein above, the antibody molecule of the invention may comprise a complete antibody molecule having full length heavy and light chains or a fragment thereof, such as a domain antibody e.g. VH, VL, VHH, Fab, modified Fab, Fab', F(ab')<sub>2</sub>, Fv or scFv fragment.

It will be appreciated that the antibodies of the invention, in particular the antibody fragments described above, may be incorporated into other antibody formats, in particular, multi-specific 20 antibodies, such as bi or tri specific antibodies, where specificity is provided by an antibody of the invention, i.e., specificity for IL-17A and IL-17F (including IL-17A/F heterodimer).

Accordingly, in one embodiment, the invention provides a multi-specific antibody comprising one or more of the antibody fragments described herein above. Such multi-specific antibodies may comprise one or more further antibody fragments with binding specificity for another

25 antigen, such as serum albumin, such as human serum albumin in order to extend the half life of the multi-specific antibody. For example, antibody fragments described in WO2012/156219 and combinations or variants thereof which comprise both an anti-IL-17A/F VHH binding domain and a serum albumin VHH binding domain.

Examples of multi-specific antibodies include bi, tri or tetra-valent antibodies, Bis-scFv, diabodies, triabodies, tetrabodies, bibodies and tribodies (see for example Holliger and Hudson, 2005, *Nature Biotech* 23(9): 1126-1136; Schoonjans et al. 2001, *Biomolecular Engineering*, 17 (6), 193-202). Other multi-specific antibodies include Fab-Fv, Fab-dsFv, Fab-Fv-Fv, Fab-Fv-Fc 5 and Fab-dsFv-PEG fragments described in WO2009040562, WO2010035012, WO2011/08609, WO2011/030107 and WO2011/061492 respectively.

The constant region domains of the antibody molecule of the invention, if present, may be selected having regard to the proposed function of the antibody molecule, and in particular the effector functions which may be required. For example, the constant region domains may be 10 human IgA, IgD, IgE, IgG or IgM domains. In particular, human IgG constant region domains may be used, especially of the IgG1 and IgG3 isotypes when the antibody molecule is intended for therapeutic uses and antibody effector functions are required. Alternatively, IgG2 and IgG4 isotypes may be used when the antibody molecule is intended for therapeutic purposes and antibody effector functions are not required, e.g. for simply blocking IL-17 activity. For example 15 IgG4 molecules in which the serine at position 241 has been changed to proline as described in Angal et al., *Molecular Immunology*, 1993, 30 (1), 105-108 may be used. Particularly preferred is the IgG4 constant domain that comprises this change.

It will also be understood by one skilled in the art that antibodies may undergo a variety of posttranslational modifications. The type and extent of these modifications often depends on the 20 host cell line used to express the antibody as well as the culture conditions. Such modifications may include variations in glycosylation, methionine oxidation, diketopiperazine formation, aspartate isomerization and asparagine deamidation. A frequent modification is the loss of a carboxy-terminal basic residue (such as lysine or arginine) due to the action of carboxypeptidases (as described in Harris, R J. *Journal of Chromatography* 705:129-134, 1995). 25 Accordingly, the C-terminal lysine of the antibody heavy chain, for example as given in FIG.1 SEQ ID NO: 16, may be absent.

In one embodiment, the antibody heavy chain comprises a CH1 domain and the antibody light chain comprises a CL domain, either kappa or lambda.

Fully human antibodies are those antibodies in which the variable regions and the constant 30 regions (where present) of both the heavy and the light chains are all of human origin, or

substantially identical to sequences of human origin, not necessarily from the same antibody. Examples of fully human antibodies may include antibodies produced for example by the phage display methods described above and antibodies produced by mice in which the murine immunoglobulin variable and constant region genes have been replaced by their human counterparts, e.g., as described in general terms in EP0546073 B1, U.S. Pat. No. 5,545,806, U.S. Pat. No. 5,569,825, U.S. Pat. No. 5,625,126, U.S. Pat. No. 5,633,425, U.S. Pat. No. 5,661,016, U.S. Pat. No. 5,770,429, EP 0438474 B1 and EP0463151 B1.

The above antibodies are described for purposes of reference and example only and do not limit the scope of invention.

10 Inhibitors of IL-17A and IL-17F activity are known in the art, for example those described herein. Antibodies which bind both IL-17A and IL-17F have been described in WO2007/106769, WO2008/047134, WO2009/136286, WO2010/025400, and WO2012/156219. IL-17A and IL-17F activity can also be antagonized through use of an anti-IL-17RC antibody or an IL-17RC fusion protein, as described in US2007196371A.

15 U.S. Patent No. 8,303,953 (October 18, 2006 priority date) describes a high affinity antibody, CA028\_00496 which binds human IL-17A, IL-17F and IL-17A/F heterodimer, the sequence of which is provided herein in Figure [1]. CA028\_0496 is a humanised neutralising antibody which comprises the grafted variable regions gL7 and gH9, the sequences of which are provided in U.S. Patent No. 8,303,953 (priority date 18 Oct. 2006) and herein in Figure [1]. The heavy chain acceptor framework is the human germline sequence VH3 1-3 3-07 with framework 4 coming from this portion of the human JH-region germline JH4. The light chain acceptor framework is the human germline sequence VK1 2-1-(1) L4, with framework 4 coming from this portion of the human JK-region germline JK1. Examples 2-4 of U.S. Patent No. 8,303,953, as well as the DNA Manipulations and General Methods section therein, describe characterization and testing 20 of the neutralizing activity and affinity of CA028\_0496.

25 U.S. Patent No. 8,580,265 (January 14, 2011 priority date) describes a second, higher affinity antibody, CA028\_00496.g3, also known as UCB4940 or Bimekizumab, which binds human IL-17A, IL-17F and IL-17A/F heterodimer, the sequence of which is provided herein in Figure [1]. As described in U.S. Patent No. 8,580,265, antibody CA028\_0496 was affinity matured to 30 improve the affinity of the antibody for IL-17F while retaining affinity for IL-17A. This affinity

matured antibody, CA028\_0496.g3 (also known as UCB4940 or bimekizumab), was expressed as an IgG1. The final sequence of the affinity matured variable regions of CA028\_0496.g3 is given in FIGS. 1a and 1b of U.S. Patent No. 8,580,265, and herein in Figure [1]. U.S. Patent No. 8,679,494 (April 23, 2008 priority date) provides novel neutralising epitopes on IL-17A and IL-5 17F and antibodies which bind to, and/or interact with, those epitopes, the sequences of which are provided herein in Figure [1]. The aforementioned patents are incorporated by reference as if fully set forth herein.

In antibody CA028\_0496.g3, the heavy chain variable region sequence is the same as that of the parent antibody CA028\_0496. In contrast, the light chain variable region differs by 5 amino 10 acids. The five residues that differ between the light chain of antibody CA028\_0496 and antibody CA028\_0496.g3 are underlined in FIG. 1a of U.S. Patent No. 8,580,265. Three residues were in the CDRs and two in the framework. Accordingly in one embodiment, the light chain variable domain comprises an arginine residue at position 30, a serine residue at position 54, an isoleucine residue at position 56, an aspartic acid residue at position 60 and an arginine 15 residue at position 72.

Antibody CA028\_0496.g3 selectively and potently inhibits the activity of both IL-17A and IL-17F isoforms in-vitro. Antibody CA028\_0496.g3 binds to IL-17A, IL-17F and the IL-17A/F heterodimer and neutralizes the bioactivity of each cytokine by blocking the cytokines from signalling through the IL-17RA/RC complex.

20 Characterization of CA028\_0496.g3 and CA028\_0496 and their properties is described in Examples 2 and 3 of U.S. Patent No. 8,580,265 as if fully set forth herein. As detailed in U.S. Patent No. 8,580,265, biomolecular analysis of antibody CA028\_0496.g3 was performed using the Biacore 3000 (Biacore AB). The assay format was a capture of the antibody CA028\_0496.g3 by an immobilised anti-human IgG Fc-specific antibody, followed by the 25 titration of recombinant human IL-17A or human IL-17F over the captured surface. Additional detail regarding surface plasmon resonance (Biacore) assays are as follows; while the details are described by referencing a particular antibody, the parameters described herein are suitable for use in characterizing any antibody described herein. Assays were performed at 25° C. Affinipure F(ab')<sub>2</sub> fragment goat anti-human IgG Fc specific (Jackson ImmunoResearch) was 30 immobilised on a CM5 Sensor Chip (Biacore AB) via amine coupling chemistry to a level of

approximately 6000 response units (RU). HBS-EP buffer (10 mM HEPES pH7.4, 0.15M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore AB) was used as the running buffer with a flow rate of 10 microL/minute (min). A 10  $\mu$ L injection of CA028\_00496.g3 at 0.5  $\mu$ g/mL was used for capture by the immobilised anti-human IgG Fc. Human IL-17A was titrated over the captured 5 CA028\_00496.g3 from 5 nM at a flow rate of 30  $\mu$ L/min for 3 min followed by a 20 min dissociation. Human IL-17F (R&D systems) was titrated over the captured CA028\_00496.g3 from 10 nM at a flow rate of 30  $\mu$ L/min for 3 min followed by a 5 min dissociation. The surface 10 was regenerated at a flow rate of 10  $\mu$ L/min by a 10  $\mu$ L injection of 40 mM HCl followed by a 5  $\mu$ L injection of 5 mM NaOH. Double referenced background subtracted binding curves were analysed using the BIA evaluation software (version 4.1) following standard procedures. Kinetic parameters were determined from the fitting algorithm.

Data are detailed in Table 1, average values are highlighted in grey.

**Table 1. Affinity of bimekizumab against human IL-17F and IL-17A.**

	ka (M-1s-1)	kd (s-1)	KD (M)	KD (pM)
<b>hIL-17F</b>	2.49E+06	8.74E-05	3.51E-11	35
	3.49E+06	5.08E-05	1.46E-11	15
	2.99E+06	6.91E-05	2.31E-11	23
<b>hIL-17A</b>	4.66E+06	2.04E-05	4.38E-12	4.4
	4.52E+06	8.66E-06	1.92E-12	1.9
	4.59E+06	1.45E-05	3.17E-12	3.2

15 As described in U.S. Patent No. 8,580,265, the preferred framework region for the heavy chain of CA028\_0496.g3 is derived from the human sub-group VH3 sequence 1-3 3-07 together with JH4, as previously described in WO2008/047134. Accordingly, an embodiment of the invention may be a neutralising CDR-grafted antibody comprising at least one non-human donor CDR 20 wherein the heavy chain framework region is derived from the human subgroup sequence 1-3 3-07 together with JH4. The sequence of human JH4 is as follows: (YFDY)WGQGTLVTVSS. The YFDY motif is part of CDR-H3 and is not part of framework 4 (Ravetch, J V. et al., 1981, Cell, 27, 583-591).

As described in U.S. Patent No. 8,580,265, the preferred framework region for the light chain of CA028\_0496.g3 is derived from the human germline sub-group VK1 sequence 2-1-(1) L4 together with JK1, as previously described in WO2008/047134. Accordingly, an embodiment of the invention may be a neutralising CDR-grafted antibody comprising at least one non-human  
5 donor CDR wherein the light chain framework region is derived from the human subgroup sequence VK1 2-1-(1) L4 together with JK1. The JK1 sequence is as follows:  
(WT)FGQQGTKVEIK. The WT motif is part of CDR-L3 and is not part of framework 4 (Hieter, P A., et al., 1982, *J. Biol. Chem.*, 257, 1516-1522).

Also, in CA028\_0496.g3, the framework regions need not have exactly the same sequence as  
10 those of the acceptor antibody. For instance, unusual residues may be changed to more frequently-occurring residues for that acceptor chain class or type. Alternatively, selected residues in the acceptor framework regions may be changed so that they correspond to the residue found at the same position in the donor antibody (see Reichmann et al., 1998, *Nature*, 332, 323-324). Such changes should be kept to the minimum necessary to recover the affinity of  
15 the donor antibody. A protocol for selecting residues in the acceptor framework regions which may need to be changed is set forth in WO 91/09967.

In one embodiment, in CA028\_0496.g3, if the acceptor heavy chain has the human VH3 sequence 1-3 3-07 together with JH4, then the acceptor framework regions of the heavy chain comprise, in addition to one or more donor CDRs, a donor residue at least position 94 (according  
20 to Kabat et al., (supra)). Accordingly, an embodiment of the invention may be a CDR-grafted antibody, wherein at least the residue at position 94 of the variable domain of the heavy chain is a donor residue.

In one embodiment, in CA028\_0496.g3, if the acceptor light chain has the human sub-group VK1 sequence 2-1-(1) L4 together with JK1, then no donor residues are transferred i.e. only the  
25 CDRs are transferred. Accordingly, an embodiment of the invention may be a CDR-grafted antibody wherein only the CDRs are transferred to the donor framework.

Donor residues are residues from the donor antibody, i.e. the antibody from which the CDRs were originally derived.

Antibody CA028\_0496.g3 is not pharmacologically active in rodents as it does not bind to either  
30 IL-17A or IL-17F from rat or mouse. Antibody CA028\_0496.g3 has been shown to bind to IL-

17A and IL-17F in the cynomolgus monkey and nonclinical evaluation demonstrates it to be pharmacologically active *in vivo* in the cynomolgus monkey. In humans, antibody CA028\_0496.g3 displays a long half-life in a dose-proportional manner, with PK for doses between 8mg and 640mg ranging between 17.00 days and 25.55 days (e.g., 23.6 days) across the 5 treatment groups.

The above antibodies are described for purposes of reference and example only and do not limit the scope of invention. For example, as described herein, it will be appreciated that the affinity of antibodies provided by the invention may be altered using any suitable method known in the art. The invention therefore also relates to variants of the antibody molecules of the invention, 10 which have an improved affinity for IL-17A and/or IL-17F. Such variants can be obtained by a number of affinity maturation protocols including mutating the CDRs (Yang et al., *J. Mol. Biol.*, 254, 392-403, 1995), chain shuffling (Marks et al., *Bio/Technology*, 10, 779-783, 1992), use of mutator strains of *E. coli* (Low et al., *J. Mol. Biol.*, 250, 359-368, 1996), DNA shuffling (Patten et al., *Curr. Opin. Biotechnol.*, 8, 724-733, 1997), phage display (Thompson et al., *J. Mol. Biol.*, 15 256, 77-88, 1996) and sexual PCR (Crameri et al., *Nature*, 391, 288-291, 1998). Vaughan et al. (*supra*) discusses these methods of affinity maturation.

Screening for antibodies can be performed using assays to measure binding to human IL-17A and human IL-17F, for example BIAcore™ assays. BIAcore™ (i.e., surface plasmon resonance assays) are described herein. Suitable neutralisation assays are known in the art, see for example 20 WO2008/047134. An exemplary cell-based neutralization assay utilizes HeLa cells. For example, HeLa cells are grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal calf serum, penicillin, gentamycin and glutamine.  $1 \times 10^4$  cells are plated out into 96 well flat bottomed tissue culture plates. Cells are incubated overnight and washed once in assay buffer. HeLa cells are stimulated with a combination of recombinant human IL-17F (125 25 ng/ml) or human IL-17A (25 ng/ml) and tumour necrosis factor-alpha (TNF- $\alpha$ ) (1 ng/ml) for 48 hours in the presence of varying concentrations of candidate antibody. In the HeLa cell line, IL-17A or IL-17F synergises with TNF-alpha to induce the production of IL-6, which can be quantified using a specific MSD assay kit. The resulting amount of secreted IL-6 is measured using Meso Scale Discovery (MSD) assay technology and IC50 values calculated. The activity

of an antibody can be expressed as the dose required to inhibit 50% of the activity of IL-17A or IL-17F (IC<sub>50</sub>).

“Identity”, as used herein, indicates that at any particular position in the aligned sequences, the amino acid residue is identical between the sequences. “Similarity”, as used herein, indicates

5 that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. For example, leucine may be substituted for isoleucine or valine. Other amino acids which can often be substituted for one another include but are not limited to: phenylalanine, tyrosine and tryptophan (amino acids having aromatic side chains); lysine, arginine and histidine (amino acids having basic side chains); aspartate and glutamate (amino 10 acids having acidic side chains); asparagine and glutamine (amino acids having amide side chains); and cysteine and methionine (amino acids having sulphur-containing side chains).

Degrees of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing. Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of

15 Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heijne, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).

The residues in antibody variable domains are conventionally numbered according to a system devised by Kabat et al. This system is set forth in Kabat et al., 1987, in Sequences of Proteins of

20 Immunological Interest, US Department of Health and Human Services, NIH, USA (hereafter “Kabat et al. (supra)”). This numbering system is used in the present specification except where otherwise indicated.

The Kabat residue designations do not always correspond directly with the linear numbering of the amino acid residues. The actual linear amino acid sequence may contain fewer or additional 25 amino acids than in the strict Kabat numbering corresponding to a shortening of, or insertion into, a structural component, whether framework or complementarity determining region (CDR), of the basic variable domain structure. The correct Kabat numbering of residues may be determined for a given antibody by alignment of residues of homology in the sequence of the antibody with a “standard” Kabat numbered sequence.

The CDRs of the heavy chain variable domain are located at residues 31-35 (CDR-H1), residues 50-65 (CDR-H2) and residues 95-102 (CDR-H3) according to the Kabat numbering system.

However, according to Chothia (Chothia, C. and Lesk, A. M. J. Mol. Biol., 196, 901-917 (1987)), the loop equivalent to CDR-H1 extends from residue 26 to residue 32. Thus 'CDR-H1', 5 as used herein, comprises residues 26 to 35, as described by a combination of the Kabat numbering system and Chothia's topological loop definition.

The CDRs of the light chain variable domain are located at residues 24-34 (CDR-L1), residues 50-56 (CDR-L2) and residues 89-97 (CDR-L3) according to the Kabat numbering system.

In one embodiment, the antibody provided by the invention is a CDR-grafted antibody molecule 10 comprising one or more of the CDRs provided in SEQ ID NOs:1 to 8.

In one embodiment, the invention provides a neutralising antibody having specificity for human IL-17A and human IL-17F, comprising a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3.

15 In one embodiment, the invention provides a neutralising antibody having specificity for human IL-17A and human IL-17F, comprising a light chain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 or SEQ ID NO:7 for CDR-L1, the sequence given in SEQ ID NO:5 or SEQ ID NO:8 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3.

20 It will be appreciated that one or more amino acid substitutions may be made to the CDRs provided by the invention without significantly altering the ability of the antibody to bind to IL-17A and IL-17F and to neutralise IL-17A and IL-17F activity. The effect of any amino acid substitutions on binding and neutralisation can be readily tested by one skilled in the art, for example by using the methods described herein. Accordingly, the invention provides an antibody 25 comprising one or more CDRs selected from CDR-H1 (SEQ ID NO:1), CDR-H2 (SEQ ID NO:2), CDR-H3 (SEQ ID NO:3), CDR-L1 (SEQ ID NO:4 or SEQ ID NO:7), CDR-L2 (SEQ ID NO:5 or SEQ ID NO:8) and CDR-L3 (SEQ ID NO:6) in which one or more amino acids in one or more of the CDRs has been substituted with another amino acid. It will also be appreciated that the length of one or more of the CDRs may be altered without significantly altering the

ability of the antibody to bind to IL-17A and IL-17F and to neutralise IL-17A and IL-17F activity.

In another embodiment, the invention provides a neutralising antibody having specificity for human IL-17A and human IL-17F, comprising a heavy chain, wherein at least two of CDR-H1,

5 CDR-H2 and CDR-H3 of the variable domain of the heavy chain are selected from the following: the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3. For example, the antibody may comprise a heavy chain wherein CDR-H1 has the sequence given in SEQ ID NO:1 and CDR-H2 has the sequence given in SEQ ID NO:2. Alternatively, the antibody may comprise 10 a heavy chain wherein CDR-H1 has the sequence given in SEQ ID NO:1 and CDR-H3 has the sequence given in SEQ ID NO:3, or the antibody may comprise a heavy chain wherein CDR-H2 has the sequence given in SEQ ID NO:2 and CDR-H3 has the sequence given in SEQ ID NO:3. For the avoidance of doubt, it is understood that all permutations are included.

In another embodiment, the invention provides a neutralising antibody having specificity for

15 human IL-17A and human IL-17F, comprising a light chain, wherein at least two of CDR-L1, CDR-L2 and CDR-L3 of the variable domain of the light chain are selected from the following: the sequence given in SEQ ID NO:4 or SEQ ID NO:7 for CDR-L1, the sequence given in SEQ ID NO:5 or 8 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3. For example, the antibody may comprise a light chain wherein CDR-L1 has the sequence given in SEQ ID 20 NO:4 and CDR-L2 has the sequence given in SEQ ID NO:5. Alternatively, the antibody may comprise a light chain wherein CDR-L1 has the sequence given in SEQ ID NO:4 and CDR-L3 has the sequence given in SEQ ID NO:6, or the antibody may comprise a light chain wherein CDR-L2 has the sequence given in SEQ ID NO:5 and CDR-L3 has the sequence given in SEQ ID NO:6. For the avoidance of doubt, it is understood that all permutations are included.

25 In one embodiment, an antibody according to the invention comprises a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and a light chain wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the 30 sequence given in SEQ ID NO:6 for CDR-L3.

In one embodiment, an antibody according to the invention comprises a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and a light chain wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:7 for CDR-L1, the sequence given in SEQ ID NO:8 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3.

In one embodiment, an antibody of the invention comprises a heavy chain, wherein the variable domain of the heavy chain comprises three CDRs wherein the sequence of CDR-H1 has at least 60% identity or similarity to the sequence given in SEQ ID NO:1, CDR-H2 has at least 60% identity or similarity to the sequence given in SEQ ID NO:2 and/or CDR-H3 has at least 60% identity or similarity to the sequence given in SEQ ID NO:3. In another embodiment, an antibody of the invention comprises a heavy chain, wherein the variable domain of the heavy chain comprises three CDRs wherein the sequence of CDR-H1 has at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:1, CDR-H2 has at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:2 and/or CDR-H3 has at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:3.

In another embodiment, an antibody of the invention comprises a light chain, wherein the variable domain of the light chain comprises three CDRs wherein the sequence of CDR-L1 has at least 60% identity or similarity to the sequence given in SEQ ID NO:4, CDR-L2 has at least 60% identity or similarity to the sequence given in SEQ ID NO:5 and/or CDR-L3 has at least 60% identity or similarity to the sequence given in SEQ ID NO:6. In another embodiment, an antibody of the invention comprises a light chain, wherein the variable domain of the heavy chain comprises three CDRs wherein the sequence of CDR-L1 has at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:4, CDR-L2 has at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:5, and/or CDR-L3 has at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:6.

In another embodiment, an antibody of the invention comprises a light chain, wherein the variable domain of the light chain comprises three CDRs wherein the sequence of CDR-L1 has

at least 60% identity or similarity to the sequence given in SEQ ID NO:4, CDR-L2 has at least 60% identity or similarity to the sequence given in SEQ ID NO:5 and/or CDR-L3 has at least 60% identity or similarity to the sequence given in SEQ ID NO:6. In another embodiment, an antibody of the invention comprises a light chain, wherein the variable domain of the heavy

5 chain comprises three CDRs wherein the sequence of CDR-L1 has at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:7, CDR-L2 has at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:8, and/or CDR-L3 has at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:6.

10 In one embodiment, an antibody of the invention comprises a light chain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:9 (gL7).

In another embodiment, an antibody of the invention comprises a light chain, wherein the variable domain of the light chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:9. In one embodiment, the antibody of the

15 invention comprises a light chain, wherein the variable domain of the light chain comprises a sequence having at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:9.

In one embodiment, an antibody of the invention comprises a light chain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10 (gL57).

20 In another embodiment, an antibody of the invention comprises a light chain, wherein the variable domain of the light chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:10. In one embodiment, the antibody of the invention comprises a light chain, wherein the variable domain of the light chain comprises a sequence having at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:10.

25 In one embodiment, an antibody of the invention comprises a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:11 (gH9).

In another embodiment, an antibody of the invention comprises a heavy chain, wherein the variable domain of the heavy chain comprises a sequence having at least 60% identity or

similarity to the sequence given in SEQ ID NO:11. In one embodiment, an antibody of the invention comprises a heavy chain, wherein the variable domain of the heavy chain comprises a sequence having at least 70%, 80%, 90%, 95%, 96, 97, 98 or 99% identity or similarity to the sequence given in SEQ ID NO:11.

5 In one embodiment, an antibody of the invention comprises a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:11 and a light chain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:9.

In another embodiment of the invention, the antibody comprises a heavy chain and a light chain, wherein the variable domain of the heavy chain comprises a sequence having at least 60%

10 identity or similarity to the sequence given in SEQ ID NO:11 and the variable domain of the light chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:9. Preferably, the antibody comprises a heavy chain, wherein the variable domain of the heavy chain comprises a sequence having at least 70%, 80%, 90%, 95%, 96%, 97%, 98 or 99% identity or similarity to the sequence given in SEQ ID NO:11 and a light chain, wherein the  
15 variable domain of the light chain comprises a sequence having at least 70%, 80%, 90%, 95% 96, 97, 98 or 99% identity or similarity to the sequence given in SEQ ID NO:9.

In one embodiment, an antibody of the invention comprises a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:11 and a light chain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:10.

20 In another embodiment of the invention, the antibody comprises a heavy chain and a light chain, wherein the variable domain of the heavy chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:11 and the variable domain of the light chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:10. Preferably, the antibody comprises a heavy chain, wherein the variable  
25 domain of the heavy chain comprises a sequence having at least 70%, 80%, 90%, 95%, 96%, 97%, 98 or 99% identity or similarity to the sequence given in SEQ ID NO:11 and a light chain, wherein the variable domain of the light chain comprises a sequence having at least 70%, 80%, 90%, 95% 96, 97, 98 or 99% identity or similarity to the sequence given in SEQ ID NO:10.

In a preferred embodiment the antibody provided by the invention is a neutralising antibody

30 having specificity for human IL-17A and human IL-17F in which the heavy chain constant

region comprises the human IgG1 constant region. Accordingly, the invention provides an antibody in which the heavy chain comprises or consists of the sequence given in SEQ ID NO:15.

5 In one embodiment, of the invention, the antibody comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:15. Preferably, the antibody comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity or similarity to the sequence given in SEQ ID NO:15.

10 In one embodiment, an antibody molecule according to the invention comprises a light chain comprising the sequence given in SEQ ID NO:12.

15 In one embodiment, of the invention, the antibody comprises a light chain, wherein the light chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:12. Preferably, the antibody comprises a light chain, wherein the light chain comprises a sequence having at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:12.

20 In one embodiment, the invention provides an antibody in which the heavy chain comprises or consists of the sequence given in SEQ ID NO:15, and the light chain comprises or consists of the sequence given in SEQ ID NO:12.

25 In one embodiment, of the invention, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:15 and the light chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:12. Preferably, the antibody comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:15 and a light chain, wherein the light chain comprises a sequence having at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:12.

30 In a preferred embodiment the antibody provided by the invention is a neutralising antibody having specificity for human IL-17A and human IL-17F in which the heavy chain constant region comprises the human IgG1 constant region. Accordingly, the invention provides an

antibody in which the heavy chain comprises or consists of the sequence given in SEQ ID NO:16.

In one embodiment, of the invention, the antibody comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:16. Preferably, the antibody comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity or similarity to the sequence given in SEQ ID NO:16.

In one embodiment, an antibody molecule according to the invention comprises a light chain comprising the sequence given in SEQ ID NO:13.

- 10 In one embodiment, of the invention, the antibody comprises a light chain, wherein the light chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:13. Preferably, the antibody comprises a light chain, wherein the light chain comprises a sequence having at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:13.
- 15 In one embodiment, the invention provides an antibody in which the heavy chain comprises or consists of the sequence given in SEQ ID NO:16 and the light chain comprises or consists of the sequence given in SEQ ID NO:13.

- 20 In one embodiment, of the invention, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:16 and the light chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:13. Preferably, the antibody comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:16 and a light chain, wherein the light chain comprises a sequence having at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:13.
- 25 In one embodiment, the invention provides an antibody in which the heavy chain comprises or consists of the sequence given in SEQ ID NO:15 and the light chain comprises or consists of the sequence given in SEQ ID NO:13.

In one embodiment, the invention provides an antibody in which the heavy chain comprises or consists of the sequence given in SEQ ID NO:15 and the light chain comprises or consists of the sequence given in SEQ ID NO:13.

In one embodiment, of the invention, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:15 and the light chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:13. Preferably, the antibody comprises  
5 a heavy chain, wherein the heavy chain comprises a sequence having at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:15 and a light chain, wherein the light chain comprises a sequence having at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:13.

In one embodiment, the invention provides an antibody in which the heavy chain comprises or  
10 consists of the sequence given in SEQ ID NO:16 and the light chain comprises or consists of the sequence given in SEQ ID NO:12.

In one embodiment, of the invention, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises a sequence having at least 60% identity or similarity to the sequence given in SEQ ID NO:16 and the light chain comprises a sequence having at least 60%  
15 identity or similarity to the sequence given in SEQ ID NO:12. Preferably, the antibody comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:16 and a light chain, wherein the light chain comprises a sequence having at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:12.

20 Binding Affinity

The neutralising antibody molecule of any aspect of the invention preferably has a high binding affinity, preferably nanomolar, even more preferably picomolar. It will be appreciated that the binding affinity of an antibody according to the invention for human IL-17A may be different from the binding affinity of the same antibody for human IL-17F and/or the IL-17A/F  
25 heterodimer.

In one example, the antibody molecule of the invention has an affinity for IL-17A that is greater than its affinity for IL-17F. In one example, the antibody molecule of the invention has an affinity for IL-17A which is at least 10 fold greater than its binding affinity for IL-17F. In one example, the antibody molecule of the invention has an affinity for IL-17A which is at least 50

fold greater than its binding affinity for IL-17F. In one example, the antibody molecule of the invention has an affinity for IL-17A which is at least 100 fold greater than its binding affinity for IL-17F. In one example, the antibody molecule of the invention has a nanomolar affinity for IL-17F and a picomolar affinity for IL-17A.

5 In one example, the antibody molecule of the invention has an affinity for IL-17F that is greater than its affinity for IL-17A. In one example, the antibody molecule of the invention has an affinity for IL-17F which is at least 10 fold greater than its binding affinity for IL-17A. In one example, the antibody molecule of the invention has an affinity for IL-17F which is at least 50 fold greater than its binding affinity for IL-17A. In one example, the antibody molecule of the  
10 invention has an affinity for IL-17F which is at least 100 fold greater than its binding affinity for IL-17A. In one example, the antibody molecule of the invention has a picomolar affinity for IL-17A and a nanomolar affinity for IL-17F.

In one example, the antibody molecule of the invention has an affinity for IL-17A that is the same as its affinity for IL-17F. In one example, the antibody molecule of the invention has a  
15 nanomolar affinity for both IL-17A and IL-17F. In one example, the antibody molecule of the invention has a picomolar affinity for both IL-17A and IL-17F.

Affinity may be measured using any suitable method known in the art, including BIACore<sup>TM</sup>, using isolated natural or recombinant IL-17A and IL-17F which both exist as homodimers.

Preferably the antibody molecule of the invention has a binding affinity for IL-17A of less than  
20 10 nM. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17A of less than 500 pM. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17A of 100 pM or less. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17A of 20 pM or less. In one embodiment, the antibody molecule of the invention has an affinity for IL-17A of 16 pM. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17A of 10 pM or less. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17A of 5 pM or less. In one embodiment, the antibody molecule of the invention has an affinity for IL-17A of 3.2 pM.

Preferably the antibody molecule of the invention has a binding affinity for IL-17F of less than  
25 10 nM. In one embodiment, the antibody molecule of the invention has an affinity for IL-17F of less than 2 nM. In one embodiment, the antibody molecule of the invention has an affinity for IL-17F of 1.75 nM.

In one embodiment, the antibody of the invention has an affinity for IL-17F of less than 500 pM. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17F of 100 pM or less. In one embodiment, the antibody of the invention has an affinity for IL-17F of 50 pM or less. In one embodiment, the antibody of the invention has an affinity for IL-17F of 23 pM. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17F of 10 pM or less. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17F of 5 pM or less.

Preferably the antibody molecule of the invention has a binding affinity for IL-17A/F heterodimer of 10 nM or less. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17A/F heterodimer of 500 pM or less. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17A/F heterodimer of 150 pM or less. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17A/F heterodimer of 116 pM. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17A/F heterodimer of better than 100 pM. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17A/F heterodimer of 10 pM or less. In one embodiment, the antibody molecule of the invention has a binding affinity for IL-17A/F heterodimer of 5 pM or less.

In one embodiment, the antibody molecule of the invention has a binding affinity for cynomolgus IL-17F of less than 2 nM. In one embodiment, the antibody molecule of the invention has a binding affinity for cynomolgus IL-17F of 1.03 nM.

#### Cross-blocking Antibodies

Antibodies which cross-block the binding of an antibody according to the invention, in particular, an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL57 (SEQ ID NO:10) or the light chain sequence gL7 (SEQ ID NO:9), is useful in neutralising IL-17A and IL-17F activity. Accordingly, the invention also provides a neutralising antibody which binds human IL-17A and human IL-17F, which cross-blocks the binding of any one of the antibodies described above to human IL-17A and/or human IL-17F and/or human IL-17A/F heterodimer and/or is cross-blocked from binding IL-17A and/or IL-17F and/or human IL-17A/F heterodimer by any one of those antibodies. In one embodiment, such an

antibody binds to the same epitope as an antibody described herein above. In another embodiment the cross-blocking neutralising antibody binds to an epitope which borders and/or overlaps with the epitope bound by an antibody described herein above. In another embodiment the cross-blocking neutralising antibody of this aspect of the invention does not bind to the same epitope as an antibody of the invention or an epitope that borders and/or overlaps with said epitope.

Cross-blocking antibodies can be identified using any suitable method in the art, for example by using competition ELISA or BIACore where binding of the cross blocking antibody to human IL-17A and/or human IL-17F prevents the binding of an antibody of the invention or vice versa.

10 For surface plasmon resonance (BIACore), target molecules are immobilized on a solid phase and exposed to ligands in a mobile phase running along a flow cell. If ligand binding to the immobilized target occurs, the local refractive index changes, leading to a change in SPR angle, which can be monitored in real time by detecting changes in the intensity of the reflected light. The rates of change of the SPR signal can be analyzed to yield apparent rate constants for the 15 association and dissociation phases of the binding reaction. The ratio of these values gives the apparent equilibrium constant (affinity) (see, e.g., Wolff et al., Cancer Res. 53:2560 65 (1993)). Conditions suitable for surface plasmon resonance (BIACore) assays are known in the art and described elsewhere herein.

ELISA-based methods for determining cross-blocking also are well known in the art. A non- 20 limiting, exemplary assay format suitable for both IL-17A and IL-17F is as follows, illustrated with IL-17A. An anti-IL-17A/F antibody (Ab-1) is coated (e.g., 50  $\mu$ L of 1  $\mu$ g/ml) onto a 96-well ELISA plate [e.g. Corning 96 Well EIA/RIA Flat Bottom Microplate (Product # 3590), Corning Inc., Acton, MA] for at least one hour. After this coating step the antibody solution is removed, the plate is washed once or twice with wash solution (e.g., PBS and 0.05% Tween 20) 25 and is then blocked using an appropriate blocking solution (e.g., PBS, 1% BSA, 1% goat serum and 0.5% Tween 20) and procedures known in the art. Blocking solution is then removed from the ELISA plate and a second anti-IL17A/F antibody (Ab-2), which is being tested for its ability to cross-block the coated antibody, is added in excess (e.g., 50  $\mu$ l of 10  $\mu$ g/ml) in blocking solution to the appropriate wells of the ELISA plate. Following this, a limited amount (e.g. 50  $\mu$ l 30 of 10 ng/ml) of IL-17A in blocking solution is then added to the appropriate wells and the plate

is incubated for at least one hour at room temperature while shaking. The plate is then washed 2-4 times with wash solution. An appropriate amount of a IL-17A detection reagent [e.g., biotinylated anti-IL-17 polyclonal antibody that has been pre-complexed with an appropriate amount of a streptavidin-horseradish peroxidase (HRP) conjugate] in blocking solution is added

5 to the ELISA plate and incubated for at least one hour at room temperature. The plate is then washed with wash solution and is developed with an appropriate reagent [e.g. HRP substrates such as TMB (colorimetric) or various HRP luminescent substrates]. The background signal for the assay is defined as the signal obtained in wells with the coated antibody (in this case Ab-1), second solution phase antibody (in this case Ab-2), IL-17A buffer only (i.e., no IL-17A) and IL-17A detection reagents. The positive control signal for the assay is defined as the signal obtained in wells with the coated antibody (in this case Ab-1), second solution phase antibody buffer only (i.e. no second solution phase antibody), IL-17A and IL-17A detection reagents. Preferably, the ELISA assay is run in such a manner so as to have the positive control signal be at least six times the background signal.

10

15 In one embodiment, there is provided a neutralising antibody which binds to human IL-17A and human IL-17F, which cross-blocks the binding of an antibody whose heavy chain comprises the sequence gH9 (SEQ ID NO:11) and whose light chain comprises the sequence gL57 (SEQ ID NO:10) to human IL-17A and to human IL-17F. In one embodiment, the cross-blocking antibodies provided by the invention inhibit the binding of an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL57 (SEQ ID NO:10) to IL-17A by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95% and to IL-17F by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

20

25 In one embodiment, there is provided a neutralising antibody which binds to human IL-17A and human IL-17F, which cross-blocks the binding of an antibody whose heavy chain comprises the sequence gH9 (SEQ ID NO:11) and whose light chain comprises the sequence gL7 (SEQ ID NO:9) to human IL-17A and to human IL-17F. In one embodiment, the cross-blocking antibodies provided by the invention inhibit the binding of an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL7 (SEQ ID NO:9) to IL-17A by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%,

30

even more preferably by greater than 95% and to IL-17F by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

In one embodiment, there is provided a neutralising antibody which binds to human IL-17A and

5 human IL-17F, which cross-blocks the binding of an antibody whose heavy chain comprises the sequence gH9 (SEQ ID NO:11) and whose light chain comprises the gL57 (SEQ ID NO:10) to human IL-17A and to human IL-17F and to human IL-17A/F heterodimer. In one embodiment, the cross-blocking antibodies provided by the invention inhibit the binding of an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL57 10 (SEQ ID NO:10) to IL-17A by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95% and to IL-17F by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95% and to IL-17A/F heterodimer to IL-17F by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more 15 preferably by greater than 95%.

In one embodiment, there is provided a neutralising antibody which binds to human IL-17A and human IL-17F, which cross-blocks the binding of an antibody whose heavy chain comprises the sequence gH9 (SEQ ID NO:11) and whose light chain comprises the gL7 (SEQ ID NO:9) to human IL-17A and to human IL-17F and to human IL-17A/F heterodimer. In one embodiment,

20 the cross-blocking antibodies provided by the invention inhibit the binding of an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL7 (SEQ ID NO:9 )to IL-17A by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95% and to IL-17F by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more 25 preferably by greater than 95% and to IL-17A/F heterodimer to IL-17F by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

In one embodiment, there is provided a neutralising antibody which binds to human IL-17A and

30 human IL-17F, which cross-blocks the binding of an antibody whose heavy chain comprises the sequence gH9 (SEQ ID NO:11) and whose light chain comprises the sequence gL57 (SEQ ID

NO:10) to human IL-17A or to human IL-17F or human IL-17A/F heterodimer. In one embodiment, the cross-blocking antibodies provided by the invention inhibit the binding of an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL57 (SEQ ID NO:10) to IL-17A or IL-17F or IL-17A/F by greater than 80%, 5 preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

In one embodiment, there is provided a neutralising antibody which binds to human IL-17A and human IL-17F, which cross-blocks the binding of an antibody whose heavy chain comprises the sequence gH9 (SEQ ID NO:11) and whose light chain comprises the sequence gL7 (SEQ ID 10 NO:9) to human IL-17A or to human IL-17F or human IL-17A/F heterodimer. In one embodiment, the cross-blocking antibodies provided by the invention inhibit the binding of an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL7 (SEQ ID NO:9) to IL-17A or IL-17F or IL-17A/F by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 15 95%.

Alternatively or in addition, neutralising antibodies according to this aspect of the invention may be cross-blocked from binding to human IL-17A and human IL-17F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL57 (SEQ ID NO:10). Also provided therefore is a neutralising antibody molecule which binds to human IL- 20 17A and to human IL-17F which is cross-blocked from binding human IL-17A and human IL-17F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL57 (SEQ ID NO:10). In one embodiment, the neutralising antibodies provided by this aspect of the invention are inhibited from binding to human IL-17A and human IL-17F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain 25 sequence gL57 (SEQ ID NO:10) by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

Alternatively or in addition, neutralising antibodies according to this aspect of the invention may be cross-blocked from binding to human IL-17A and human IL-17F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL7 (SEQ ID 30 NO:9). Also provided therefore is a neutralising antibody molecule which binds to human IL-

17A and to human IL-17F which is cross-blocked from binding human IL-17A and human IL-17F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL7 (SEQ ID NO:9). In one embodiment, the neutralising antibodies provided by this aspect of the invention are inhibited from binding to human IL-17A and human IL-17F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL7 (SEQ ID NO:9) by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

5 In another embodiment there is provided a neutralising antibody molecule which binds to human IL-17A and to human IL-17F which is cross-blocked from binding human IL-17A and human IL-17F and IL-17A/F heterodimer by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL57 (SEQ ID NO:10). In one embodiment, the neutralising antibodies provided by this aspect of the invention are inhibited from binding to human IL-17A and human IL-17F and human IL-17A/F heterodimer by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL57 (SEQ ID NO:10) by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

10 In another embodiment there is provided a neutralising antibody molecule which binds to human IL-17A and to human IL-17F which is cross-blocked from binding human IL-17A and human IL-17F and IL-17A/F heterodimer by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL7 (SEQ ID NO:9). In one embodiment, the neutralising antibodies provided by this aspect of the invention are inhibited from binding to human IL-17A and human IL-17F and human IL-17A/F heterodimer by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL7 (SEQ ID NO:9) by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

15 Also provided therefore is a neutralising antibody molecule which binds to human IL-17A and to human IL-17F which is cross-blocked from binding human IL-17A or human IL-17F or human IL-17A/F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL57 (SEQ ID NO:10). In one embodiment, the neutralising antibodies provided by this aspect of the invention are inhibited from binding to human IL-17A or human

IL-17F or human IL-17A/F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL57 (SEQ ID NO:10) by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

5 Also provided therefore is a neutralising antibody molecule which binds to human IL-17A and to human IL-17F which is cross-blocked from binding human IL-17A or human IL-17F or human IL-17A/F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL7 (SEQ ID NO:9). In one embodiment, the neutralising antibodies provided by this aspect of the invention are inhibited from binding to human IL-17A or human

10 IL-17F or human IL-17A/F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and the light chain sequence gL7 (SEQ ID NO:9) by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

#### Epitopes of IL-17A/17-F

15 Also provided by the invention is a specific region or epitope of human IL-17A and/or a specific region or epitope of human IL-17F and/or a specific region or epitope of human IL-17A/F heterodimer which is bound by an antibody provided by the invention, in particular an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:11) and/or the light chain sequence gL7 (SEQ ID NO:9) and/or the light chain sequence gL57 (SEQ ID NO:10). The sequences for

20 human IL-17A and human IL-17F are provided herein in Figure [1] (SEQ ID NOS: 27 and 28).

Examples of epitopes of the invention, and methods of determining those epitopes, are provided in Examples 5-7 of U.S. Patent No. 8,679,494 (April 23, 2008 priority date).

Any suitable method known in the art may be used to determine the residues bound by an antibody provided by the invention e.g. hydrogen-deuterium exchange, site-directed mutagenesis, mass spectrometry, NMR and X-ray crystallography. See for example the methods described in WO2007/149032.

The specific region or epitope of the human IL-17A polypeptide and/or the specific region or epitope of the human IL-17F polypeptide and /or the specific region or epitope of the human IL-17A/F heterodimer can be identified by any suitable epitope mapping method known in the art in

combination with any one of the antibodies provided by the invention. Examples of such methods include screening peptides of varying lengths derived from IL-17A and IL-17F for binding to the antibody of the invention with the smallest fragment that can specifically bind to the antibody containing the sequence of the epitope recognised by the antibody. The IL-17 peptides may be produced synthetically or by proteolytic digestion of the appropriate IL-17 polypeptide. Peptides that bind the antibody can be identified by, for example, mass spectrometric analysis. In another example, NMR spectroscopy can be used to identify the epitope bound by an antibody of the invention. In another example, NMR spectroscopy can be used to identify residues which interact with an antibody of the invention. Once identified, the epitopic fragment which binds an antibody of the invention can be used, if required, as an immunogen to obtain additional neutralising antibodies which bind the same epitope.

In one embodiment, the invention provides a neutralising epitope of IL-17A which comprises or consists of one or more of the residues selected from the group consisting of TYR44, ASN45, TRP51, ASN52 and ASP84 of human IL-17A (SEQ ID NO:27).

15 In one embodiment, the invention provides a neutralising epitope of IL-17A which comprises or consists of one or more of the residues selected from the group consisting of SER41, TYR44, ASN45, TRP51, ASN52, HIS54, ARG72, HIS73 and ASP84 of human IL-17A (SEQ ID NO:27).

20 In one embodiment, the invention provides a neutralising epitope of IL-17A which comprises or consists of one or more of the residues selected from the group consisting of SER41, TYR44, ASN45, ARG46, TRP51, ASN52, HIS54, ARG72, HIS73, ASP84, HIS86, VAL128, HIS129 and VAL131 of human IL-17A (SEQ ID NO:27).

25 In one embodiment, the invention provides a neutralising epitope of IL-17A which comprises one or more of the residues selected from the group consisting of TYR44, ASN45, TRP51, ASN52 and ASP84 of human IL-17A (SEQ ID NO:27) and optionally one or more of the residues selected from the group consisting of SER41, ARG46, HIS54, ARG72, HIS73, HIS86, VAL128, HIS129 and VAL131 of human IL-17A (SEQ ID NO:27).

30 In one embodiment, the invention provides a neutralising epitope of IL-17A which comprises amino acid residues TYR44, ASN45, TRP51, ASN52 and ASP84 of human IL-17A (SEQ ID NO:27) and optionally one or more of the residues selected from the group consisting of SER41,

ARG46, HIS54, ARG72, HIS73, HIS86, VAL128, HIS129 and VAL131 of human IL-17A (SEQ ID NO:27).

IL-17A is a dimer, and in various embodiments, the epitope bound by the antibody comprises one or more residues selected from the group consisting of ARG72, HIS73, ASP80, GLY81,

5 ASN82, ASP84, HIS86, VAL128, HIS129, and VAL131 (of SEQ ID NO: 27) from the first chain of the dimer, and one or more residues selected from the group consisting of SER41, TYR44, ASN45, ARG46, TRP51, ASN52, and HIS54 (e.g., selected from the group consisting of SER41, TYR44, ASN45, and ARG46) (of SEQ ID NO: 27) from the second chain of the dimer.

10 In various embodiments, the neutralizing antibody specifically binds an epitope of human IL-17A comprising or consisting of one or more of the residues L74, Y85, H73, N82 and R72, preferably L74 and Y85 of SEQ ID NO:27.

In various embodiments, the neutralizing antibody specifically binds an epitope of human IL-17A (e.g., the sequence of which is set forth in GenBank Accession No. Q16552) comprising or 15 consisting of one or more of the residues L74 and G75.

The invention also provides a novel neutralising epitope of human IL-17F (SEQ ID NO:28) which comprises or consists of one or more of the following residues: SER39, MET40, SER41, ARG42, ARG47, ASN53, ARG73, ASN74, LEU75, LYS83, GLU84, ASP85, ILE86, SER87, MET88, ASN89, VAL91, PRO92, GLN94, THR126, PRO127, VAL128.

20 The invention also provides a novel neutralising epitope of human IL-17F (SEQ ID NO:28) which comprises or consists of one or more of the following residues: SER39, MET40, SER41, ARG42, ARG47, ASN53, CYS72, ARG73, ASN74, LEU75, LYS83, GLU84, ASP85, ILE86, SER87, MET88, ASN89, SER90, VAL91, PRO92, GLN94, THR119, CYS122, VAL125, THR126, PRO127, VAL128.

25 In one embodiment, the neutralising epitope of human IL-17F (SEQ ID NO:28) comprises or consists of one or more of the following residues: SER39, MET40, SER41, ARG42, ARG47, ASN53, ARG73, ASN74, LEU75, LYS83, GLU84, ASP85, ILE86, SER87, MET88, ASN89, VAL91, PRO92, GLN94, THR126, PRO127, VAL128.

In one embodiment, the neutralising epitope of human IL-17F (SEQ ID NO:28) comprises or consists of (or further comprises or further consists of) one or more of the following residues: GLN71, CYS72, ILE86, ASN89, SER90 and VAL128, for example, from a first chain in an IL17F dimer.

5 In one embodiment, the neutralising epitope of human IL-17F (SEQ ID NO:28) comprises or consists of (or further comprises or further consists of) one or more of the following residues: ARG47, for example, from a second chain in an IL17F dimer.

In one embodiment, the neutralising epitope of human IL-17F (SEQ ID NO:28) comprises or consists of one or more of the following residues: GLN71, CYS72, ASN74, LEU75, ILE86,

10 ASN89, SER90, PRO92, VAL128, HIS131 and GLN133, for example, from a first chain in an IL17F dimer.

In one embodiment, the neutralising epitope of human IL-17F (SEQ ID NO:28) comprises or consists of (or further comprises or further consists of) one or more of the following residues: ARG37, SER39, SER41 and ARG47, for example, from a second chain in an IL17F dimer.

15 In one embodiment, the neutralising epitope of human IL-17F (SEQ ID NO:28) comprises or consists of one or more of the following residues: GLN71, CYS72, ARG73, ASN74, LEU75, ILE86, SER87 ASN89, SER90, VAL91, PRO92, VAL128, HIS131 and GLN133, for example, from a first chain in an IL17F dimer.

20 In one embodiment, the neutralising epitope of human IL-17F (SEQ ID NO:28) comprises or consists of (or further comprises or further consists of) one or more of the following residues: ASN33, GLN36, ARG37, SER39, SER41, ARG42, ILE44 and ARG47, for example, from a second chain in an IL17F dimer.

25 In one embodiment, the neutralising epitope of human IL-17F (SEQ ID NO:28) comprises or consists of one or more of the following residues: GLN12, LYS13, SER24, ISO32, ASN33 GLU34, ASN35, GLN36, VAL38, SER46, ASN53, TYR54, GLN69, ISO78, ASP85, SER87, MET88, ASM89, GLN94, LYS103 and THR126.

In one embodiment, the neutralising epitope of human IL-17F (SEQ ID NO:28) comprises or consists of one or more of the following residues: GLN12, SER24, ASN33, GLU34, GLN36, VAL38, ASN53, TYR54, ASP85, MET88, ASM89, and THR126.

In one embodiment, the neutralising epitope of human IL-17F (SEQ ID NO:28) comprises or consists of one or more of the following residues: GLN12, SER24, ASN33, GLU34, ASP85 and MET88.

5 In one embodiment, the neutralising epitope of human IL-17F (SEQ ID NO:28) comprises or consists of amino acids V33 to V38 inclusive.

In one embodiment, the neutralising epitope of human IL-17F (SEQ ID NO:28) comprises or consists of amino acids V87 to Q94 inclusive.

In one embodiment, the neutralising epitope of IL-17F (SEQ ID NO:28) further comprises one or more of the following residues: ILE129, HIS130, H131, V132, Q133.

10 In one embodiment, there is provided one or more neutralising epitopes of human IL-17F (SEQ ID NO:28) that each independently comprise or consist of amino acids V33 to V38 inclusive and/or V87 to Q94 inclusive.

In various embodiments, the antibody specifically binds an epitope of human IL-17F comprising or consisting of R73, I86, N89, and R47 of SEQ ID NO: 28.

15 In various embodiments, the neutralizing antibody specifically binds an epitope of human IL-17F (e.g., the sequence of which is set forth in GenBank Accession No. Q96PD4) comprising or consisting of one or more of the residues L75 and G76.

In various embodiments, the antibody specifically binds an epitope of human IL-17F comprising or consisting of S39, S41, N89, C72, N74, L75, S90, V91, P92, V198 of SEQ ID NO: 28.

20 In various embodiments, the epitope bound by the antibody comprises one or more residues selected from the group consisting of GLN71, CYS72, ARG73, ASN74, LEU75, ILE86, SER87, ASN89, SER90, VAL91, PRO92, VAL128, HIS131, and GLN133 (of SEQ ID NO: 28) from the first chain of the dimer, and one or more residues selected from the group consisting of ASN33, GLN36, ARG37, SER39, SER41, ARG42, ILE44, ARG47 (of SEQ ID NO: 28) from the second chain of the dimer.

25 In one embodiment, the epitope is defined as amino acid residues located within 4 Angstroms, 3.5 Angstroms, or 3.0 Angstroms of a binding entity, such as an antibody or fragment.

The invention also provides epitopic fragments of IL-17A that can be used, if required, as an immunogen to obtain neutralising antibodies which bind to the neutralising epitope of IL-17A. For example, epitopic fragments comprising one or more of the amino acid residues of IL-17A provided herein above may be used as an immunogen.

5 The invention also provides epitopic fragments of IL-17F that can be used, if required, as an immunogen to obtain neutralising antibodies which bind to the neutralising epitope of IL-17F. For example, epitopic fragments comprising one or more of the amino acid residues of IL-17F provided herein above may be used as an immunogen.

10 The invention also provides antibodies which bind to, and/or interact with, a neutralising epitope provided by the invention. It will be appreciated that an antibody can interact directly or indirectly with an epitope of the invention, e.g. by direct binding or by allosteric interaction.

In one embodiment, the invention provides antibodies which bind to, and/or interact with, a neutralising epitope of IL-17A provided by the invention.

15 Accordingly, in one embodiment, the invention provides a neutralising antibody which binds human IL-17A and human IL-17F that binds to, and/or interacts with, an epitope of human IL-17A comprising or consisting of one or more of the residues selected from the group consisting of TYR44, ASN45, TRP51, ASN52 and ASP84 of human IL-17A (SEQ ID NO:27).

20 In one embodiment, the invention provides a neutralising antibody which binds human IL-17A and human IL-17F that binds to an epitope of human IL-17A comprising ASN52 of human IL-17A (SEQ ID NO:27).

In one embodiment, the invention provides a neutralising antibody which binds human IL-17A and human IL-17F that binds to an epitope of human IL-17A comprising ASN52 and ASP84 of human IL-17A (SEQ ID NO:27).

25 In one embodiment, the invention provides a neutralising antibody which binds human IL-17A and human IL-17F that binds to an epitope of human IL-17A comprising ARG46 and HIS54 of human IL-17A (SEQ ID NO:27).

In one embodiment, the invention provides a neutralising antibody which binds human IL-17A and human IL-17F that binds to an epitope of human IL-17A which comprises or consists of one

or more of the residues selected from the group consisting of SER41, ASN52, ARG72, HIS73 and ASP84 of human IL-17A (SEQ ID NO:27).

In one embodiment, the invention provides a neutralising antibody which binds human IL-17A and human IL-17F that binds to an epitope of human IL-17A which comprises or consists of one or more of the residues selected from the group consisting of SER41, TYR44, ASN45, ARG46, TRP51, ASN52, HIS54, ARG72, HIS73, ASP84, HIS86, VAL128, HIS129 and VAL131 of human IL-17A (SEQ ID NO:27).

In one embodiment, the invention provides antibodies which bind to, and/or interact with, a neutralising epitope of IL-17F provided by the invention.

10 Accordingly, in one embodiment, the invention provides a neutralising antibody which binds human IL-17F that binds to an epitope of human IL-17F comprising one or more of the following residues: SER39, MET40, SER41, ARG42, ARG47, ASN53, ARG73, ASN74, LEU75, LYS83, GLU84, ASP85, ILE86, SER87, MET88, ASN89, SER90, VAL91, PRO92, GLN94, THR126, PRO127, VAL128 of IL-17F (SEQ ID NO:28).

15 In one embodiment, the invention provides a neutralising antibody which binds human IL-17F that binds to an epitope of human IL-17F within one or more of the following regions: (i) 39-42 (SER39, MET40, SER41, ARG42) (ii) 47 (ARG47) (iii) 53 (ASN53) (iv) 72-75 (CYS72, ARG73, ASN74, LEU75) (v) 83-92 (LYS83, GLU84, ASP85, ILE86, SER87, MET88, ASN89, SER90, VAL91, PRO92) (vi) 94 (GLN94) (vii) 119 (THR119) (viii) 122 (CYS122) (ix) 125-128 (VAL125, THR126, PRO127, VAL128).

20 In one embodiment, an antibody of the invention binds human IL-17A and human IL-17F. In one embodiment, an antibody of the invention binds human IL-17A/F heterodimer. In one embodiment, an antibody of the invention binds human IL-17A and human IL-17A/F heterodimer. In one embodiment, an antibody of the invention binds human IL-17F and human IL-17A/F heterodimer. In a preferred embodiment, an antibody of the invention binds human IL-17A, human IL-17F and human IL-17A/F heterodimer.

25 In one embodiment, the invention provides a neutralising antibody which binds human IL-17A and IL-17F that binds to an epitope of human IL-17F within one or more of the following regions: (i) 39-42 (SER39, MET40, SER41, ARG42) (ii) 47 (ARG47) (iii) 53 (ASN53) (iv) 72-

75 (CYS72, ARG73, ASN74, LEU75) (v) 83-92 (LYS83, GLU84, ASP85, ILE86, SER87, MET88, ASN89, SER90, VAL91, PRO92) (vi) 94 (GLN94) (vii) 119 (THR119) (viii) 122 (CYS 122) (ix) 125-128 (VAL125, THR126, PRO127, VAL128).

Accordingly, in one embodiment, the invention provides a neutralising antibody which binds 5 human IL-17A and human IL-17F that binds to, and/or interacts with, an epitope of human IL-17F comprising or consisting of one or more of the residues selected from the group consisting of SER39, MET40, SER41, ARG42, ARG47, ASN53, ARG73, ASN74, LEU75, LYS83, GLU84, ASP85, ILE86, SER87, MET88, ASN89, SER90, VAL91, PRO92, GLN94, THR126, PRO127, VAL128 of SEQ ID NO:28 (IL-17F).

10 In one embodiment, the invention provides a neutralising antibody which binds human IL-17A and human IL-17F that binds, and/or interacts with, an epitope of human IL-17A which comprises or consists of one or more of the residues selected from the group consisting of SER41, TYR44, ASN45, ARG46, TRP51, ASN52, HIS54, ARG72, HIS73, ASP84, HIS86, VAL128, HIS129 and VAL131 of human IL-17A (SEQ ID NO:27) and binds to, and/or interacts 15 with, an epitope of human IL-17F comprising or consisting of one or more of the residues selected from the group consisting of SER39, MET40, SER41, ARG42, ARG47, ASN53, ARG73, ASN74, LEU75, LYS83, GLU84, ASP85, ILE86, SER87, MET88, ASN89, SER90, VAL91, PRO92, GLN94, THR126, PRO127, VAL128 of SEQ ID NO:28 (IL-17F).

20 In one embodiment, the invention provides a neutralising antibody which binds human IL-17A and human IL-17F that binds to, and/or interacts with, an epitope of human IL-17F comprising or consisting of one or more of the residues selected from the group consisting of SER39, SER41, ASN74, LEU75, ASN89, SER90, VAL91, PRO92 and VAL128 of SEQ ID NO:28 (IL-17F).

25 Accordingly, in one embodiment, the invention provides a neutralising antibody which binds human IL-17A and human IL-17F that binds to, and/or interacts with, an epitope of human IL-17F comprising or consisting of one or more of the residues selected from the group consisting of ARG47, ARG73, LEU75 and ILE86 of SEQ ID NO:28 (IL-17F).

30 Accordingly, in one embodiment, the invention provides a neutralising antibody which binds human IL-17A and human IL-17F that binds to, and/or interacts with, an epitope of human IL-17F comprising LEU75 of SEQ ID NO:28 (IL-17F).

### Isolated DNA Sequences of Antibodies

The invention also provides an isolated DNA comprising a nucleic acid sequence encoding the heavy and/or light chain(s) of an antibody molecule of the invention. Preferably, the DNA sequence encodes the heavy or the light chain of an antibody molecule of the invention.

5 DNA of the invention may comprise synthetic DNA, for instance produced by chemical processing, cDNA, genomic DNA or any combination thereof.

DNA comprising nucleic acid sequences which encode an antibody molecule of the invention can be obtained by methods well known to those skilled in the art. For example, DNA comprising nucleic acid sequences coding for part or all of the antibody heavy and light chains

10 may be synthesised as desired from the determined DNA sequences or on the basis of the corresponding amino acid sequences.

DNA coding for acceptor framework sequences is widely available to those skilled in the art and can be readily synthesised on the basis of their known amino acid sequences.

Standard techniques of molecular biology may be used to prepare DNA sequences coding for the 15 antibody molecule of the invention. Desired DNA sequences may be synthesised completely or in part using oligonucleotide synthesis techniques. Site-directed mutagenesis and polymerase chain reaction (PCR) techniques may be used as appropriate.

Examples of suitable sequences are provided in SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; and 20 SEQ ID NO:26. The invention also relates to a cloning or expression vector comprising one or more DNA sequences of the invention. Accordingly, the invention provides a cloning or expression vector comprising one or more DNA sequences encoding an antibody of the invention. Preferably, the cloning or expression vector comprises two DNA sequences, encoding the light chain and the heavy chain of the antibody molecule of the invention, respectively, along 25 with suitable signal sequences. Preferably, a vector according to the invention comprises the sequences given in SEQ ID NO:21 and SEQ ID NO:24. In one embodiment, a vector according to the invention comprises the sequences given in SEQ ID NO:21 and SEQ ID NO:24.

General methods by which the vectors may be constructed, transfection methods and culture methods are well known to those skilled in the art. In this respect, reference is made to "Current

Protocols in Molecular Biology", 1999, F. M. Ausubel (ed), Wiley Interscience, New York and the Maniatis Manual produced by Cold Spring Harbor Publishing.

Also the invention provides a host cell comprising one or more cloning or expression vectors comprising one or more DNA sequences encoding an antibody of the invention. Any suitable

5 host cell/vector system may be used for expression of the DNA sequences encoding the antibody molecule of the invention. Bacterial, for example *E. coli*, and other microbial systems may be used or eukaryotic, for example mammalian, host cell expression systems may also be used. Suitable mammalian host cells include CHO, myeloma or hybridoma cells.

The invention also provides a process for the production of an antibody molecule according to

10 the invention comprising culturing a host cell containing a vector of the invention under conditions suitable for leading to expression of protein from DNA encoding the antibody molecule of the invention, and isolating the antibody molecule.

The antibody molecule may comprise only a heavy or light chain polypeptide, in which case only a heavy chain or light chain polypeptide coding sequence needs to be used to transfect the host

15 cells. For production of products comprising both heavy and light chains, the cell line may be transfected with two vectors, a first vector encoding a light chain polypeptide and a second vector encoding a heavy chain polypeptide. Alternatively, a single vector may be used, the vector including sequences encoding light chain and heavy chain polypeptides.

#### Conjugation with Effector Molecules

20 If desired, an antibody for use in the invention may be conjugated to one or more effector molecule(s). It will be appreciated that the effector molecule may comprise a single effector molecule or two or more such molecules so linked as to form a single moiety that can be attached to the antibodies of the invention. Where it is desired to obtain an antibody fragment linked to an effector molecule, this may be prepared by standard chemical or recombinant DNA procedures

25 in which the antibody fragment is linked either directly or via a coupling agent to the effector molecule. Techniques for conjugating such effector molecules to antibodies are well known in the art (see, Hellstrom et al., Controlled Drug Delivery, 2nd Ed., Robinson et al., eds., 1987, pp. 623-53; Thorpe et al., 1982, Immunol. Rev., 62:119-58 and Dubowchik et al., 1999, Pharmacology and Therapeutics, 83, 67-123). Particular chemical procedures include, for

example, those described in WO 93/06231, WO 92/22583, WO 89/00195, WO 89/01476 and WO03031581. Alternatively, where the effector molecule is a protein or polypeptide the linkage may be achieved using recombinant DNA procedures, for example as described in WO 86/01533 and EP0392745.

5 The term effector molecule as used herein includes, for example, antineoplastic agents, drugs, toxins, biologically active proteins, for example enzymes, other antibody or antibody fragments, synthetic or naturally occurring polymers, nucleic acids and fragments thereof, e.g., DNA, RNA and fragments thereof, radionuclides, particularly radioiodide, radioisotopes, chelated metals, nanoparticles and reporter groups such as fluorescent compounds or compounds which may be  
10 detected by NMR or ESR spectroscopy.

Examples of effector molecules may include cytotoxins or cytotoxic agents including any agent that is detrimental to (e.g. kills) cells. Examples include combrestatins, dolastatins, epothilones, staurosporin, maytansinoids, spongistatins, rhizoxin, halichondrins, roridins, hemiasterlins, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide,  
15 vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof.

Effector molecules also include, but are not limited to, antimetabolites (e.g. methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g.  
20 mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g. daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g. dactinomycin (formerly actinomycin), bleomycin, mithramycin, anthramycin (AMC), calicheamicins or duocarmycins), and anti-mitotic agents (e.g. vincristine and vinblastine).  
25

Other effector molecules may include chelated radionuclides such as  $^{111}\text{In}$  and  $^{90}\text{Y}$ ,  $\text{Lu}^{177}$ , Bismuth $^{213}$ , Californium $^{252}$ , Iridium $^{192}$  and Tungsten $^{188}$ /Rhenium $^{188}$ ; or drugs such as but not limited to, alkylphosphocholines, topoisomerase I inhibitors, taxoids and suramin.

Other effector molecules include proteins, peptides and enzymes. Enzymes of interest include,  
30 but are not limited to, proteolytic enzymes, hydrolases, lyases, isomerases, transferases. Proteins,

polypeptides and peptides of interest include, but are not limited to, immunoglobulins, toxins such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin, a protein such as insulin, tumour necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor or tissue plasminogen activator, a thrombotic agent or an anti-angiogenic agent, e.g., 5 angiostatin or endostatin, or, a biological response modifier such as a lymphokine, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), nerve growth factor (NGF) or other growth factor and immunoglobulins.

Other effector molecules may include detectable substances useful for example in diagnosis.

10 Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive nuclides, positron emitting metals (for use in positron emission tomography), and nonradioactive paramagnetic metal ions. See generally U.S. Pat. No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics. Suitable enzymes include horseradish peroxidase, alkaline 15 phosphatase, beta-galactosidase, or acetylcholinesterase; suitable prosthetic groups include streptavidin, avidin and biotin; suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride and phycoerythrin; suitable luminescent materials include luminol; suitable bioluminescent materials include luciferase, luciferin, and aequorin; and suitable radioactive nuclides include  $^{125}\text{I}$ ,  $^{131}\text{I}$ , 20  $^{111}\text{In}$  and  $^{99}\text{Tc}$ .

In another example the effector molecule may increase the half-life of the antibody *in vivo*, and/or reduce immunogenicity of the antibody and/or enhance the delivery of an antibody across an epithelial barrier to the immune system. Examples of suitable effector molecules of this type include polymers, albumin, albumin binding proteins, or albumin binding compounds, such as 25 those described in WO05/117984.

Where the effector molecule is a polymer it may, in general, be a synthetic or a naturally occurring polymer, for example an optionally substituted straight or branched chain polyalkylene, polyalkenylene or polyoxyalkylene polymer or a branched or unbranched polysaccharide, e.g., a homo- or hetero-polysaccharide.

Particular optional substituents which may be present on the above-mentioned synthetic polymers include one or more hydroxy, methyl or methoxy groups.

Particular examples of synthetic polymers include optionally substituted straight or branched chain poly(ethyleneglycol), poly(propyleneglycol) poly(vinylalcohol) or derivatives thereof, 5 especially optionally substituted poly(ethyleneglycol) such as methoxypoly(ethyleneglycol) or derivatives thereof.

Particular naturally occurring polymers include lactose, amylose, dextran, glycogen or derivatives thereof.

“Derivatives” as used herein is intended to include reactive derivatives, for example thiol-10 selective reactive groups such as maleimides and the like. The reactive group may be linked directly or through a linker segment to the polymer. It will be appreciated that the residue of such a group will in some instances form part of the product as the linking group between the antibody fragment and the polymer.

The size of the polymer may be varied as desired, but will generally be in an average molecular 15 weight range from 500 Da to 50000 Da, preferably from 5000 to 40000 Da and more preferably from 20000 to 40000 Da. The polymer size may in particular be selected on the basis of the intended use of the product for example ability to localize to certain tissues such as tumors or extend circulating half-life (for review see Chapman, 2002, Advanced Drug Delivery Reviews, 54, 531-545). Thus, for example, where the product is intended to leave the circulation and 20 penetrate tissue, for example for use in the treatment of a tumour, it may be advantageous to use a small molecular weight polymer, for example with a molecular weight of around 5000 Da. For applications where the product remains in the circulation, it may be advantageous to use a higher molecular weight polymer, for example having a molecular weight in the range from 20000 Da to 40000 Da.

25 Particularly preferred polymers include a polyalkylene polymer, such as a poly(ethyleneglycol) or, especially, a methoxypoly(ethyleneglycol) or a derivative thereof, and especially with a molecular weight in the range from about 15000 Da to about 40000 Da.

In one example, antibodies for use in the invention are attached to poly(ethyleneglycol) (PEG) moieties. In one particular example the antibody is an antibody fragment and the PEG molecules

may be attached through any available amino acid side-chain or terminal amino acid functional group located in the antibody fragment, for example any free amino, imino, thiol, hydroxyl or carboxyl group. Such amino acids may occur naturally in the antibody fragment or may be engineered into the fragment using recombinant DNA methods (see for example U.S. Pat. No.

5 5,219,996; U.S. Pat. No. 5,667,425; WO98/25971). In one example, the antibody molecule of the invention is a modified Fab fragment wherein the modification is the addition to the C-terminal end of its heavy chain one or more amino acids to allow the attachment of an effector molecule. Preferably, the additional amino acids form a modified hinge region containing one or more cysteine residues to which the effector molecule may be attached. Multiple sites can be used to  
10 attach two or more PEG molecules.

Preferably PEG molecules are covalently linked through a thiol group of at least one cysteine residue located in the antibody fragment. Each polymer molecule attached to the modified antibody fragment may be covalently linked to the sulphur atom of a cysteine residue located in the fragment. The covalent linkage will generally be a disulphide bond or, in particular, a  
15 sulphur-carbon bond. Where a thiol group is used as the point of attachment appropriately activated effector molecules, for example thiol selective derivatives such as maleimides and cysteine derivatives may be used. An activated polymer may be used as the starting material in the preparation of polymer-modified antibody fragments as described above. The activated polymer may be any polymer containing a thiol reactive group such as an  $\alpha$ -halocarboxylic acid  
20 or ester, e.g. iodoacetamide, an imide, e.g., maleimide, a vinyl sulphone or a disulphide. Such starting materials may be obtained commercially (for example from Nektar, formerly Shearwater Polymers Inc., Huntsville, Ala., USA) or may be prepared from commercially available starting materials using conventional chemical procedures. Particular PEG molecules include 20K  
25 methoxy-PEG-amine (obtainable from Nektar, formerly Shearwater; Rapp Polymere; and SunBio) and M-PEG-SPA (obtainable from Nektar, formerly Shearwater).

In one embodiment, the antibody is a modified Fab fragment which is PEGylated, i.e., has PEG (poly(ethyleneglycol)) covalently attached thereto, e.g. according to the method disclosed in EP 0948544 [see also "Poly(ethyleneglycol) Chemistry, Biotechnical and Biomedical Applications", 1992, J. Milton Harris (ed), Plenum Press, New York, "Poly(ethyleneglycol) Chemistry and  
30 Biological Applications", 1997, J. Milton Harris and S. Zalipsky (eds), American Chemical Society, Washington D.C. and "Bioconjugation Protein Coupling Techniques for the Biomedical

Sciences", 1998, M. Aslam and A. Dent, Grove Publishers, New York; Chapman, A. 2002, Advanced Drug Delivery Reviews 2002, 54:531-545]. In one example, PEG is attached to a cysteine in the hinge region. In one example, a PEG modified Fab fragment has a maleimide group covalently linked to a single thiol group in a modified hinge region. A lysine residue may 5 be covalently linked to the maleimide group and to each of the amine groups on the lysine residue may be attached a methoxypoly (ethyleneglycol) polymer having a molecular weight of approximately 20,000 Da. The total molecular weight of the PEG attached to the Fab fragment may therefore be approximately 40,000 Da.

In one embodiment, a neutralising antibody molecule of the invention is a modified Fab 10 fragment having at the C-terminal end of its heavy chain a modified hinge region containing at least one cysteine residue to which an effector molecule is attached. In one embodiment, the invention provides a neutralising antibody molecule having specificity for human IL-17A and human IL-17F, which is a modified Fab fragment having a heavy chain comprising the sequence given in SEQ ID NO:11 and a light chain comprising the sequence given in SEQ ID NO:9 or the 15 sequence given in SEQ ID NO:10 and having at the C-terminal end of its heavy chain a modified hinge region containing at least one cysteine residue to which an effector molecule is attached. Preferably the effector molecule is PEG and is attached using the methods described in (WO98/25971 and WO2004072116) whereby a lysyl-maleimide group is attached to the cysteine residue at the C-terminal end of the heavy chain, and each amino group of the lysyl residue has 20 covalently linked to it a methoxypoly(ethyleneglycol) residue having a molecular weight of about 20,000 Da. The total molecular weight of the PEG attached to the antibody is therefore approximately 40,000 Da.

In another example effector molecules may be attached to antibody fragments using the methods described in International patent applications WO2005/003169, WO2005/003170 and 25 WO2005/003171.

#### Pharmaceutical Compositions, Administration Regimens

As the antibodies of the invention are useful in the treatment and/or prophylaxis of a pathological condition, the invention also provides a pharmaceutical or diagnostic composition comprising an antibody molecule of the invention in combination with one or more of a pharmaceutically

acceptable excipient, diluent or carrier. Accordingly, provided is the use of an antibody according to the invention for the manufacture of a medicament. The composition will usually be supplied as part of a sterile, pharmaceutical composition that will normally include a pharmaceutically acceptable carrier. A pharmaceutical composition of the invention may 5 additionally comprise a pharmaceutically-acceptable adjuvant.

The invention also provides a process for preparation of a pharmaceutical or diagnostic composition comprising adding and mixing the antibody molecule of the invention together with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

10 The antibody molecule may be the sole active ingredient in the pharmaceutical or diagnostic composition or may be accompanied by other active ingredients including other antibody ingredients, for example, anti-TNF, anti-IL-1 $\beta$ , anti-T cell, anti-IFN $\gamma$  or anti-LPS antibodies, or non-antibody ingredients such as xanthines or a small molecule inhibitor.

15 The pharmaceutical compositions preferably comprise a therapeutically effective amount of the antibody of the invention. The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate or prevent a targeted disease or condition, or to exhibit a detectable therapeutic or preventative effect.

20 The precise therapeutically effective amount for a human subject will depend upon the severity of the disease state, the general health of the subject, the age, weight and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgment of the clinician. Generally, a therapeutically effective amount will be from 0.01 mg/kg to 50 mg/kg, preferably 0.1 mg/kg to 20 mg/kg (e.g., 5 mg/kg to 10 mg/kg, such as about 8 mg/kg). Pharmaceutical compositions may be conveniently presented in unit dose forms containing a predetermined amount of an active agent of the invention per dose. Unit doses may 25 range from 10 mg to 1,000 mg (e.g., between 80 mg and 720 mg, between 100 mg and 680 mg or between 160 mg and 640 mg), preferably 8 mg, 16 mg, 32 mg, 40 mg, 80 mg, 160 mg, 240 mg, 320 mg, 480 mg, 560 mg, and 640 mg.

30 In various embodiments of methods of treating psoriasis, such as plaque psoriasis, the amount of neutralizing antibody administered to the subject is an amount that achieves at least a 50% change, at least a 60% change, at least a 75% change (e.g., at least an 80% change, at least an

85% change, at least a 90% change, or at least a 95% change) in lesion severity score (LSS) compared to pre-treatment (i.e., LSS prior to administration of the neutralizing antibody) at two, four, six, or eight weeks following administration of the antibody. Alternatively or in addition, the amount of neutralizing antibody administered is an amount that achieves at least a 50% 5 change, at least a 60% change, at least a 75% change (e.g., at least an 80% change, at least an 85% change, at least a 90% change, or at least a 95% change) in Psoriasis Area and Severity Index (PASI) compared to pre-treatment at two, four, six, or eight weeks following administration of the antibody. Alternatively or in addition the amount of neutralising antibody is an amount that achieves at least a 50% change, a 60% change, a 75% change (e.g., an 80% 10 change, an 85% change, a 90% change, or a 95% change) in PASI compared to pre-treatment at two, four, six or eight weeks following administration of the antibody and which maintains or increases the change in PASI response for an additional two, four, six, eight, ten, twelve, fourteen, sixteen, eighteen, twenty or more weeks following administration of the antibody. Optionally, the amount of neutralizing antibody is an amount that achieves at least a 50% 15 change, a 60% change, a 75% change (e.g., an 80% change, an 85% change, a 90% change, or a 95% change) in PASI compared to pre-treatment at two, four, six or eight weeks following administration of the antibody, and the PASI score does not change more than 5%, more than 10%, more than 20%, more than 25%, more than 30%, more than 35%, or more than 40% toward baseline (pre-treatment level) for an additional two, four, six, eight, ten, twelve, fourteen, 20 sixteen, eighteen, twenty or more weeks following administration of the antibody.

An alternative means of evaluating treatment of psoriasis is the Physician's Global Assessment score. The PGA scoring system is based on lesion erythema, induration, and scale, with score assignments that range from clear to severe, typically using a 5 or 6-level scale See, e.g., Langley et al., J Am Acad Dermatol. 2004;51(4):563-569. In various aspects, the method of treating 25 psoriasis described herein results in a reduction of PGA score of at least 20%, at least 50%, or at least 70% from baseline at week 2, week 6, week 8, and/or week 12 following administration.

In various embodiments concerning treatment of psoriatic arthritis, the amount of neutralizing antibody administered to the subject is an amount that achieves (i) at least a 50% change, at least a 60% change, at least a 75% change (e.g., at least an 80% change, at least an 85% change, at 30 least a 90% change, or at least a 95% change) in lesion severity score (LSS) compared to pre-treatment (i.e., LSS prior to administration of the neutralizing antibody) at two, four, six, or eight

weeks following administration of the antibody and/or (ii) at least a 50% change, at least a 60% change, at least a 75% change (e.g., at least an 80% change, at least an 85% change, at least a 90% change, or at least a 95% change) in Psoriasis Area and Severity Index (PASI) compared to pre-treatment at two, four, six, or eight weeks following administration of the antibody and/or

5 (iii) at least a 20% change, at least a 30%, at least a 50%, at least 60% or at least a 70% change in American College of Rheumatology (“ACR”) response compared to pre-treatment at two, four, six, or eight weeks following administration of the antibody. Alternatively or in addition, the amount of neutralising antibody is an amount that achieves the aforementioned changes in LSS, PASI, and/or ACR scores at two, four, six or eight weeks following administration of the

10 antibody and maintains or increases the change in LSS, PASI, and/or ACR response for an additional two, four, six, eight, ten, twelve, fourteen, sixteen, eighteen, twenty or more weeks following administration of the antibody. Optionally, the amount of neutralizing antibody is an amount that achieves the aforementioned change in LSS, PASI, and/or ACR score at two, four, six or eight weeks following administration of the antibody, and the LSS, PASI, and/or ACR

15 score does not change more than 5%, more than 10%, more than 20%, more than 25%, more than 30%, more than 35%, or more than 40% toward baseline (pre-treatment level) for an additional two, four, six, eight, ten, twelve, fourteen, sixteen, eighteen, twenty or more weeks following administration of the antibody.

CA028\_0496.g3 has been tested in patients following single intravenous dose administration

20 over the dose range of 8 mg to 640 mg. CA028\_0496.g3 has also been tested as a repeat dose administration with different dosing regimens involving a loading dose followed by maintenance doses at weeks 3 and 6. A multiple dose regimen without a loading dose also is contemplated as part of the invention.

It will be appreciated that a suitable dosage regimen for any given anti-IL-17A/F antibody may

25 be designed using PK and PD (efficacy) information determined for the antibody, as described in the Examples herein for CA028\_0496.g3 (bimekizumab). Typically a dosing regimen for use in the present invention will provide a mean trough level of between around 1 and 50 micro g/ml following single or multiple dose (steady state), for example a mean trough level of greater than 10 micro g/ml.

Potential dose ranges and regimens for any of the embodiments described herein include, but are not limited to, dosages ranging from 10 mg – 1000 mg unit doses (e.g., 8 mg, 16 mg, 32 mg, 40 mg, 64 mg, 80 mg, 160 mg, 240 mg, 320 mg, 480 mg, 560 mg, or 640 mg), given every 1-10 weeks (by any route of administration, such as by as either a subcutaneous or intravenous administration). Optionally, a dose of neutralizing antibody is administered every 1-20 weeks, for example every 2 weeks, every 3 weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, or every 8-12 weeks (e.g., every 8 weeks, every 9 weeks, every 10 weeks, every 11 weeks, or every 12 weeks). The treatment period (i.e., the period of time during which one or more doses of antibody are administered to a subject) may comprise at least two weeks, at least 10 four weeks, at least eight weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, at least 24 weeks, at least 30 weeks, at least 36 weeks, at least 40 weeks, at least 44 weeks, at least 48 weeks, at least 52 weeks, or more. Any suitable number of doses may be administered within the treatment period, such as the doses and time between administrations described above. For example, one, two, three, or four doses of antibody are administered to a subject over, e.g., a 12 week treatment period (optionally at week 0, week 4, week 8, and week 12). In one exemplary embodiment, the method comprises administering 320 mg of antibody to a subject every four weeks for at least twelve weeks. In one exemplary embodiment, the method comprises administering 160 mg of antibody to a subject every four weeks for at least twelve weeks. In one example the method comprises administering 160mg, 240mg or 320mg every four weeks. In one 20 example the method comprises a 320mg loading dose followed by a maintenance dose of 160mg or 240mg every four weeks. It will be appreciated that the doses may be given at these intervals for a first treatment period, then given at a different interval for a second treatment period (e.g., administered every four or eight weeks for a first treatment period of, for example, 12 or 16 or 20 weeks, then administered every eight, 12, or 16 weeks for a second treatment period lasting an 25 additional, e.g., 24 or 36 weeks or more).

In some examples of the invention the dosage regimen used in an intial treatment period, such as the first 12 or 16 or 24 weeks of treatment, may be considered an ‘induction period’, after which a different regimen, such as a maintenance regimen, may be used in which typically a lower dosage or reduced frequency of dosing may be used.

30 In some instances it may be possible to reduce the dosing frequency and/or dose once a certain level of efficacy has been achieved. For example, in the method of treating psoriasis of the

present invention, at week 12 or week 16 or week 24 the dosing frequency and/or dose may be changed if the subject has achieved a PASI 75 or PASI 90. For example, in the method of treating psoriatic arthritis of the present invention, at week 12 or week 16 or week 24 the dosing frequency and/or dose may be changed if the patient has achieved an ACR50. For example, in

5 the method of treating ankylosing spondylitis or nr-axSpa of the present invention, at week 12 or week 16 or week 24 the dosing frequency and/or dose may be changed if the patient has achieved an ASAS40. Similarly in each of these examples, if at week 12 or week 16 or week 20 or week 24, the subject has not achieved a desired clinical score, the dose and/or dosing frequency may be increased.

10 In various embodiments, including embodiments comprising treating psoriasis in a subject, an initial dose of antibody is administered then a subsequent dose of neutralizing antibody (such as CA028\_0496.g3) is administered 8-20 weeks (e.g., 8 weeks, 12 weeks, 16 weeks, or 20 weeks) after an initial administration. The subsequent dose may be the same as the initial dose, an increased amount of neutralizing antibody, or a decreased amount of neutralizing antibody (i.e., a

15 maintenance dose). Dosing with a neutralizing antibody described herein (e.g., CA028\_0496.g3 (Bimekizumab)) demonstrated rapid onset and remarkable, prolonged beneficial effect in humans, such as humans suffering from psoriasis and psoriatic arthritis. For example, a single administration of doses of 160 mg or more (e.g., 160 mg, 480 mg, and 640 mg) achieved clinically relevant and statistically significant differences from placebo in lesion severity score

20 (LSS) and psoriasis area and severity index (PASI) from week 2, with near-maximal improvements achieved by about four to six weeks post-administration, which were maintained until around 16-20 weeks post-administration. In the 480 mg and 640 mg dose groups, on average 83% of patients experienced PASI 90 from weeks 6-12 and 90% at week 12. In subjects suffering from psoriatic arthritis, clinically relevant responses in disease activity measures were

25 observed at 20 weeks following initial administration of neutralizing antibody (followed by two maintenance doses as described in Example 1).

An exemplary method of treating psoriatic arthritis provided by the disclosure comprises administering to a subject an antibody described herein using any one of the following dosage regimens: 16 mg every four weeks, 160 mg every four weeks, 320 mg loading dose at week 0 followed by a maintenance dose of 160 mg every four weeks, and 320 mg every four weeks. In one example, the method of treating psoriatic arthritis provided by the disclosure comprises

administering to a subject an antibody described herein using any one of the following dosage regimens: 160 mg every four weeks, 320mg every four weeks, 320 mg loading dose at week 0 followed by a maintenance dose of 160 mg every four weeks or 320mg loading dose at week 0 followed by a maintenance dose of 240mg every four weeks. The treatment period can

5 comprise, e.g., 12 weeks (for a total of at least three or four administrations of antibody), 16 weeks, 24 weeks, or 48 weeks, or more. It will be appreciated that the doses may be given at these intervals for a first treatment period, then given at a different interval for a second treatment period (e.g., administered every four or eight weeks for a first treatment period of, for example, 12 or 16 or 20 weeks, then administered every eight, 12, or 16 weeks for a second

10 treatment period lasting an additional, e.g., 24 or 36 weeks or more). For example, the dosage regimen, such as the dosing frequency, may change after a period of time, such that in one example the antibody is administered using a dosage regimen of 160mg every four weeks until week 12, week 16 or week 24 followed by 160mg every eight weeks, starting at week 20, week 24 or week 32 respectively. In one example the antibody is administered using a dosage

15 regimen of 320mg every four weeks until week 12, week 16 or week 24 followed by 320mg every eight weeks starting at week 20, week 24 or week 32 respectively. Optionally the dosage regimen, such as dosage amount, may change after a period of time, such that in one example the antibody is administered using a dosage regimen of 160mg or 320mg every four weeks until week 12 or week 16 or week 24 followed by a dosage regimen of 320mg or 160mg every four

20 weeks respectively. Optionally both the dosage amount and dosage frequency may change, such that in one example the antibody is administered using a dosage regimen of 160mg every four weeks until week 12 or week 16 or week 24 followed by a dosage regimen of 320mg every eight weeks.

In the case of psoriatic arthritis, it will be appreciated that the dosage regimen may differ

25 depending on whether the subject has coexistent psoriasis and/or a history of psoriasis or not. For example, the dosage regimen for psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis or a history of psoriasis may comprise higher dosages and/or more frequent dosing than the dosage regimen for those subjects who do not have coexistent psoriasis and/or a history of psoriasis.

30 An exemplary method of treating psoriasis provided by the disclosure comprises administering to a subject an antibody described herein using any one of the following dosage regimens: 64 mg

every four weeks, 160 mg every four weeks or every 8 weeks, 320 mg every four weeks or every eight weeks, 320 mg loading dose administered at week 0 followed by maintenance doses of 160 mg every four weeks, or 480 mg every four weeks. The doses may be given at these intervals over any suitable treatment period such as at least four weeks, at least eight weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, at least 24 weeks, at least 28 weeks, at least 30 weeks, at least 36 weeks, at least 40 weeks, at least 44 weeks, at least 48 weeks, at least 52 weeks, or more. It will be appreciated that the doses may be given at these intervals for a first treatment period, then given at a different interval for a second treatment period (e.g., administered every four or eight weeks for a first treatment period of, for example, 12 or 16 or 20 or 24 weeks, then administered every eight, 12, or 16 weeks for a second treatment period lasting an additional, e.g., 24 or 36 weeks). For example, the dosage regimen, such as the dosing frequency, may change after a period of time, such that in one example the antibody is administered using a dosage regimen of 160mg every four weeks until week 8, 12 or 16 followed by 160mg every eight weeks, starting at week 16, 20 or 24 respectively. In one example the antibody is administered using a dosage regimen of 320mg every four weeks until week 8, 12 or 16 followed by 320mg every eight weeks starting at week 16, 20 or 24 respectively. In one example the antibody is administered using a dosage regimen of 320mg or 160mg every four weeks until week 8, 12 or 16 followed by 320mg or 160mg every twelve weeks. Optionally the dosage regimen, such as dosage amount, may change after a period of time, such that in one example the antibody is administered using a dosage regimen of 320mg every four weeks until week 8 or week 12 followed by a reduction to 160mg every four weeks starting at week 12 or week 16 respectively.

An exemplary method of treating ankylosing spondylitis or nr-axSpA provided by the disclosure comprises administering to a subject an antibody described herein using any one of the following dosage regimens: 16 mg every four weeks, 160 mg every four weeks, 320 mg loading dose at week 0 followed by a maintenance dose of 160 mg every four weeks or 320 mg every four weeks. Preferably the dosage regimen is 160mg or 320mg every four weeks. The treatment period can comprise, e.g., 12 weeks (for a total of at least three or four administrations of antibody), 16 weeks, 24 weeks, or 48 weeks, or more. It will be appreciated that the doses may be given at these intervals for a first treatment period, then given at a different interval for a second treatment period (e.g., administered every four or eight weeks for a first treatment period

of, for example, 12 or 16, 20 or 24 weeks, then administered every eight, 12, or 16 weeks for a second treatment period lasting an additional, e.g., 24 or 36 weeks or more). For example, the dosage regimen, such as frequency, may change after a period of time, such that in one example the antibody is administered using a dosage regimen of 160mg every four weeks until week 12,

5 16 or 24 followed by 160mg every eight weeks. In one example the antibody is administered using a dosage regimen of 320mg every four weeks until week 12, 16 or 24 followed by 320mg every eight weeks. Optionally the dosage regimen, such as dosage amount, may change after a period of time, such that in one example the antibody is administered using a dosage regimen of 160mg or 320mg every four weeks until week 12 or week 16 or week 24 followed by a dosage

10 regimen of 320mg or 160mg every four weeks respectively. Optionally both the dosage amount and dosage frequency may change, such that in one example the antibody is administered using a dosage regimen of 160mg every four weeks until week 12 or week 16 or week 24 followed by a dosage regimen of 320mg every eight weeks.

Compositions may be administered individually to a patient or may be administered in

15 combination (e.g., simultaneously, sequentially or separately) with other agents, drugs or hormones.

The dose at which the antibody molecule of the invention is administered depends on the nature of the condition to be treated, the extent of the inflammation present and on whether the antibody molecule is being used prophylactically or to treat an existing condition.

20 The frequency of dose will depend on the half-life of the antibody molecule and the duration of its effect. If the antibody molecule has a short half-life (e.g., 2 to 10 hours) it may be necessary to give one or more doses per day. Alternatively, if the antibody molecule has a long half-life (e.g., 2 to 15 days) it may only be necessary to give a dosage once per day, once per week or even once every 1 or 2 months.

25 It may be necessary to administer a loading dose followed by one or more maintenance doses. The loading dose and maintenance doses may be the same dosage amount, or they may be different. In one embodiment, the maintenance doses may be one-quarter, one-third, one-half, two-thirds, three-quarters, the same as, one and one-quarter, one and one-third, one and one-half, one and two-thirds, one and three-quarters, double, or more of the loading dose.

In one embodiment, the maintenance doses may be administered at an interval after administration of the loading dose. This interval may be consistent for each dose or may vary. This interval may be 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, monthly, 6 weeks, 8 weeks, every other month, or at any other interval. In one embodiment, two maintenance doses are 5 administered every three weeks after a loading dose for a total of three doses. In one embodiment, maintenance doses are administered every four weeks.

The pharmaceutically acceptable carrier should not itself induce the production of antibodies harmful to the individual receiving the composition and should not be toxic. Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polypeptides, liposomes, 10 polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.

Pharmaceutically acceptable salts can be used, for example mineral acid salts, such as hydrochlorides, hydrobromides, phosphates and sulphates, or salts of organic acids, such as acetates, propionates, malonates and benzoates.

15 Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents or pH buffering substances, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries and suspensions, for ingestion by the patient.

20 Preferred forms for administration include forms suitable for parenteral administration, e.g., by injection or infusion, for example by bolus injection or continuous infusion. Where the product is for injection or infusion, it may take the form of a suspension, solution or emulsion in an oily or aqueous vehicle and it may contain formulatory agents, such as suspending, preservative, stabilising and/or dispersing agents. Alternatively, the antibody molecule may be in dry form, 25 for reconstitution before use with an appropriate sterile liquid.

Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals. However, it is preferred that the compositions are adapted for administration to human subjects.

The pharmaceutical compositions of this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, transcutaneous (for example, see WO 98/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal routes.

5 Hyposprays may also be used to administer the pharmaceutical compositions of the invention. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.

10 Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule. A preferred embodiment of the invention involves subcutaneous or intravenous administration of the antibody.

15 It will be appreciated that the active ingredient in the composition will be an antibody molecule. As such, it will be susceptible to degradation in the gastrointestinal tract. Thus, if the composition is to be administered by a route using the gastrointestinal tract, the composition will need to contain agents which protect the antibody from degradation but which release the antibody once it has been absorbed from the gastrointestinal tract.

20 A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Publishing Company, N.J. 1991).

25 It is also envisaged that the antibody of the invention will be administered by use of gene therapy. In order to achieve this, DNA comprising nucleic acid sequences encoding the heavy and light chains of the antibody molecule under the control of appropriate DNA components are introduced into a patient such that the antibody chains are expressed from the DNA sequences and assembled in situ.

30 In one embodiment, the formulation is provided as a formulation for topical administrations including inhalation. Suitable inhalable preparations include inhalable powders, metering aerosols containing propellant gases or inhalable solutions free from propellant gases. Inhalable powders according to the disclosure containing the active substance may consist solely of the abovementioned active substances or of a mixture of the abovementioned active substances with

physiologically acceptable excipient. These inhalable powders may include monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextrans), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these with one another. Mono- or disaccharides are 5 suitably used, the use of lactose or glucose, particularly but not exclusively in the form of their hydrates.

Particles for deposition in the lung require a particle size less than 10 microns, such as 1-9 microns, for example, from 0.1 to 5 microns, in particular from 1 to 5 microns. The particle size of the active ingredient (such as the antibody or fragment) is of primary importance.

10 The propellant gases which can be used to prepare the inhalable aerosols are known in the art. Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The above-mentioned propellant gases may be used on their own or in mixtures thereof. Particularly suitable propellant gases are 15 halogenated alkane derivatives selected from among TG 11, TG 12, TG 134a and TG227. Of the abovementioned halogenated hydrocarbons, TG134a (1,1,1,2-tetrafluoroethane) and TG227 (1,1,1,2,3,3,3-heptafluoropropane) and mixtures thereof are particularly suitable. The propellant-gas-containing inhalable aerosols may also contain other ingredients such as cosolvents, stabilisers, surface-active agents (surfactants), antioxidants, lubricants and means for adjusting 20 the pH. All these ingredients are known in the art.

The propellant-gas-containing inhalable aerosols according to the invention may contain up to 5% by weight of active substance. Aerosols according to the invention contain, for example, 0.002 to 5% by weight, 0.01 to 3% by weight, 0.015 to 2% by weight, 0.1 to 2% by weight, 0.5 to 2% by weight or 0.5 to 1% by weight of active ingredient.

25 Alternatively topical administrations to the lung may also be by administration of a liquid solution or suspension formulation, for example employing a device such as a nebulizer, for example, a nebulizer connected to a compressor (e.g., the Pari LC-Jet Plus® nebulizer connected to a Pari Master® compressor manufactured by Pari Respiratory Equipment, Inc., Richmond, Va.).

The antibody of the invention can be delivered dispersed in a solvent, e.g., in the form of a solution or a suspension. It can be suspended in an appropriate physiological solution, e.g., saline or other pharmacologically acceptable solvent or a buffered solution. Buffered solutions known in the art may contain 0.05 mg to 0.15 mg disodium edetate, 8.0 mg to 9.0 mg NaCl, 0.15 mg to 0.25 mg polysorbate, 0.25 mg to 0.30 mg anhydrous citric acid, and 0.45 mg to 0.55 mg sodium citrate per 1 ml of water so as to achieve a pH of about 4.0 to 5.0. A suspension can employ, for example, lyophilised antibody.

The therapeutic suspensions or solution formulations can also contain one or more excipients. Excipients are well known in the art and include buffers (e.g., citrate buffer, phosphate buffer, 10 acetate buffer and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins (e.g., serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol. Solutions or suspensions can be encapsulated in liposomes or biodegradable microspheres. The formulation will generally be provided in a substantially sterile form employing sterile manufacture processes.

15 This may include production and sterilization by filtration of the buffered solvent/solution used for the formulation, aseptic suspension of the antibody in the sterile buffered solvent solution, and dispensing of the formulation into sterile receptacles by methods familiar to those of ordinary skill in the art.

Nebulizable formulation according to the present disclosure may be provided, for example, as 20 single dose units (e.g., sealed plastic containers or vials) packed in foil envelopes. Each vial contains a unit dose in a volume, e.g., 2 mL, of solvent/solution buffer.

The invention has been described by way of example only, is in no way meant to be limiting, and that modifications of detail can be made within the scope of the claims hereinafter. Preferred features of each embodiment of the invention are as for each of the other embodiments mutatis 25 mutandis. All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

## Examples

### Example 1 – Clinical Trial of CA028\_0496.g3 (UCB4940 or Bimekizumab); Loading dose and Maintenance doses

In one embodiment, an early proof-of-concept, investigator blind, placebo-controlled study

5 evaluating the safety, pharmacokinetics and pharmacodynamics of multiple doses of CA028\_0496.g3 in subjects with psoriatic arthritis has been performed. This is identified as UCB study PA0007.

The study comprised four active dose arms and placebo administered intravenously as an infusion on three occasions given every three weeks: **Cohort 1** (240 mg loading dose at week 0 followed by 160 mg at week 3 and week 6 [N=20 (active), 3 placebo]; **Cohort 2** (80 mg loading dose at week 0 followed by 40 mg at week 3 and week 6) [N=6 (active), 3 placebo]; **Cohort 3** (160 mg loading dose at week 0, followed by 80 mg at week 3 and week 6), N=6 (active), 3 placebo; **Cohort 4** (560 mg loading dose at week 0, followed by 320 mg at week 3 and week 6), N=6 (active), 3 placebo.

15 The objectives of this study included the safety, tolerability and pharmacokinetics of multiple-dose administration of CA028\_0496.g3 in subjects with psoriatic arthritis. The objectives also included the evaluation of the effect of multiple-dose administration of CA028\_0496.g3 on the severity of psoriatic arthritis in the joints (American College of Rheumatology (“ACR”) 20/50/70 response) and, for skin, the clinical features of plaque psoriasis (Psoriasis Area and 20 Severity Index (“PASI”) 50/75/90 response). ACR score is a scale that measures improvement in joint effects associated with psoriatic arthritis and rheumatoid arthritis, and improvements in ACR score are also associated with the treatment of rheumatoid arthritis.

**Patient Population:** All eligible subjects were required to be at least 18 years of age and have a diagnosis of adult-onset psoriatic arthritis made at least 6 months prior to screening for the study 25 as defined by the classification criteria for psoriatic arthritis (“CASPAR”) criteria (i.e., inflammatory articular disease (joint, spine or enthesal) and  $\geq 3$  points of the 5 CASPAR categories). The CASPAR criteria used may be found in Figure [2]. Subjects were also required to have active psoriatic lesions or a history of psoriatic lesions. In terms of joint involvement,

subjects were required to have active arthritis as defined by:  $\geq 3$  tender joints at screening and baseline,  $\geq 3$  swollen joints at screening and baseline, and fulfilling at least one of the following during screening (either ESR  $\geq 28$  mm/hour or CRP  $\geq 3$  mg/L). Subjects were all inadequate responders to at least one non-biologic disease-modifying antirheumatic drug (“DMARD”)

5 and/or 1 approved biologic DMARD. Subjects must have been taking concurrent methotrexate at the start of treatment for at least 3 months, and be on a stable dose at least 4 weeks prior to baseline. Subjects who were intolerant to methotrexate may have been eligible if they had received non-steroidal anti-inflammatory drugs (NSAIDs) and/or steroids for at least 8 weeks and were on a stable dose at least 4 weeks prior to baseline.

10 **Study Disposition:** 50 subjects completed all doses of the study, of which 38 subjects received at least one dose of the investigational medicinal product, CA028\_0496.g3. Including subjects who received placebo, a total of 48 subjects formed the overall analysis data set as two subjects were excluded for being potentially un-blinded at the site.

15 **Clinical Outcomes:** Clinically significant effects were observed for both joints and skin at week 8 from start of treatment:

20 **Skin Effects:** 23 subjects had skin involvement at baseline, with body surface area (BSA)  $\geq 3\%$  and a mean baseline PASI of 15.9 (SD=14.6). Only 22 subjects were in the analysis data set due to missed dosing by one subject. Results on skin effects are described in Figure [3a] and Figure [3b]. Onset of response was rapid for both skin and joints. Out of the eligible subjects for skin assessment, for the combined top 3 doses, a PASI75 response of 100% was observed at week 8 from start of treatment, and a PASI90 response of 87% and appear to have been maintained until the end of the study at week 20 post-start of treatment. In contrast, in the Future 1 trial for Secukinumab in psoriatic arthritis, the observed PASI75 response at week 24 was 64.8% and PASI 90 response at week 24 was 49%. (Glottieb AB et al. Arthritis Rheum. 2014, 66(Suppl 25 11):S233; Mease P et al. Ann Rheum Dis. 2014; 73(1):48–55.) This is further depicted in Figure [4].

**Joint Effects:** Results on joint effects are described in Figures [5a]- [5d]. An 80% ACR20 response, a 40% ACR50 response and a 23% ACR70 response were observed at week 8 from start of treatment was observed for the combined top 3 doses of the group. The ACR20 response

appeared to be sustained at this level through to week 20 (day 140), albeit with an increased placebo response (see Figure 5b-5d). Following week 8 (2 weeks after the last dose) background medication was un-controlled.

The time to maximum ACR50 and 70 responses took longer (post week 12), with responses of 5 56.7 % and 36.7 % by week 20, respectively. In contrast, in the Future 1 trial for Secukinumab in psoriatic arthritis, the observed ACR20 response at week 24 was 50%. Mease P et al., 2014, *Arthritis Rheum.*, 66(Suppl 11):S423–S424; Mease P et al., 2014, *Ann Rheum Dis.*, 73(1):48–55. This is further depicted in Figure [6].

**Bayesian Analysis:** A Bayesian analysis of ACRn(tr) at week 8 from start of treatment was performed using a Gaussian-likelihood model with an informative prior on the placebo group. An assessment of the equality of the treatment effect size as well as homogeneity of variances was performed and it was deemed to be appropriate to pool the top three doses together for CA028\_0496.g3. The informed prior on the placebo group for ACRn(tr) was estimated by using data from a previous Cimzia® study in psoriatic arthritis (PsA001, A phase 3, multicenter, randomized, double-blind, parallel- group, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in subjects with adult-onset active and progressive psoriatic arthritis.).

The Bayesian analysis indicated strong statistical evidence (probability > 99%) that CA028\_0496.g3 achieves higher values of ACRn(tr) compared to placebo. Furthermore, the probability that the median treatment difference in ACRn(tr) compared to placebo is greater than 0.31 (difference observed in previous Cimzia® studies) was more than 99% in the pooled CA028\_0496.g3 top 3 doses group.

For ACR20 response, a Bayesian analysis was performed at Week 8 post start of dosing using a logistic model with an informative prior on the placebo group. The informed prior for the placebo group on ACR20 was estimated using data from a previous Cimzia® study (PsA001).

The Bayesian analysis indicated that the probability of CA028\_0496.g3 inducing greater ACR20 response rates than placebo was over 99% for the pooled CA028\_0496.g3 top 3 doses groups. In addition, there was a > 99% probability that the median treatment difference in ACR20

compared to placebo is greater than 25% (difference observed in PsA001) for the pooled top 3 doses of CA028\_0496.g3. These results are presented in Figure [7].

The validity of these results in terms of benchmarking against other biological therapies (anti-TNFs and IL17As and anti-IL12/23) in psoriatic arthritis was made by comparing with literature data for ACR20 response at week 8. (Adalimumab, Golimumab, Secukinumab and Ustekinumab, *see* Figure [8]), ensuring overall concordance in the results. In conclusion, a high posterior probability (>99%) for observed effects on ACR20 response is greater than anti-TNFs or anti-IL-17As at week 8 in this PA0007.

**Pharmacokinetic-Pharmacodynamic Targeting:** In order to achieve the pharmacologically active dose levels to achieve the desired clinical effects, four active dosing arms were selected. The aim was to achieve trough concentrations over the first 8 week period of 10 x the Ec50 (derived from mild psoriasis response in UP0008 described in Example 2) of approximately 10  $\mu$ g/mL and higher. The results of this study are included in Figure [9]. In UP0008, bimekizumab demonstrated dose-proportional PK (half-life of about 22 days).

**Predicted Sub-Cutaneous Dosing:** A bioavailability study (RA0124) was conducted for CA028\_0496.g3 to evaluate the pharmacokinetics of CA028\_0496.g3 following subcutaneous administrations of 80mg and 160mg doses compared to 160mg given by i.v. The results indicate that based on the principles of super-position, it should be possible to achieve the target concentrations of CA028\_0496.g3 summarized in Figure [9] (achieved in PA0007) via monthly subcutaneous doses of 160 mg or greater, such as 320mg, using a Q4W regimen (Figure [10]) or via a 320mg loading dose followed by a 160mg Q4W regimen.

#### Example 2 - Clinical Trial of CA028\_0496.g3 (UCB4940 or Bimekizumab); Single dose

UP0008 is a single ascending dose Phase 1 study (NCT02529956) of the safety of intravenously administered CA028\_0496.g3 in subjects with mild to moderate psoriasis affecting  $\leq 5\%$  body surface area (BSA). Inclusion criteria included, e.g., male or female ( $\geq 18$  to  $\leq 70$  years), confirmed diagnosis of mild-to-moderate plaque-type psoriasis for  $\geq 6$  months involving  $\leq 5\%$  of body surface area (excluding the scalp), and  $\geq 2$  psoriatic lesions with  $\geq 1$  plaques in suitable biopsy sites. Exclusion criteria included, e.g., use of systemic non-biologic psoriasis therapy

(methotrexate, cyclophosphamide) or psoralen plus ultraviolet A/ultraviolet A phototherapy within 4 weeks prior to screening, treatment with biologic agents  $\leq$ 12 months before the study, and use or planned use of live attenuated vaccines  $\leq$ 6 weeks of screening. A total of 39 patients received a single i.v. dose of bimekizumab (8–640 mg) or placebo (randomized, double-blind).

5 Five dosages were employed: 8 mg, 40 mg, 160, mg, 480 mg, and 640 mg. Following single-dose administration, bimekizumab (8–640 mg) was well tolerated and no patient discontinued due to treatment-emergent AEs; no severe AEs were reported. Indeed, doses of up to 640 mg (approximately 8mg/kg body weight) have been well tolerated to date in UP0008.

After administration, bimekizumab produced improvements across the evaluated clinical features 10 of plaque psoriasis, LSS, PASI and PGA (Figure 14). A fast onset of response was observed with a reduction of  $>$ 80% from baseline LSS in the top two dose cohorts at study Week 2. For doses 160, 480, and 640 mg (N=6 each), clinically-relevant and statistically significant differences from placebo (N=13) were observed in lesion severity score (LSS) (Figure [11]) and psoriasis area and severity index (PASI) from week 2 (Figure [12]), with near-maximal 15 improvements observed by week 4.

Specifically with respect to LSS, the magnitude of response was reflected by a maximal reduction in mean change from baseline in LSS of  $>$ 90% in the 160 mg group. This was achieved 20 by Week 8 and demonstrated durability, being maintained to Week 16. In the 480 mg cohort a maximal magnitude of response, 100%, was achieved as early as Week 4. The response also was durable, being maintained to Week 16. In the 640 mg cohort, the maximal reduction (100%) was achieved by Week 8 and was durable, being maintained between Weeks 12 and 20 (Figure 14A). In addition to the 640 mg cohort, no overlap in CIs between the other bimekizumab cohorts (40–480 mg) at Week 2 vs placebo was observed, indicating a difference between the two cohorts. Similar results were obtained for the area under the effect curve (Weeks 0–4, [AUEC0-4w]) 25 variable (data not shown).

With respect to PASI, a fast onset of response was observed with a reduction of  $>$ 65% from baseline PASI scores in the top two cohorts at Week 2. Bayesian analysis revealed that the posterior probability of  $\geq$ 60% improvement over placebo at this time point was  $>$ 80%. For the bimekizumab 160 mg cohort, the magnitude of response was reflected by a maximal reduction in 30 the mean change from baseline in PASI score of  $>$ 85% achieved by Week 6. This response was

durable, being maintained to study Week 12. In the 480 mg and 640 mg cohorts, a maximal magnitude of response of  $\geq 94\%$  was observed. This was achieved by Week 6 in the 480 mg cohort and Week 4 in the 640 mg cohort. In both cohorts the response was durable, being maintained to Week 12 (Figure 5b). Additionally, for bimekizumab 40–640 mg cohorts at Week 5 2, the posterior probability of a  $>0\%$  improvement in PASI score over placebo was 99%.

The significant level of improvement (as indicated by LSS percent change and PASI percent change from baseline) was maintained until the final timepoint measured – 20 weeks. In the top two dose groups, 83% of patients experienced PASI 90 (a 90% improvement in PASI score), from weeks 6-12 and 90% at week 12 (Figure [13]). At the top three doses, 100% of patients 10 achieved PASI75, and 53% achieved PASI100.

PGA (Physicians Global Assessment) also was assessed using a seven-point scale (0=clear, 6=severe). See Figure [14]. A reduction of  $>50\%$  from baseline in PGA was observed at the highest doses of bimekizumab (480 mg and 640 mg) assessed. Maximal reductions in mean change from baseline in PGA scores of  $>75\%$  were observed in the bimekizumab 160 mg cohort. 15 This reduction was achieved by Week 6 and was durable, being maintained to Week 12. Maximal reductions in mean change from baseline in PGA scores were 100% and 94%, respectively for bimekizumab 480 mg and 640 mg cohorts (Figure 5c). These reductions were achieved by Week 8 and were durable, being maintained to Week 12 in the 480 mg cohort, and achieved by Week 4 and maintained to Week 12 in the 640 mg cohort.

20

#### Example 3 – Anti-IL17A/F antibody down regulates bone formation processes

Prototypical phenotypic subsets of spondyloarthritis are ankylosing spondylitis (AS) for axial disease and psoriatic arthritis (PsA) for the combination of peripheral arthritis with psoriasis. Individual patients often display multi-system disease; a significant proportion of patients with 25 AS exhibit skin psoriasis and a significant proportion of patients with PsA develop axial disease. AS and PsA share a common genetic background, familial aggregation of the different subforms, shared histopathological findings, and similar responses to therapy (e.g., efficacy of TNF blockade and IL-17A blockade in both AS and PsA and failure of B cell depleting therapy and IL-6 blockade in AS as well as PsA). The results described herein with respect to psoriatic

arthritis suggest therefore that anti-IL-17A/F antibodies may also be effective in the treatment of ankylosing spondylitis.

Pathological bone formation associated with the spondyloarthropathies (SpA) is a major cause of structural tissue damage resulting in permanent patient disability. Patients with AS experience

5 excessive bone formation on the periosteal surface near joints and intervertebral spaces, resulting in bone spurs that fuse joints and aggrevate tendon and ligament insertion sites, causing pain and limited mobility associated with the disease. Previous studies using recombinant IL-17A and IL-17F revealed divergent effects in osteogenic differentiation. Osta et al., *Frontiers in Immunology* 5, (2014), have demonstrated that IL-17 positively influences osteogenic differentiation in  
10 human mesenchymal stem cells (hMSCs). In agreement, Huang et al, *Cell Death Differ.* 16, 1332–43 (2009) have reported that IL-17 stimulates proliferation and osteogenic differentiation of hMSCs. In addition, Croes et al. *Bone* 84, 262–270 (2016), demonstrated osteogenic stimulation of hMSCs with IL-17A and IL-17F over a range of concentrations. Conversely, others demonstrated that IL-17 inhibited the osteogenic differentiation of rat calvarial cells,  
15 mouse MSCs and adult human MSCs, and implicated that IL-17 was pro-osteogenic. See, e.g., Chang et al., *Proc. Natl. Acad. Sci. U.S.A.* 110, 9469–74 (2013); Nam et al., *PLoS One* 7, e40044 (2012).

This Example demonstrates that an anti-IL-17A/F monoclonal antibody (CA028\_0496.g3

(Bimekizumab)) reduced biomarkers associated with periosteal stem cell osteogenic

20 differentiation *in vitro*, reduced matrix mineralization, and reduced bone nodule formation *in vitro*, demonstrating that an anti-IL-17A/F monoclonal antibody (CA028\_0496.g3 (Bimekizumab)) is likely to be effective in treating (e.g., slowing the progression of, reducing the symptoms of) AS.

**Methodology:** As the periosteum gives rise to reparative tissues for fracture repair, a human

25 periosteal stem cell model (Eyckmans et al., *Biomaterials* 34, 4612–21 (2013)) was employed to probe the IL-17 axis in the context of pathological bone formation. Periosteum was harvested from patients undergoing lower limb orthopedic surgery, as previously described. Roberts et al., *Biomaterials* 32, 4393–4405 (2011); Roberts et al., *Stem Cell Res.* 7, 137–144 (2011). Adherent human periosteum derived stem cells (hPDSCs) were enzymatically released from the matrix and  
30 expanded in growth media (DMEM medium supplemented with 10% fetal bovine serum, 1%

sodium pyruvate, 1%antibiotics and antimycotics). For *in vitro* osteogenic differentiation assays, passage 6 hPDSCs were seeded at 3000 cells/cm<sup>2</sup> in 24-well plates to allow quantification of gene expression and mineralization in response to TH-17 supernatant exposure. These cultures were incubated with TH-17 supernatant (1:50 dilution) containing vehicle (PBS) or anti-IL-17A,  
5 anti-IL-17F, or anti-IL-17A/F antibody (10µg/ml) in combination with an osteogenic growth factor cocktail (GFC); 10 ng/ml TGF-β1 (Peprotech), 20 ng/ml EGF (Invitrogen), 10 ng/ml IL-6 (Peprotech), 3 mM Ca<sup>2+</sup> ions and 2 mM PO<sub>4</sub><sup>-</sup> (prepared in HEPES buffered saline) as previously described. Chai et al., *Tissue Eng. Part A* 17, 1083–1097 (2011). IL-6 was replaced (GFC-IL-6) with TH-17 supernatants in test conditions as an inflammatory trigger for differentiation. The  
10 mixtures were incubated in a shaking water-bath for 1 hour at 37°C to allow for efficient neutralization of the IL-17 isoforms. Each condition was applied to the relevant hPDSC monolayer every other day until the end of culture period at day 8. Monolayers were either fixed in 10% neutral buffered formalin or stained with 1% alizarin red to measure deposited mineral, or lysed to isolate total RNA for osteogenic marker gene expression analysis. Prior to fixation,  
15 monolayers were visualised using standard microscopy techniques and the appearance of bone nodules was visually assessed.

To examine the effect of human serum from AS patients on hPDSC IL-17 mediated signalling, 10,000 cells/cm<sup>2</sup> cells were seeded in 24 well plates. The following day the media was removed and the monolayers were washed with sterile warmed PBS, following which the media was  
20 replaced with DMEM containing either 10% healthy human serum (HS) or AS patient serum (SRSC01, SRSC03, SRSC04, SRSC05, SRSC06 and SRSC07) with 1% sodium pyruvate and 1% antibiotics/antimycotics. The monolayers were incubated for 48 hours after which the media were discarded and monolayers terminated for total RNA isolation. Subsequently, expression of the downstream target gene IL-6 and osteogenic marker RUNX2 were evaluated.

25 *Total RNA extraction, cDNA synthesis and qPCR:* Monolayers were lysed using the RNeasy mini kit according to the kit instructions (Qiagen). Complementary DNA (cDNA) was synthesized by reverse transcription of 500 ng of total RNA using the high capacity cDNA reverse transcription kit (Applied Biosciences) under the following thermal cycling conditions; 25°C for 10 mins, 37°C for 120 mins and 85°C for 5minutes. To quantify the level of gene  
30 transcripts within each sample, primers (designed using Primer3 Plus, NCBI) were combined

with iTaq universal SYBR green supermix (Biorad) and 10 ng cDNA, subsequently 10 µL aliquots were applied to Hard-Shell® 96-Well PCR Plates (Biorad). Thermal cycling conditions were as follows: 10 min at 95°C, with 40 cycles of 15 s at 95° C, 30 s at 60° C, and 20 s at 72° C, on a Bio-Rad CFX1000 Real-Time System. Each run consisted of melt curve analysis and 5 template-free controls to confirm specific, single product amplification. All primer pairs produced single amplicons and reactions were of similar efficiency (95-100 %), as established by standard dilution curve and analysis. Target gene quantification was achieved using the 2- $\Delta\Delta CT$  method described by Livak et al, relative to HPRT1.

10 *IL-17A and IL-17F measurement by ELISA:* IL-17A and IL-17F protein was measured in patient serum from AS patients using sandwich ELISA (Peprotech, London, UK). AS patient blood was isolated in BD Vacutainer SST tubes in the Rheumatology clinic at the Royal National Orthopaedic Hospital (Stanmore, UK). The NHS Research Ethics Committee approved all procedures. Following collection, the blood was centrifuged at 1000g for 10 minutes at room temperature. The separated serum was then filtered through a 0.2-µm membrane. Aliquots of 15 serum were stored at -80°C prior to analysis. A 1:2 dilution of each AS patient serum was performed in diluent buffer provided in the human IL-17A and IL-17F ABTS kits (Peprotech, London, UK) prior to analysis to reduce effects of serum matrix. Measurement of IL-17A and IL-17F was performed as per kit instructions.

20 **Results:** Utilising a biomimetic osteogenic assay (described in International Patent Publication WO2013189975), TH-17 supernatant (TH-17SN) was either treated with or without the inclusion of monoclonal antibodies directed towards IL-17A, IL-17F, or IL-17A/F. Osteogenic transcripts such as RUNX2, SP7 and BMP2 were analysed alongside markers of osteogenic matrix formation (BGLAP) and mineralisation (PHOSPHO1), in addition to assessment of the extent of mineralisation by alizarin red staining and assessment of the appearance of bone nodules. TH-17 25 cell supernatant potently enhanced hPDSC osteogenic differentiation and mineralisation (p<0.01). Both IL-6 expression and *in vitro* bone formation were blocked by neutralisation of IL-17A, IL-17F and IL-17A/F in the inflammatory milieu, with neutralisation of IL-17A/F exhibiting the largest effect. Figures 15A-G. Also, the appearance of bone nodules were visibly less in anti-IL-17A/F treated samples compared to treatment with anti-IL-17A or anti-IL-17F 30 alone.

The presence of IL-17A and IL-17F in the serum of patients presenting with AS was quantified by ELISA. Both IL-17A and IL-17F proteins were measured in six patients and compared to the level in healthy human serum (HS). Varying levels of IL-17A and IL-17F were identifiable across the different patients with significantly greater levels of both IL-17A and IL-17F in three 5 patients ( $P<0.01$ ) compared to healthy human serum control group. Serum from patient samples from the remaining three patients appeared to exhibit similar IL-17A, however greater IL-17F expression in one patient compared to HAS control. To investigate the relevance of this, hPDSCs were treated with AS patient serum and incubated for 48 hours. The down-stream target IL-6 and osteogenic marker RUNX2 were elevated. To define the importance of IL-17A and IL-17F 10 in the expression of these markers, hPDSCs were treated with serum from AS patients (serum samples that exhibited significantly higher levels of both IL-17A and IL-17F and stimulated IL-6 and RUNX2 mRNA expression) following pre-incubation with either control IgG antibody or antibodies specific to IL-17A, IL-17F or IL-17A/F. The results indicated that blocking both IL-17A and IL-17F resulted in potent and significant decreases in IL-6 and RUNX2 mRNA 15 expression. This effect was greatest with the antibody that had high affinity for IL-17A/F.

Figures 16A & 16B.

**Discussion:** Inflammatory and degenerative joint diseases frequently elicit proliferative responses of the periarticular periosteal bone, leading to the formation of bony spurs (osteophytes). In inflammatory diseases such as AS, enthesophytes originate at the tendon 20 insertion site (enthesis) in peripheral joint and the vertebral bodies. It is hypothesized that the progenitor cells within the periosteum are intimately involved with this bone forming process and can lead to ankylosis with impairment of motion and joint dysfunction. The results described herein demonstrate that both IL-17A and IL-17F enhance *in vitro* osteogenic differentiation and bone formation from hPDSCs. Neutralization of IL-17A and IL-17F via a 25 monoclonal antibody that binds both IL-17A/F (CA028\_0496.g3 (Bimekizumab)) inhibited IL-6 gene expression and abrogated osteogenic gene (*RUNX2*, *SP7*, and *BMP2*) expression. CA028\_0496.g3 also significantly mediated bone matrix mineralization effectors (BGLAP and PHOSPHO1), resulting in an observable reduction in matrix mineralization and bone nodule formation. Neutralization of IL-17A/F resulted in greatest inhibition of osteogenic 30 differentiation markers and matrix mineralization compared to neutralization of IL-17A or IL-17F alone). Current therapeutics display limited efficacy in blocking enthesophyte formation;

hence, the materials and methods described herein present a significant technical advantage for blocking this debilitating tissue morbidity.

In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word

5 "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

**Claims**

1. A method of treating psoriatic arthritis in a human comprising administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F, wherein the antibody comprises a light chain and a heavy chain, wherein the light chain variable domain comprises SEQ ID NO:10 and the heavy chain variable domain comprises SEQ ID NO:11, and wherein the human is administered 160mg of antibody every four weeks or 320mg of antibody every four weeks.
2. Use of a neutralizing antibody which binds human IL-17A and human IL-17F in the manufacture of a medicament for treating psoriatic arthritis in a human, wherein the antibody comprises a light chain and a heavy chain, wherein the light chain variable domain comprises SEQ ID NO:10 and the heavy chain variable domain comprises SEQ ID NO:11, and wherein the human is administered 160mg of antibody every four weeks or 320mg of antibody every four weeks.
3. The method of claim 1 or use of claim 2, wherein the antibody is bimekizumab.
4. The method or use of any one of claims 1 through 3, wherein the method comprises administering multiple doses over a treatment period of at least 12 weeks.
5. The method or use of any one of claims 1 through 3, wherein the antibody is administered as a pharmaceutical composition.
6. The method or use of any one of claims 1 through 4, wherein the antibody is administered as a pharmaceutical composition in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
- 20 7. The method of any one of claims 1 through 6, wherein the antibody is administered subcutaneously or intravenously.
8. The method or use of any one of claims 1 through 7, wherein the human has a diagnosis of adult-onset psoriatic arthritis.
- 25 9. The method or use of claim 8, wherein the human is at least 18 years of age and/or was diagnosed at least six months prior to administration of the antibody.

10. The method or use of claim 9, wherein the human was diagnosed based on CASPAR criteria.
11. The method or use of any one of claims 1 through 10, wherein the human has active arthritis.
- 5 12. The method or use of any one of claims 1 through 11, wherein the human has active psoriatic lesions or a history of psoriatic lesions.

**Figure 1: Nucleotide and Amino Acid Sequences**

CDRH1: GFTFSDYNMA (SEQ ID NO:1)  
CDRH2: TITYEGRNTYYRDSVKG (SEQ ID NO:2)  
CDRH3: PPQYYEGSIYRLWFAH (SEQ ID NO:3)  
CDRL1: RADESVTTLMH (SEQ ID NO:4)  
CDRL2: LVSNRES (SEQ ID NO:5)  
CDRL3: QQTWSDPWT (SEQ ID NO:6)

CDRL1 for CA028 496.g3: RADESVRTLHM (SEQ ID NO:7)  
CDRL2 for CA028 496.g3: LVSNSEI (SEQ ID NO:8)

Light Chain variable region of antibody CA028 496 (gL7) (SEQ ID NO:9)  
AIQLTQSPSSLSASVGDRTVTITCRADESVTIMHWYQQKPGKAPKLLIYLVSNRESGVPSRFSGSGSGTDFITLTISSLQPEDFATYYCQQTWSDPWTFGQ  
GTKVEIKR

Light Chain variable region of antibody CA028 496.g3 (gL57) (SEQ ID NO:10)  
AIQLTQSPSSLSASVGDRTVTITCRADESVTIMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQ  
GTKVEIK

Heavy Chain variable region of antibody CA028 496 and CA028 496.g3 (gh9) (SEQ ID NO:11)  
EVQLVESGGGLVQPGGSLRLSCAASGFTFSVDNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRTIISRDNAKNNSLYLQMNSLRAEDTAVYYCASPQQYEGSIYRLWFAHWGQGTLTVVSS

Light chain of antibody CA028 496 (without signal) (SEQ ID NO:12)  
AIQLTQSPSSLSASVGDRTVTITCRADESVTIMHWYQQKPGKAPKLLIYLVSNRESGVPSRFSGSGSGTDFITLTISSLQPEDFATYYCQQTWSDPWTFGQ  
GTKVEIKRTVAAAPSVFIFPPSDEQLKSGTAVVCLNNFYPREAKVQMKVDNALQSGNQESVTEQDSKDSITYSLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFMRGEC

Light chain of antibody CA028 496.g3 (without signal) (SEQ ID NO:13)

AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVNSEIGVPDRFSGSGTDFRLTISSLIQPEDFATYYCQQTWSDPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQEVTEQDSKDKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRC

Light chain of antibody CA028 496.g3 including signal (SEQ ID NO:14)

MSVPTQVLGLLWLTDARCAIQLTQSPPSILSASVGDRVTITCRADESVRTLIMHWYQQKPGKAPKLLIYLVNSEIGVPDRFSGSGTDFRLTISSLIQPEDFATYYCQQTWSDPWTFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQEVTEQDSKDKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRC

Heavy chain of antibody CA028 496 SEQ ID NO:15)

EVQIVESGGGLVQPGGSTRLSCAASGFTFSdynMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRTFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRIWFAHWGQGTILTVSSASTKGPSVFPPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDDHKPSNTKVDKRVESKYGPPCPAPAEFLGGPSVFLFPKPKDITLMISRTPEVTCVYVDVSQEDPEVQENWYVVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISSAKGQPREPVQYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTPPVLDSDGSFFFLYSRLLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLK

Heavy chain of antibody CA028 496.g3 (without signal) (SEQ ID NO:16)

EVQIVESGGGLVQPGGSTRLSCAASGFTFSdynMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRTFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRIWFAHWGQGTILTVSSASTKGPSVFPPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTQTYICNVNHHKPSNTKVDKVEPKSCDKTHTCPCPAPELLGGPSVFLFPKPKDITLMSRTPEVTCVYVDVDSHEDPEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISSAKGQPREPVQYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLDSDGSFFFLYSKLTVDKSRWQOGNVFSCSVMHEALHNHYTQKSLSLSPGK

Heavy chain of antibody CA028 496.g3 including signal (SEQ ID NO:17)

MEWSWVFFELLSVTTGVHSEVOLVESGGGLVQPGGSLRLSCAASGFTFSdynMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRTFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTILTVSSASTKGPSVFPPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTQTYICNVNHHKPSNTKVDKVEPKSCDKTHTCPCPAPELLGGPSVFLFPKPKDITLMSRTPEVTCVYVDVDSHEDPEVKENWYVVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISSAKGQPREPVQYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLDSDGSFFFLYSKLTVDKSRWQOGNVFSCSVMHEALHNHYTQKSLSLSPGK

DNA encoding Light Chain variable region of antibody CA028 496.g3 (SEQ\_ID NO: 18)

ggcataccaggctgaccagccaggcccttcctcaagcgccaggctcgaggacagacttacactcgaggctgacgaaaggctgagaacatgtatgc  
actggtaacctaaacagaaggccctggcaaaaggccccaaatctgttccaaattcgaggatggatctgatctatctggcacttgcggcacttggacatttggacat

DNA encoding Heavy Chain variable region of antibody CA028 496 and CA028 496.g3 (SEQ ID NO:19)  
gaggttcagtcgttgaatccggaggactcgtgcaggctggctccttgcggctggctggaggctggcttcactttcagcggattacaata  
tggccctgggtcgcccaaggccaggcaaaacacttacccatgaggggcagaatttaccatggggatccatggggatcgtgaaaggcg  
atttaccatcaggcaggataatgtcaaaaggaaacacgtctgtacccgtcaagatgaaactctctgtctactatattgtqcaagccaccc  
cagttactatgagggtcaatctacagatttgcggccatggccatgtgggttgcggaaacacttgcggcagggtctcgagc

the DNA encoding light chain of antibody CA028 496 including signal sequence (SEQ ID NO:20)

DNA encoding light chain of antibody CA028 (no signal sequence) (SEQ ID NO:21)

CDNA encoding light chain of antibody CA028 496.93 including signal sequence (SEQ ID NO: 22)

DNAs encoding heavy chain of antibody CA028 496 (including signal sequence) (SEQ ID NO: 23)

encoding heavy chain of antibody CA028 496·g3 (including exons but without signal sequence) (SEQ ID

Human IL-17A (SEQ ID NO: 27)  
GITIPRNPNGCPNSEDKNFPTVMVNNTIHNRTNTNPKRSSDYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQETILVLRREPPPHCPNSFRLEKTLVSYVGCTCYTPVHHVA

Human IL-17F (SEQ ID NO: 28)  
RKIPKVGHFFQKPESCPPVPGGSMKLDIGIINENQRVSMRNTESRSTSPWNYTVTWDPNRYSEVVQACRNLGCINAQGKEDISMNSVPIQQETLVV  
RRKHQGCSVSFQLEKVLVTVGCTCVPVIIHHVQ

**Figure 2: CASPAR criteria**

Inflammatory articular disease (joint, spine, or entheses) AND at least 3 points of the following 5 categories:

Category	Definition	Points
1) Evidence of psoriasis: (Score for 1 of the following)		
Current psoriasis	Psoriatic skin or scalp disease present today as judged by a dermatologist or rheumatologist	2 points
Personal history of psoriasis	A history of psoriasis that may be obtained from the subject, family physician, dermatologist, rheumatologist, or other qualified health care provider	1 point
Family history of psoriasis	A history of psoriasis in a first- or second-degree relative according to subject report	1 point
2) Psoriatic nail dystrophy	Typical psoriatic nail dystrophy, including onycholysis, pitting, and hyperkeratosis, observed on current physical examination	1 point
3) A negative test for rheumatoid factor	By any method except latex, but preferably by enzyme-linked immunosorbent assay (ELISA) or nephelometry, according to the local laboratory reference range	1 point
4) Dactylitis: (Score for 1 of the following)		
Current dactylitis	Swelling of an entire digit	1 point
History of dactylitis	A history of dactylitis recorded by a rheumatologist	1 point
5) Radiologic evidence of juxta-articular new bone formation	Ill-defined ossification near joint margins (but excluding osteophyte formation) on plain radiographs of the hand or foot	1 point

CASPAR=Classification Criteria for Psoriatic Arthritis

a "Score for 1 of the following" means that only 1 of the 3 criteria is applicable (either current psoriasis [scores 2 points], personal history [scores 1 point], or family history [scores 1 point]).

Figure 3a: PASI 50/75/90 response at week 8

	Placebo	UCB4940 80mg/ 40mg/ 40mg	UCB4940 160mg/ 80mg/ 80mg	UCB4940 240mg/ 160mg/ 160mg	UCB4940 560mg/ 320mg/ 320mg	UCB4940 Combined 3 top doses group
<b>Subjects with BSA ≥ 3% psoriasis n (%)</b>	5 (50%)	2 (50%)	4 (67%)	9 (60%)	2 (40%)	15 (58%)
<b>PASI50 n (%) [95% CI]</b>	1 (20%) [4% - 62%]	2 (100%) [34% - 100%]	4 (100%) [51% - 100%]	9 (100%) [70% - 100%]	2 (100%) [34% - 100%]	15 (100%) [80% - 100%]
<b>PASI75 n (%) [95% CI]</b>	0 [0% - 43%]	1 (50%) [10% - 91%]	4 (100%) [51% - 100%]	9 (100%) [70% - 100%]	2 (100%) [34% - 100%]	15 (100%) [80% - 100%]
<b>PASI90 n (%) [95% CI]</b>	0 [0% - 43%]	1 (50%) [10% - 91%]	4 (100%) [51% - 100%]	8 (89%) [57% - 98%]	1 (50%) [10% - 91%]	13 (87%) [62% - 96%]





Figure 4: Secukinumab Future 1 Results: PASI (week 24)



**Figure 5a: ACR20/50/70 response at week 8**

	Placebo (N=12)	UCB4940 80mg/ 40mg/ 40mg (N=6)	UCB4940 160mg/ 80mg/ 80mg (N=6)	UCB4940 240mg/ 160mg/ 160mg (N=19)	UCB4940 560mg/ 320mg/ 320mg (N=5)	UCB4940 Combined 3 top doses group (N=30)
<b>ACR20</b> n (%) [95% CI]	2 (17%) [5% - 45%]	3 (50%) [19% - 81%]	5 (83%) [44% - 97%]	15 (79%) [57% - 92%]	4 (80%) [38% - 96%]	24 (80%) [63% - 91%]
<b>ACR50</b> n (%) [95% CI]	1 (8%) [2% - 35%]	1 (17%) [3% - 56%]	3 (50%) [19% - 81%]	7 (37%) [19% - 59%]	2 (40%) [12% - 77%]	12 (40%) [25% - 58%]
<b>ACR70</b> n (%) [95% CI]	0 [0% - 24%]	0 [0% - 39%]	0 [0% - 39%]	5 (26%) [12% - 49%]	2 (40%) [12% - 77%]	7 (23%) [12% - 41%]

Figure 5b: Summary Plot of the ACR20 response rates from PA0007 from start of study (day 0) to day 140 (week 20).






Figure 5c: Summary Plot of the ACR50 response rates from PA0007 from start of study (day 0) to day 140 (week 20).



**Figure 5d: Summary Plot of the ACR70 response rates from PA0007 from start of study (day 0) to day 140 (week 20).**



## ACR20 Response, FUTURE 1 study

■ Results from two different studies are reported, this is not a H2H comparison.




Figure 6: Secukinumab Future 1 Results and Cimzia RAPID-PsA Results: ACR20

**Figure 7: Summary Table of Bayesian Analysis**

Dose Group	N	Observed ACR20	Estimated ACR20	Credible Intervals	
				95%	99%
Placebo	12	16.7%	22%	12% - 36%	9% - 41%
Pooled top doses	30	80.0%	81%	64% - 92%	59% - 94%

**Figure 8: Summary Table of ACR20 response at week 8 in psoriatic arthritis for registered anti-TNFs or Phase III results. Observed ACR20 response rates for registered Anti-TNF's at Week 8 when administered at registered doses**

Drug name (Active ingredient)	Active	Placebo	Δ (Difference between active and placebo)	Reference
ANTI-TNF's				
Humira (Adalimumab)	56.7	11.6	45.1	(1)
Simponi (Golimumab)	43.5	8.3	35.2	(2)
Cimzia (Cetolizumab Pegol)	49.4	22.3	27.1	(3)
ANTI-IL17's				
Cosentyx (Secukinumab)	59.73	21.25	38.5	(4)
ANTI-IL12/23				
Stelara (Ustekinumab)	33.34	20.83	12.51	(5)

Figure 9: Targeted UCB4940 PK concentrations




Figure 9 continued

	Week 0	Week 3	Week 6	Czp (TBC) Trough
<b>Group 1</b>	240 mg	160 mg	160 mg	>20 µg/mL
<b>Group 2</b>	160 mg	80 mg	80 mg	> 10 µg/mL
<b>Group 3</b>	560 mg	320 mg	320 mg	> 40 µg/mL
<b>Group 4</b>	80mg	80 mg	80 mg	< 10 µg/mL

**Figure 10:** Summary PK plot of predicted SC dosing, illustrating that a dose of 320 loading followed by 160mg Q4W or 160 mg Q4W and higher, are able to achieve the plasma concentrations studied in PA0007 at the top 3 doses.





Figure 11: Percent change from baseline in lesional severity score






Figure 12: Percent Change for baseline in PASI

Week	PASI90 (%)					
	Placebo N=13	8mg N=4	40mg N=4	160mg N=6	480mg N=6*	640mg N=6
4	0	0	0	3 (50%)	4 (67%)	5 (83%)
6	0	0	0	2 (33%)	5 (83%)	5 (83%)
12	0	0	0	4 (67%)	5 (100%)	5 (83%)

**Figure 13:Summary Table of PASI 90 response**

**Figure 14: Mean percentage change from baseline in (a) LSS, (b) PASI and (c) PGA in the placebo and bimekizumab cohorts**

Treatment group: ●—● Placebo   ◆◆◆ Bimekizumab 8 mg   ■■■ Bimekizumab 40 mg  
 □□□ Bimekizumab 160 mg   ◇◇◇ Bimekizumab 480 mg   △△△ Bimekizumab 640 mg






Figure 15B

*RUNX2*

Fold change compared to GM relative expression (GOI/Hprt1)

Figure 15A

*SP7*

Fold change compared to GM relative expression (GOI/Hprt1)

Figure 15C




**BMP2**

Figure 15D

**BGLAP**

Fold change compared to GM relative expression (GOI/Hprt1)

Figure 15E

**PHOSPHO1**

Fold change compared to GM relative expression (GOI/Hprt1)

Figure 15G





Figure 15F



29/29

Figure 16A





Figure 16B



SEQUENCE LISTING  
eol f-seqI

<110> UCB BIOPHARMA SPRL  
<120> METHODS OF TREATMENT USING ANTI-IL-17A/F ANTI BODIES  
<130> PF0044W0  
<160> 28  
<170> PatentIn version 3.5  
<210> 1  
<211> 10  
<212> PRT  
<213> Artificial Sequence  
<220>  
<223> Synthetic peptide

<220>  
<221> MI SC FEATURE  
<223> CDRH1

<400> 1

Gly Phe Thr Phe Ser Asp Tyr Asn Met Ala  
1 5 10

<210> 2  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC FEATURE  
<223> CDRH2

<400> 2

Thr Ile Thr Tyr Glu Gly Arg Asn Thr Tyr Tyr Arg Asp Ser Val Lys  
1 5 10 15

Gly

<210> 3  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC FEATURE  
<223> CDRH3

<400> 3

eol f-seql

Pro Pro Glu Tyr Tyr Glu Gly Ser Ile Tyr Arg Leu Trp Phe Ala His  
1 5 10 15

<210> 4  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC\_FEATURE  
<223> CDRL1

<400> 4

Arg Ala Asp Glu Ser Val Thr Thr Leu Met His  
1 5 10

<210> 5  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC\_FEATURE  
<223> CDRL2

<400> 5

Leu Val Ser Asn Arg Glu Ser  
1 5

<210> 6  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC\_FEATURE  
<223> CDRL3

<400> 6

Gln Gln Thr Trp Ser Asp Pro Trp Thr  
1 5

<210> 7  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>

eol f-seqI

<223> Synthetic peptide

<220>

<221> MI SC\_FEATURE

<223> CDRL1 for CA028\_496.g3

<400> 7

Arg Ala Asp Glu Ser Val Arg Thr Leu His Met  
1 5 10

<210> 8

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MI SC\_FEATURE

<223> CDRL2 for CA028\_496.g3

<400> 8

Leu Val Ser Asn Ser Glu Ile  
1 5

<210> 9

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MI SC\_FEATURE

<223> Light chain variable region - CA028\_496 (gL7)

<400> 9

Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Asp Glu Ser Val Thr Thr Leu  
20 25 30

Met His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Leu Val Ser Asn Arg Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Gl u Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Trp Ser Asp Pro Trp  
Page 3

85 eol f-seqI 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg  
100 105

<210> 10  
<211> 107  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC\_FEATURE  
<223> Light Chain variable region - CA028\_496.g3 (gL57)

<400> 10

Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Asp Glu Ser Val Arg Thr Leu  
20 25 30

Met His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Leu Val Ser Asn Ser Glu Ile Gly Val Pro Asp Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Arg Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Gl u Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Trp Ser Asp Pro Trp  
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 11  
<211> 125  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC\_FEATURE  
<223> Heavy chain variable region - CA028\_496 and CA028\_496.g3 (gH9)

<400> 11

Gl u Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly  
1 5 10 15

eol f-seql

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr  
20 25 30

Asn Met Ala Trp Val Arg Glu Ala Pro Gly Lys Glu Leu Glu Trp Val  
35 40 45

Ala Thr Ile Thr Tyr Glu Gly Arg Asn Thr Tyr Tyr Arg Asp Ser Val  
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
65 70 75 80

Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Ser Pro Pro Glu Tyr Tyr Glu Gly Ser Ile Tyr Arg Leu Trp Phe  
100 105 110

Ala His Trp Gly Glu Gly Thr Leu Val Thr Val Ser Ser  
115 120 125

<210> 12

<211> 214

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MI SC\_FEATURE

<223> Light chain - CA028\_496 (w/o signal)

<400> 12

Ala Ile Glu Leu Thr Glu Ser Pro Ser Ser Leu Ser Ala Ser Val Glu  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Asp Glu Ser Val Thr Thr Leu  
20 25 30

Met His Trp Tyr Glu Glu Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Leu Val Ser Asn Arg Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Glu Glu Thr Trp Ser Asp Pro Trp  
85 90 95

Thr Phe Gly Glu Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala  
100 105 110  
eol f-seqI  
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Glu Leu Lys Ser Gly  
115 120 125  
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala  
130 135 140  
Lys Val Glu Trp Lys Val Asp Asn Ala Leu Glu Ser Gly Asn Ser Glu  
145 150 155 160  
Glu Ser Val Thr Glu Glu Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser  
165 170 175  
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr  
180 185 190  
Ala Cys Glu Val Thr His Glu Glu Leu Ser Ser Pro Val Thr Lys Ser  
195 200 205  
Phe Asn Arg Gly Glu Cys  
210

<210> 13  
<211> 214  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC\_FEATURE  
<223> Light chain - CA028\_496.g3 (w/o signal)

<400> 13  
Ala Ile Glu Leu Thr Glu Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Asp Glu Ser Val Arg Thr Leu  
20 25 30

Met His Trp Tyr Glu Glu Lys Pro Glu Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Leu Val Ser Asn Ser Glu Ile Glu Val Pro Asp Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Arg Leu Thr Ile Ser Ser Leu Glu Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Glu Glu Thr Trp Ser Asp Pro Trp  
Page 6

85 eol f-seql 90 95

Thr Phe Gl y Gl n Gl y Thr Lys Val Gl u Ile Lys Arg Thr Val Al a Al a  
100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Gl u Gl n Leu Lys Ser Gl y  
115 120 125

Thr Al a Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Gl u Al a  
130 135 140

Lys Val Gl n Trp Lys Val Asp Asn Al a Leu Gl n Ser Gl y Asn Ser Gl n  
145 150 155 160

Gl u Ser Val Thr Gl u Gl n Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser  
165 170 175

Ser Thr Leu Thr Leu Ser Lys Al a Asp Tyr Gl u Lys His Lys Val Tyr  
180 185 190

Al a Cys Gl u Val Thr His Gl n Gl y Leu Ser Ser Pro Val Thr Lys Ser  
195 200 205

Phe Asn Arg Gl y Gl u Cys  
210

<210> 14  
<211> 234  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC\_FEATURE  
<223> Light chain - CA028\_496.g3 (w/ signal)

<400> 14

Met Ser Val Pro Thr Gl n Val Leu Gl y Leu Leu Leu Leu Trp Leu Thr  
1 5 10 15

Asp Al a Arg Cys Al a Ile Gl n Leu Thr Gl n Ser Pro Ser Ser Leu Ser  
20 25 30

Al a Ser Val Gl y Asp Arg Val Thr Ile Thr Cys Arg Al a Asp Gl u Ser  
35 40 45

Val Arg Thr Leu Met His Trp Tyr Gl n Gl n Lys Pro Gl y Lys Al a Pro  
50 55 60

Lys Leu Leu Ile Tyr Leu Val Ser Asn Ser Gl u Ile Gl y Val Pro Asp  
65 70 75 80

eol f-seqI

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Arg Leu Thr Ile Ser  
85 90 95

Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Trp  
100 105 110

Ser Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg  
115 120 125

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln  
130 135 140

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr  
145 150 155 160

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser  
165 170 175

Gly Asn Ser Gln Glu Ser Val Thr Gln Gln Asp Ser Lys Asp Ser Thr  
180 185 190

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys  
195 200 205

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro  
210 215 220

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys  
225 230

<210> 15

<211> 452

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MI SC\_FEATURE

<223> Heavy chain - CA028\_496

<400> 15

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr  
20 25 30

Asn Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45

eol f-seql

Ala Thr Ile Thr Tyr Glu Glu Arg Asn Thr Tyr Tyr Arg Asp Ser Val  
50 55 60

Lys Glu Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
65 70 75 80

Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Ser Pro Pro Glu Tyr Tyr Glu Glu Ser Ile Tyr Arg Leu Trp Phe  
100 105 110

Ala His Trp Glu Glu Glu Thr Leu Val Thr Val Ser Ser Ala Ser Thr  
115 120 125

Lys Glu Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser  
130 135 140

Glu Ser Thr Ala Ala Leu Glu Cys Leu Val Lys Asp Tyr Phe Pro Glu  
145 150 155 160

Pro Val Thr Val Ser Trp Asn Ser Glu Ala Leu Thr Ser Glu Val His  
165 170 175

Thr Phe Pro Ala Val Leu Glu Ser Ser Glu Leu Tyr Ser Leu Ser Ser  
180 185 190

Val Val Thr Val Pro Ser Ser Ser Leu Glu Thr Lys Thr Tyr Thr Cys  
195 200 205

Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu  
210 215 220 225

Ser Lys Tyr Glu Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu  
225 230 235 240

Glu Glu Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu  
245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser  
260 265 270

Glu Glu Asp Pro Glu Val Glu Phe Asn Trp Tyr Val Asp Glu Val Glu  
275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Glu Phe Asn Ser Thr  
290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Glu Asp Trp Leu Asn  
305 310 315 320

eol f-seql

Gl y Lys Gl u Tyr Lys Cys Lys Val Ser Asn Lys Gl y Leu Pro Ser Ser  
325 330 335

Ile Gl u Lys Thr Ile Ser Lys Al a Lys Gl y Gl n Pro Arg Gl u Pro Gl n  
340 345 350

Val Tyr Thr Leu Pro Pro Ser Gl n Gl u Gl u Met Thr Lys Asn Gl n Val  
355 360 365

Ser Leu Thr Cys Leu Val Lys Gl y Phe Tyr Pro Ser Asp Ile Al a Val  
370 375 380

Gl u Trp Gl u Ser Asn Gl y Gl n Pro Gl u Asn Asn Tyr Lys Thr Thr Pro  
385 390 395 400

Pro Val Leu Asp Ser Asp Gl y Ser Phe Phe Leu Tyr Ser Arg Leu Thr  
405 410 415

Val Asp Lys Ser Arg Trp Gl n Gl u Gl y Asn Val Phe Ser Cys Ser Val  
420 425 430

Met His Gl u Al a Leu His Asn His Tyr Thr Gl n Lys Ser Leu Ser Leu  
435 440 445

Ser Leu Gl y Lys  
450

<210> 16  
<211> 455  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC\_FEATURE  
<223> Heavy chain CA028\_496.g3 (w/o signal)

<400> 16

Gl u Val Gl n Leu Val Gl u Ser Gl y Gl y Gl y Leu Val Gl n Pro Gl y Gl y  
1 5 10 15

Ser Leu Arg Leu Ser Cys Al a Al a Ser Gl y Phe Thr Phe Ser Asp Tyr  
20 25 30

Asn Met Al a Trp Val Arg Gl n Al a Pro Gl y Lys Gl y Leu Gl u Trp Val  
35 40 45

Al a Thr Ile Thr Tyr Gl u Gl y Arg Asn Thr Tyr Tyr Arg Asp Ser Val  
50 55 60

eol f-seqI

Lys Gl y Arg Phe Thr Ile Ser Arg Asp Asn Al a Lys Asn Ser Leu Tyr  
65 70 75 80

Leu Gl n Met Asn Ser Leu Arg Al a Gl u Asp Thr Al a Val Tyr Tyr Cys  
85 90 95

Al a Ser Pro Pro Gl n Tyr Tyr Gl u Gl y Ser Ile Tyr Arg Leu Trp Phe  
100 105 110

Al a His Trp Gl y Gl n Gl y Thr Leu Val Thr Val Ser Ser Al a Ser Thr  
115 120 125

Lys Gl y Pro Ser Val Phe Pro Leu Al a Pro Ser Ser Lys Ser Thr Ser  
130 135 140

Gl y Gl y Thr Al a Al a Leu Gl y Cys Leu Val Lys Asp Tyr Phe Pro Gl u  
145 150 155 160

Pro Val Thr Val Ser Trp Asn Ser Gl y Al a Leu Thr Ser Gl y Val His  
165 170 175

Thr Phe Pro Al a Val Leu Gl n Ser Ser Gl y Leu Tyr Ser Leu Ser Ser  
180 185 190

Val Val Thr Val Pro Ser Ser Ser Leu Gl y Thr Gl n Thr Tyr Ile Cys  
195 200 205

Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Gl u  
210 215 220

Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Al a Pro  
225 230 235 240

Gl u Leu Leu Gl y Gl y Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys  
245 250 255

Asp Thr Leu Met Ile Ser Arg Thr Pro Gl u Val Thr Cys Val Val Val  
260 265 270

Asp Val Ser His Gl u Asp Pro Gl u Val Lys Phe Asn Trp Tyr Val Asp  
275 280 285

Gl y Val Gl u Val His Asn Al a Lys Thr Lys Pro Arg Gl u Gl u Gl n Tyr  
290 295 300

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gl n Asp  
305 310 315 320

Trp Leu Asn Gl y Lys Gl u Tyr Lys Cys Lys Val Ser Asn Lys Al a Leu  
325 330 335

Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Glu Pro Arg  
340 345 350 eol f-seqI

Glu Pro Glu Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys  
355 360 365

Asn Glu Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp  
370 375 380

Ile Ala Val Glu Trp Glu Ser Asn Glu Glu Pro Glu Asn Asn Tyr Lys  
385 390 395 400

Thr Thr Pro Pro Val Leu Asp Ser Asp Glu Ser Phe Phe Leu Tyr Ser  
405 410 415

Lys Leu Thr Val Asp Lys Ser Arg Trp Glu Glu Glu Asn Val Phe Ser  
420 425 430

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Glu Lys Ser  
435 440 445

Leu Ser Leu Ser Pro Glu Lys  
450 455

<210> 17  
<211> 474  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC\_FEATURE  
<223> Heavy chain - CA8\_496.g3 (w/ signal)

<400> 17

Met Glu Trp Ser Trp Val Phe Leu Phe Phe Leu Ser Val Thr Thr Glu  
1 5 10 15

Val His Ser Glu Val Glu Leu Val Glu Ser Glu Glu Glu Leu Val Glu  
20 25 30

Pro Glu Glu Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Phe Thr Phe  
35 40 45

Ser Asp Tyr Asn Met Ala Trp Val Arg Glu Ala Pro Glu Lys Glu Leu  
50 55 60

Glu Trp Val Ala Thr Ile Thr Tyr Glu Glu Arg Asn Thr Tyr Tyr Arg  
65 70 75 80

Asp Ser Val Lys Glu Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn  
Page 12

eol f-seql

85	90	95
Ser Leu Tyr Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val		
100 105 110		
Tyr Tyr Cys Ala Ser Pro Pro Glu Tyr Tyr Glu Gly Ser Ile Tyr Arg		
115 120 125		
Leu Trp Phe Ala His Trp Gly Glu Gly Thr Leu Val Thr Val Ser Ser		
130 135 140		
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys		
145 150 155 160		
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr		
165 170 175		
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser		
180 185 190		
Gly Val His Thr Phe Pro Ala Val Leu Glu Ser Ser Gly Leu Tyr Ser		
195 200 205		
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Glu Thr		
210 215 220		
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys		
225 230 235 240		
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys		
245 250 255		
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro		
260 265 270		
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys		
275 280 285		
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp		
290 295 300		
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu		
305 310 315 320		
Glu Glu Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu		
325 330 335		
His Glu Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn		
340 345 350		
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly		

eol f-seql

355	360	365
Gl n Pro Arg Gl u Pro Gl n Val Tyr Thr Leu Pro Pro Ser Arg Asp Gl u		
370	375	380
Leu Thr Lys Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gl y Phe Tyr		
385	390	395
Pro Ser Asp Ile Ala Val Gl u Trp Gl u Ser Asn Gl y Gl n Pro Gl u Asn		
405	410	415
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gl y Ser Phe Phe		
420	425	430
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gl n Gl n Gl y Asn		
435	440	445
Val Phe Ser Cys Ser Val Met His Gl u Ala Leu His Asn His Tyr Thr		
450	455	460
Gl n Lys Ser Leu Ser Leu Ser Pro Gl y Lys		
465	470	

<210> 18  
 <211> 321  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic peptide

<220>  
 <221> MI SC\_FEATURE  
 <223> Light chain variable region - CA028\_496.g3  
  
 <400> 18

Gl y Cys Cys Ala Thr Cys Cys Ala Gl y Cys Thr Gl y Ala Cys Cys Cys	15	
1	5	10
Al a Gl y Ala Gl y Cys Cys Cys Thr Thr Cys Cys Thr Cys Thr Cys Thr		
20	25	30
Cys Ala Gl y Cys Gl y Cys Cys Ala Gl y Thr Gl y Thr Cys Gl y Gl y Ala		
35	40	45
Gl y Ala Cys Ala Gl y Ala Gl y Thr Gl y Ala Cys Thr Ala Thr Thr Ala		
50	55	60
Cys Cys Thr Gl y Cys Ala Gl y Gl y Gl y Cys Thr Gl y Ala Cys Gl y Ala		
65	70	75
Al a Ala Gl y Cys Gl y Thr Gl y Ala Gl y Ala Ala Cys Ala Thr Thr Gl y		
85	90	95

eol f-seql

Ala Thr Gly Cys Ala Cys Thr Gly Gly Thr Ala Cys Cys Ala Ala Cys  
100 105 110

Ala Gly Ala Ala Gly Cys Cys Thr Gly Gly Cys Ala Ala Ala Gly Cys  
115 120 125

Cys Cys Cys Cys Ala Ala Gly Cys Thr Cys Cys Thr Gly Ala Thr Cys  
130 135 140

Thr Ala Thr Cys Thr Gly Gly Thr Thr Thr Cys Cys Ala Ala Thr Thr  
145 150 155 160

Cys Gly Gly Ala Gly Ala Thr Thr Gly Gly Ala Gly Thr Cys Cys Cys  
165 170 175

Cys Gly Ala Cys Ala Gly Gly Thr Thr Cys Ala Gly Cys Gly Gly Cys  
180 185 190

Ala Gly Thr Gly Gly Thr Cys Thr Gly Gly Ala Ala Cys Thr Gly  
195 200 205

Ala Cys Thr Thr Thr Cys Gly Cys Cys Thr Gly Ala Cys Ala Ala Thr  
210 215 220

Cys Thr Cys Cys Thr Cys Ala Cys Thr Cys Cys Ala Gly Cys Cys Cys  
225 230 235 240

Gly Ala Ala Gly Ala Thr Thr Thr Cys Gly Cys Cys Ala Cys Cys Thr  
245 250 255

Ala Cys Thr Ala Thr Thr Gly Cys Cys Ala Gly Cys Ala Gly Ala Cys  
260 265 270

Thr Thr Gly Gly Ala Gly Cys Gly Ala Cys Cys Cys Thr Thr Gly Gly  
275 280 285

Ala Cys Ala Thr Thr Thr Gly Gly Ala Cys Ala Gly Gly Cys Ala  
290 295 300

Cys Ala Ala Ala Ala Gly Thr Gly Gly Ala Gly Ala Thr Cys Ala Ala  
305 310 315 320

Gly

<210> 19  
<211> 375

<212> PRT

<213> Artificial Sequence

<220>

eol f-seqI

<223> Synthetic peptide

<220>

<221> MI SC\_FEATURE

<223> Heavy chain variable region - CA028\_496.g3

<400> 19

Gly Ala Gly Gly Thr Thr Cys Ala Gly Cys Thr Cys Gly Thr Thr Gly  
1 5 10 15

Ala Ala Thr Cys Cys Gly Gly Ala Gly Gly Cys Gly Gly Ala Cys Thr  
20 25 30

Cys Gly Thr Gly Cys Ala Gly Cys Cys Thr Gly Gly Gly Gly Cys  
35 40 45

Thr Cys Cys Thr Thr Gly Cys Gly Gly Cys Thr Gly Ala Gly Cys Thr  
50 55 60

Gly Cys Gly Cys Thr Gly Cys Cys Ala Gly Thr Gly Gly Cys Thr Thr  
65 70 75 80

Cys Ala Cys Thr Thr Cys Ala Gly Cys Gly Ala Thr Thr Ala Cys  
85 90 95

Ala Ala Thr Ala Thr Gly Gly Cys Cys Thr Gly Gly Gly Thr Gly Cys  
100 105 110

Gly Cys Cys Ala Gly Gly Cys Cys Cys Ala Gly Gly Cys Ala Ala  
115 120 125

Gly Gly Gly Thr Cys Thr Gly Gly Ala Gly Thr Gly Gly Thr Gly  
130 135 140

Gly Cys Cys Ala Cys Ala Ala Thr Thr Ala Cys Cys Thr Ala Thr Gly  
145 150 155 160

Ala Gly Gly Cys Ala Gly Ala Ala Ala Cys Ala Cys Thr Thr Ala  
165 170 175

Thr Thr Ala Cys Cys Gly Gly Ala Thr Thr Cys Ala Gly Thr Gly  
180 185 190

Ala Ala Ala Gly Gly Cys Gly Ala Thr Thr Thr Ala Cys Cys Ala  
195 200 205

Thr Cys Ala Gly Cys Ala Gly Gly Ala Thr Ala Ala Thr Gly Cys  
210 215 220

Ala Ala Ala Gly Ala Ala Cys Ala Gly Thr Cys Thr Gly Thr Ala Cys  
225 230 235 240

eol f-seql

Cys Thr Gly Cys Ala Gly Ala Thr Gly Ala Ala Cys Thr Cys Thr Cys  
245 250 255

Thr Gly Ala Gly Ala Gly Cys Thr Gly Ala Gly Gly Ala Cys Ala Cys  
260 265 270

Cys Gly Cys Thr Gly Thr Cys Thr Ala Cys Thr Ala Thr Thr Gly Thr  
275 280 285

Gly Cys Ala Ala Gly Cys Cys Ala Cys Cys Cys Ala Gly Thr  
290 295 300

Ala Cys Thr Ala Thr Gly Ala Gly Gly Cys Thr Cys Ala Ala Thr  
305 310 315 320

Cys Thr Ala Cys Ala Gly Ala Thr Thr Gly Thr Gly Gly Thr Thr Thr  
325 330 335

Gly Cys Cys Cys Ala Thr Thr Gly Gly Gly Cys Cys Ala Gly Gly  
340 345 350

Gly Ala Ala Cys Ala Cys Thr Gly Gly Thr Gly Ala Cys Cys Gly Thr  
355 360 365

Cys Thr Cys Gly Ala Gly Cys  
370 375

<210> 20  
<211> 705

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC\_FEATURE  
<223> Light chain - CA028\_496 (w/ signal)

<400> 20

Ala Thr Gly Thr Cys Ala Gly Thr Thr Cys Cys Cys Ala Cys Ala Cys  
1 5 10 15

Ala Gly Gly Thr Gly Cys Thr Gly Gly Gly Cys Cys Thr Gly Cys Thr  
20 25 30

Thr Cys Thr Gly Thr Thr Gly Thr Gly Gly Cys Thr Cys Ala Cys Cys  
35 40 45

Gly Ala Thr Gly Cys Thr Ala Gly Gly Thr Gly Thr Gly Cys Cys Ala  
50 55 60

eol f-seql

Thr Cys Cys Ala Gly Cys Thr Gly Ala Cys Cys Cys Ala Gly Ala Gly  
65 70 75 80

Cys Cys Cys Thr Thr Cys Cys Thr Cys Thr Cys Thr Cys Ala Gly Cys  
85 90 95

Gly Cys Cys Ala Gly Thr Gly Thr Cys Gly Gly Ala Gly Ala Cys Ala  
100 105 110

Gly Ala Gly Thr Gly Ala Cys Thr Ala Thr Thr Ala Cys Cys Thr Gly  
115 120 125

Cys Ala Gly Gly Cys Thr Gly Ala Cys Gly Ala Ala Ala Ala Gly Cys  
130 135 140

Gly Thr Gly Ala Cys Cys Ala Cys Ala Thr Thr Gly Ala Thr Gly Cys  
145 150 155 160

Ala Cys Thr Gly Gly Thr Ala Cys Cys Ala Ala Cys Ala Gly Ala  
165 170 175

Gly Cys Cys Thr Gly Gly Cys Ala Ala Ala Gly Cys Cys Cys Cys Cys  
180 185 190

Ala Ala Gly Cys Thr Cys Cys Thr Gly Ala Thr Cys Thr Ala Thr Cys  
195 200 205

Thr Gly Gly Thr Thr Cys Cys Ala Ala Thr Cys Gly Gly Gly Ala  
210 215 220

Gly Thr Cys Thr Gly Gly Ala Gly Thr Cys Cys Cys Cys Ala Gly Cys  
225 230 235 240

Ala Gly Gly Thr Thr Cys Ala Gly Cys Gly Gly Cys Ala Gly Thr Gly  
245 250 255

Gly Gly Thr Cys Thr Gly Gly Ala Ala Cys Thr Gly Ala Cys Thr Thr  
260 265 270

Thr Ala Cys Cys Cys Thr Gly Ala Cys Ala Ala Thr Cys Thr Cys Cys  
275 280 285

Thr Cys Ala Cys Thr Cys Cys Ala Gly Cys Cys Cys Gly Ala Ala Gly  
290 295 300

Ala Thr Thr Thr Cys Gly Cys Cys Ala Cys Cys Thr Ala Cys Thr Ala  
305 310 315 320

Thr Thr Gly Cys Cys Ala Gly Cys Ala Gly Ala Cys Thr Thr Gly Gly  
325 330 335

Ala Gly Cys Gly Ala Cys Cys Cys Thr Thr Gly Gly Ala Cys Ala Thr  
340 345 350  
eol f-seql  
Thr Thr Gly Gly Ala Cys Ala Gly Gly Cys Ala Cys Ala Ala Ala  
355 360 365  
Ala Gly Thr Gly Gly Ala Gly Ala Thr Cys Ala Ala Gly Cys Gly Thr  
370 375 380  
Ala Cys Gly Gly Thr Ala Gly Cys Gly Cys Cys Cys Cys Cys Ala Thr  
385 390 395 400  
Cys Thr Gly Thr Cys Thr Cys Ala Thr Cys Thr Thr Cys Cys Cys  
405 410 415  
Gly Cys Cys Ala Thr Cys Thr Gly Ala Thr Gly Ala Gly Cys Ala Gly  
420 425 430  
Thr Thr Gly Ala Ala Ala Thr Cys Thr Gly Gly Ala Ala Cys Thr Gly  
435 440 445  
Cys Cys Thr Cys Thr Gly Thr Thr Gly Thr Gly Thr Gly Cys Cys Thr  
450 455 460  
Gly Cys Thr Gly Ala Ala Thr Ala Ala Cys Thr Thr Cys Thr Ala Thr  
465 470 475 480  
Cys Cys Cys Ala Gly Ala Gly Ala Gly Cys Cys Ala Ala Ala Gly  
485 490 495  
Thr Ala Cys Ala Gly Thr Gly Gly Ala Ala Gly Gly Thr Gly Ala  
500 505 510  
Thr Ala Ala Cys Gly Cys Cys Cys Thr Cys Cys Ala Ala Thr Cys Gly  
515 520 525  
Gly Gly Thr Ala Ala Cys Thr Cys Cys Cys Ala Gly Gly Ala Gly Ala  
530 535 540  
Gly Thr Gly Thr Cys Ala Cys Ala Gly Ala Gly Cys Ala Gly Gly Ala  
545 550 555 560  
Cys Ala Gly Cys Ala Ala Gly Gly Ala Cys Ala Gly Cys Ala Cys Cys  
565 570 575  
Thr Ala Cys Ala Gly Cys Cys Thr Cys Ala Gly Cys Ala Gly Cys Ala  
580 585 590  
Cys Cys Cys Thr Gly Ala Cys Gly Cys Thr Gly Ala Gly Cys Ala Ala  
595 600 605

Ala Gly Cys Ala Gly Ala Cys Thr Ala Cys Gly Ala Gly Ala Ala Ala  
610 615 eol f-seqI 620

Cys Ala Cys Ala Ala Ala Gly Thr Cys Thr Ala Cys Gly Cys Cys Thr  
625 630 635 640

Gly Cys Gly Ala Ala Gly Thr Cys Ala Cys Cys Cys Ala Thr Cys Ala  
645 650 655

Gly Gly Gly Cys Cys Thr Gly Ala Gly Cys Thr Cys Gly Cys Cys Cys  
660 665 670

Gly Thr Cys Ala Cys Ala Ala Gly Ala Gly Cys Thr Thr Cys Ala  
675 680 685

Ala Cys Ala Gly Gly Gly Ala Gly Ala Gly Thr Gly Thr Thr Ala  
690 695 700

Gly  
705

<210> 21  
<211> 645  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MI SC\_FEATURE  
<223> Light chain - CA028\_496.g3 (w/o signal)

<400> 21

Gly Cys Cys Ala Thr Cys Cys Ala Gly Cys Thr Gly Ala Cys Cys Cys  
1 5 10 15

Ala Gly Ala Gly Cys Cys Cys Thr Thr Cys Cys Thr Cys Thr Cys Thr  
20 25 30

Cys Ala Gly Cys Gly Cys Cys Ala Gly Thr Gly Thr Cys Gly Gly Ala  
35 40 45

Gly Ala Cys Ala Gly Ala Gly Thr Gly Ala Cys Thr Ala Thr Thr Ala  
50 55 60

Cys Cys Thr Gly Cys Ala Gly Gly Gly Cys Thr Gly Ala Cys Gly Ala  
65 70 75 80

Ala Ala Gly Cys Gly Thr Gly Ala Gly Ala Ala Cys Ala Thr Thr Gly  
85 90 95

Ala Thr Gly Cys Ala Cys Thr Gly Gly Thr Ala Cys Cys Ala Ala Cys  
Page 20

eol f-seql

100 105 110

Ala Glu Ala Ala Gly Cys Cys Thr Glu Glu Cys Ala Ala Ala Glu Cys  
115 120 125

Cys Cys Cys Cys Ala Ala Glu Cys Thr Cys Cys Thr Glu Ala Thr Cys  
130 135 140

Thr Ala Thr Cys Thr Glu Glu Thr Thr Thr Cys Cys Ala Ala Thr Thr  
145 150 155 160

Cys Glu Glu Ala Glu Ala Thr Thr Glu Glu Ala Glu Thr Cys Cys Cys  
165 170 175

Cys Glu Ala Cys Ala Glu Glu Thr Thr Cys Ala Glu Cys Glu Glu Cys  
180 185 190

Ala Glu Thr Glu Glu Thr Cys Thr Glu Glu Ala Ala Cys Thr Glu  
195 200 205

Ala Cys Thr Thr Thr Cys Glu Cys Cys Thr Glu Ala Cys Ala Ala Thr  
210 215 220

Cys Thr Cys Cys Thr Cys Ala Cys Thr Cys Cys Ala Glu Cys Cys Cys  
225 230 235 240

Glu Ala Ala Glu Ala Thr Thr Thr Cys Glu Cys Cys Ala Cys Cys Thr  
245 250 255

Ala Cys Thr Ala Thr Thr Glu Cys Cys Ala Glu Cys Ala Glu Ala Cys  
260 265 270

Thr Thr Glu Glu Ala Glu Cys Glu Ala Cys Cys Cys Thr Thr Glu Glu  
275 280 285

Ala Cys Ala Thr Thr Thr Glu Glu Ala Cys Ala Glu Glu Cys Ala  
290 295 300

Cys Ala Ala Ala Ala Glu Thr Glu Glu Ala Glu Ala Thr Cys Ala Ala  
305 310 315 320

Glu Cys Glu Thr Ala Cys Glu Glu Thr Ala Glu Cys Glu Glu Cys Cys  
325 330 335

Cys Cys Ala Thr Cys Thr Glu Thr Cys Thr Thr Cys Ala Thr Cys Thr  
340 345 350

Thr Cys Cys Cys Glu Cys Cys Ala Thr Cys Thr Glu Ala Thr Glu Ala  
355 360 365

Glu Cys Ala Glu Thr Thr Glu Ala Ala Ala Thr Cys Thr Glu Glu Ala

eol f-seql

370 375 380

Ala Cys Thr Gly Cys Cys Thr Cys Thr Gly Thr Thr Gly Thr  
385 390 395 400

Gly Cys Cys Thr Gly Cys Thr Gly Ala Ala Thr Ala Ala Cys Thr Thr  
405 410 415

Cys Thr Ala Thr Cys Cys Cys Ala Gly Ala Gly Ala Gly Gly Cys Cys  
420 425 430

Ala Ala Ala Gly Thr Ala Cys Ala Gly Thr Gly Gly Ala Ala Gly Gly  
435 440 445

Thr Gly Gly Ala Thr Ala Ala Cys Gly Cys Cys Cys Thr Cys Cys Ala  
450 455 460

Ala Thr Cys Gly Gly Thr Ala Ala Cys Thr Cys Cys Cys Ala Gly  
465 470 475 480

Gly Ala Gly Ala Gly Thr Gly Thr Cys Ala Cys Ala Gly Ala Gly Cys  
485 490 495

Ala Gly Gly Ala Cys Ala Gly Cys Ala Ala Gly Gly Ala Cys Ala Gly  
500 505 510

Cys Ala Cys Cys Thr Ala Cys Ala Gly Cys Cys Thr Cys Ala Gly Cys  
515 520 525

Ala Gly Cys Ala Cys Cys Cys Thr Gly Ala Cys Gly Cys Thr Gly Ala  
530 535 540

Gly Cys Ala Ala Ala Ala Gly Cys Ala Gly Ala Cys Thr Ala Cys Gly Ala  
545 550 555 560

Gly Ala Ala Ala Ala Cys Ala Cys Ala Ala Cys Gly Thr Cys Thr Ala Cys  
565 570 575

Gly Cys Cys Thr Gly Cys Gly Ala Ala Gly Thr Cys Ala Cys Cys Cys  
580 585 590

Ala Thr Cys Ala Gly Gly Cys Cys Thr Gly Ala Gly Cys Thr Cys  
595 600 605

Gly Cys Cys Cys Gly Thr Cys Ala Cys Ala Ala Gly Ala Gly Cys  
610 615 620

Thr Thr Cys Ala Ala Cys Ala Gly Gly Gly Ala Gly Ala Gly Thr  
625 630 635 640

Gly Thr Thr Ala Gly

<210> 22  
 <211> 705  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<220>  
 <221> MI SC\_FEATURE  
 <223> Light chain - CA028\_496.g3 (w/ signal)

<400> 22

Ala Thr Gly Thr Cys Ala Gly Thr Thr Cys Cys Cys Ala Cys Ala Cys  
 1 5 10 15

Ala Gly Gly Thr Gly Cys Thr Gly Gly Cys Cys Thr Gly Cys Thr  
 20 25 30

Thr Cys Thr Gly Thr Thr Gly Thr Gly Gly Cys Thr Cys Ala Cys Cys  
 35 40 45

Gly Ala Thr Gly Cys Thr Ala Gly Gly Thr Gly Thr Gly Cys Cys Ala  
 50 55 60

Thr Cys Cys Ala Gly Cys Thr Gly Ala Cys Cys Cys Ala Gly Ala Gly  
 65 70 75 80

Cys Cys Cys Thr Thr Cys Cys Thr Cys Thr Cys Thr Cys Ala Gly Cys  
 85 90 95

Gly Cys Cys Ala Gly Thr Gly Thr Cys Gly Gly Ala Gly Ala Cys Ala  
 100 105 110

Gly Ala Gly Thr Gly Ala Cys Thr Ala Thr Thr Ala Cys Cys Thr Gly  
 115 120 125

Cys Ala Gly Gly Gly Cys Thr Gly Ala Cys Gly Ala Ala Ala Gly Cys  
 130 135 140

Gly Thr Gly Ala Gly Ala Ala Cys Ala Thr Thr Gly Ala Thr Gly Cys  
 145 150 155 160

Ala Cys Thr Gly Gly Thr Ala Cys Cys Ala Ala Cys Ala Gly Ala Ala  
 165 170 175

Gly Cys Cys Thr Gly Gly Cys Ala Ala Ala Gly Cys Cys Cys Cys Cys  
 180 185 190

Ala Ala Gly Cys Thr Cys Cys Thr Gly Ala Thr Cys Thr Ala Thr Cys  
 195 200 205

eol f-seql

Thr Gl y Gl y Thr Thr Thr Cys Cys Al a Al a Thr Thr Cys Gl y Gl y Al a  
210 215 220

Gl y Al a Thr Thr Gl y Gl y Al a Gl y Thr Cys Cys Cys Cys Gl y Al a Cys  
225 230 235 240

Al a Gl y Gl y Thr Thr Cys Al a Gl y Cys Gl y Gl y Cys Al a Gl y Thr Gl y  
245 250 255

Gl y Gl y Thr Cys Thr Gl y Gl y Al a Al a Cys Thr Gl y Al a Cys Thr Thr  
260 265 270

Thr Cys Gl y Cys Cys Thr Gl y Al a Cys Al a Al a Thr Cys Thr Cys Cys  
275 280 285

Thr Cys Al a Cys Thr Cys Cys Al a Gl y Cys Cys Cys Gl y Al a Al a Gl y  
290 295 300

Al a Thr Thr Thr Cys Gl y Cys Cys Al a Cys Cys Thr Al a Cys Thr Al a  
305 310 315 320

Thr Thr Gl y Cys Cys Al a Gl y Cys Al a Gl y Al a Cys Thr Thr Gl y Gl y  
325 330 335

Al a Gl y Cys Gl y Al a Cys Cys Cys Thr Thr Gl y Gl y Al a Cys Al a Thr  
340 345 350

Thr Thr Gl y Gl y Al a Cys Al a Gl y Gl y Cys Al a Cys Al a Al a Al a  
355 360 365

Al a Gl y Thr Gl y Gl y Al a Gl y Al a Thr Cys Al a Al a Gl y Cys Gl y Thr  
370 375 380

Al a Cys Gl y Gl y Thr Al a Gl y Cys Gl y Gl y Cys Cys Cys Cys Al a Thr  
385 390 395 400

Cys Thr Gl y Thr Cys Thr Cys Al a Thr Cys Thr Thr Cys Cys Cys  
405 410 415

Gl y Cys Cys Al a Thr Cys Thr Gl y Al a Thr Gl y Al a Gl y Cys Al a Gl y  
420 425 430

Thr Thr Gl y Al a Al a Al a Thr Cys Thr Gl y Gl y Al a Al a Cys Thr Gl y  
435 440 445

Cys Cys Thr Cys Thr Gl y Thr Thr Gl y Thr Gl y Thr Gl y Cys Cys Thr  
450 455 460

Gl y Cys Thr Gl y Al a Al a Thr Al a Al a Cys Thr Thr Cys Thr Al a Thr  
465 470 475 480

eol f-seql

Cys Cys Cys Al a Gl y Al a Gl y Al a Gl y Gl y Cys Cys Al a Al a Al a Gl y  
485 490 495

Thr Al a Cys Al a Gl y Thr Gl y Gl y Al a Al a Gl y Gl y Thr Gl y Gl y Al a  
500 505 510

Thr Al a Al a Cys Gl y Cys Cys Cys Thr Cys Cys Al a Al a Thr Cys Gl y  
515 520 525

Gl y Gl y Thr Al a Al a Cys Thr Cys Cys Cys Al a Gl y Gl y Al a Gl y Al a  
530 535 540

Gl y Thr Gl y Thr Cys Al a Cys Al a Gl y Al a Gl y Cys Al a Gl y Gl y Al a  
545 550 555 560

Cys Al a Gl y Cys Al a Al a Gl y Gl y Al a Cys Al a Gl y Cys Al a Cys Cys  
565 570 575

Thr Al a Cys Al a Gl y Cys Cys Thr Cys Al a Gl y Cys Al a Gl y Cys Al a  
580 585 590

Cys Cys Cys Thr Gl y Al a Cys Gl y Cys Thr Gl y Al a Gl y Cys Al a Al a  
595 600 605

Al a Gl y Cys Al a Gl y Al a Cys Thr Al a Cys Gl y Al a Gl y Al a Al a Al a  
610 615 620

Cys Al a Cys Al a Al a Al a Gl y Thr Cys Thr Al a Cys Gl y Cys Cys Thr  
625 630 635 640

Gl y Cys Gl y Al a Al a Gl y Thr Cys Al a Cys Cys Cys Al a Thr Cys Al a  
645 650 655

Gl y Gl y Gl y Cys Cys Thr Gl y Al a Gl y Cys Thr Cys Gl y Cys Cys Cys  
660 665 670

Gl y Thr Cys Al a Cys Al a Al a Al a Gl y Al a Gl y Cys Thr Thr Cys Al a  
675 680 685

Al a Cys Al a Gl y Gl y Gl y Al a Gl y Al a Gl y Thr Gl y Thr Thr Al a  
690 695 700

Gl y  
705

<210> 23  
<211> 2020  
<212> DNA  
<213> Artificial Sequence

<220>

## eol f-seql

&lt;223&gt; Synthetic polynucleotide

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Heavy chain CA028\_496 (w/ signal)

&lt;400&gt; 23

atggaatggc	cctgggtctt	cctgttttc	cttctgtca	caaccgggg	gcacagcgag	60
gttcagctcg	ttgaatccgg	aggcggactc	gtgcagcctg	ggggctcctt	gcggctgagc	120
tgcgctgcca	gtggcttcac	tttcagcgat	tacaatatgg	cctgggtgcg	ccaggcccc	180
ggcaagggtc	tggagtgggt	ggccacaatt	acctatgagg	gcagaaacac	ttattaccgg	240
gattcagtga	aagggcgatt	taccatcagc	agggataatg	caaagaacag	tctgtacctg	300
cagatgaact	ctctgagagc	tgaggacacc	gctgtctact	attgtgcaag	cccaccccg	360
tactatgagg	gctcaatcta	cagattgtgg	tttgcattt	ggggccaggg	aacactggtg	420
accgtctcga	gcgcttctac	aaaggcccc	tccgtttcc	ccctggcgcc	ctgctccagg	480
agcacctccg	agagcacagc	cgccctgggc	tgcctggta	aggactactt	ccccgaaccg	540
gtgacggtgt	cgttggactc	aggccctgt	accagccgc	tgcacacctt	cccggtgtc	600
ctacagtccct	caggactcta	ctccctcagc	agcgtggta	ccgtgccctc	cagcagctt	660
ggcacgaaga	cctacacc	caacgtat	cacaagcc	gcaacaccaa	ggtgtgacaag	720
agagttggtg	agaggccagc	acagggaggg	agggtgtctg	cttggagcca	ggctcagccc	780
tcctgcctgg	acgcaccccg	gctgtcagc	cccagccag	ggcagcaagg	catgccccat	840
ctgtctcc	acccggaggc	ctctgaccac	cccactcatg	cccagggaga	gggtcttctg	900
gattttcca	ccaggctccg	ggcagccaca	ggctggatgc	ccctacccca	ggccctgcgc	960
atacaggggc	aggtgctgc	ctcagaccc	ccaagagcca	tatccggag	gaccctgccc	1020
ctgacctaag	cccacccaa	aggccaaact	ctccactccc	tcaagtcaga	cacccctct	1080
cctccagat	ctgagtaact	cccaatcttc	tctctgcaga	gtccaaatat	ggtccccat	1140
gcccaccatg	cccaggtaa	ccaacccagg	cctgcctc	cagctcaagg	cgggacaggt	1200
gcccttagat	agcctgc	cagggacagg	ccccagccgg	gtgctgacgc	atccacctcc	1260
atctcttc	cagcacctg	gttccctgggg	ggaccatcag	tcttcctgtt	cccccaaaa	1320
cccaaggaca	ctctcatgat	ctccggacc	cctgaggta	cgtgcgttgt	ggtggacgt	1380
agccaggaag	accccgaggt	ccagttcaac	tggtacgtgg	atggcgtgga	ggtgcataat	1440
gccaagacaa	agccgcggg	ggagcgttc	aacagcacgt	accgtgttgt	cagcgtcctc	1500
accgtcctgc	accaggactg	gctgaacggc	aaggagtaca	agtgcaggt	ctccaacaaa	1560
ggcctccgt	cctccatcga	gaaaaccatc	tccaaagcca	aaggtggac	ccacgggtg	1620
cgagggccac	atggacagag	gtcagctcg	cccaccctct	gccctgggg	tgaccgctgt	1680
gccaacctct	gtccctacag	ggcagcccc	agagccacag	gtgtacaccc	tgccccatc	1740
ccaggaggag	atgaccaaga	accaggtcag	cctgacc	ctggtaaa	gcttctaccc	1800

eol f-seq1

cagcgacatc	gccgtggagt	gggagagcaa	tggcagccg	gagaacaact	acaagaccac	1860
gcctccgtg	ctggactccg	acggctcctt	cttcctctac	agcaggctaa	ccgtggacaa	1920
gagcagggtgg	caggagggga	atgtcttctc	atgctccgtg	atgcatgagg	ctctgcacaa	1980
ccactacaca	cagaagagcc	tctccctgtc	tctgggtaaa			2020

<210> 24  
<211> 1365  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic polynucleotide

<220>  
<221> mi sc\_feature  
<223> Heavy chain - CA028\_496.g3 (w/ exons, w/o signal)

<400> 24  
gaggttcagc tcgttgaatc cgaggcgga ctcgtgcagc ctgggggctc cttgcggctg 60  
actgcgcgtg ccagtggctt cactttcagc gattacaata tggcctgggt gcgccagggcc  
ccaggcaagg gtctggagtg ggtggccaca attacctatg agggcagaaaa cacttattac 120  
cgggattcag taaaaggcg atttaccatc agcagggata atgcaaagaa cagtctgtac  
ctgcagatga actctctgag agctgaggac accgctgtct actattgtgc aagcccaccc 180  
cagtactatg agggctcaat ctacagattg tggggccccc attggggcca gggAACACTG  
gtgaccgtct cgagcgcttc tacaaggc ccatcggtct tccccctggc accctccctcc 240  
aagagcacct ctgggggcac agcggccctg ggctgcctgg tcaaggacta cttccccgaa  
ccggtgacgg tgcgtggaa ctcaggcgcc ctgaccagcg gcgtgcacac cttcccgct 300  
gtcctacagt cctcaggact ctactccctc agcagcgtgg tgaccgtgcc ctccagcagc  
ttgggcaccc agacctacat ctgcaacgtg aatcacaagc ccagcaacac caaggtcgac  
aagaaagttg agccaaatc ttgtgacaaa actcacacat gccaccgtg cccagcacct 360  
gaactccctgg gggaccgtc agtctccctc ttccccccaa aacccaagga caccctcatg  
atctcccgga cccctgaggt cacatcggtg gtggggacg tgaccacga agaccctgag 420  
gtcaagttca actggtagt ggacggcggt gaggtgcata atgccaagac aaagccgcgg  
gaggagcagt acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac 480  
tggctgaatg gcaaggagta caagtcaag gtctccaaca aagccctccc agccccatc  
gagaaaacca tctccaaagc caaagcgcag ccccgagaac cacaggtgtt caccctgccc 540  
ccatcccggtt atgagctgac caagaaccag gtcagcgtga cctgcctggt caaaggcttc  
tatcccagcg acatcgccgt ggagtggag agcaatggc agccggagaa caactacaag  
accacgcctc ccgtgctggc ctccgacggc tccttcttcc tctacagcaa gtcaccgtg 600  
gacaagagca ggtggcagca gggaaacgtc ttctcatgtt ccgtatgtca tgaggctctg  
cacaaccact acacgcagaa gagcctctcc ctgtctccgg gtaaa 660  
1320  
1365

eol f-seql

<210> 25  
<211> 1422  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic polynucleotide

<220>  
<221> misc\_feature  
<223> Heavy chain - CA028\_496.g3 (w/ signal and exons)

<400> 25	
atggaaatggt cctgggtctt cctgttttc ctttctgtca caaccgggggt gcacagcgag	60
gttcagctcg ttgaatccgg aggccgactc gtgcagcctg ggggctcctt gcggctgagc	120
tgcgctgcca gtggcttcac tttcagcgat tacaatatgg cctgggtgcg ccaggccccca	180
ggcaagggtc tggagtggtt ggcacaattt acctatgagg gcagaaacac ttattaccgg	240
gattcagtga aaggcgcatt taccatcagc agggataatg caaagaacag tctgtacctg	300
cagatgaact ctctgagagc tgaggacacc gctgtctact atttgcaag cccaccccg	360
tactatgagg gctcaatcta cagattgtgg tttgccattt gggccaggg aacactggtg	420
accgtctcga gcgccttctac aaaggccccca tcggtcttcc ccctggcacc ctcctccaag	480
agcacctctg gggcacagc ggcctggc tgcctggta aggactactt cccgaaccg	540
gtgacggtgt cgtggactc aggcgcctg accagccgc tgacacaccc ttggctgtc	600
ctacagtctt caggactcta ctccctcagc agcgtggta ccgtccctc cagcagcttgc	660
ggcacccaga cctacatctg caacgtaat cacaagccccca gcaacaccaa ggtcgacaag	720
aaagttgagc ccaaattttg tgacaaaact cacacatgcc caccgtgccc agcacctgaa	780
ctccctgggg gaccgtcagt ctccctttc ccccaaaaac ccaaggacac cctcatgatc	840
tcccgaccc ctgaggactc atgcgtggta gtggacgtga gccacgaaga ccctgaggta	900
aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa gccgcgggag	960
gagcagtaca acagcacgta ccgtgtggc agcgtctca ccgtccctgca ccaggactgg	1020
ctgaatggca aggagtacaa gtgcaaggta tccaacaaag ccctcccgcc cccatcgag	1080
aaaaccatct ccaaagccaa agcgcagccc cgagaaccac aggtgtacac cctgccccca	1140
tcccgatg agctgaccaa gaaccaggta agcctgaccc gcctggtaaa aggcttctat	1200
cccaaggaca tcgcccgtgaa gtggagagc aatggcagc cggagaacaa ctacaagacc	1260
acgcctcccg tgctggactc cgacggctcc ttcttcctct acagcaagct caccgtggac	1320
aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tcatgcatga ggctctgcac	1380
aaccactaca cgcagaagag cctccctg tctccggta aa	1422

<210> 26  
<211> 1422  
<212> DNA

## eol f-seql

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Heavy chain - CA028\_496.g3 (w/ signal)

&lt;400&gt; 26

atggaatgg	cctgggtctt	cctgttttc	cttctgtca	caaccgggg	gcacagcgag	60
gttcagctcg	ttgaatccgg	aggcggactc	gtgcagcctg	ggggctcctt	gcccgtgagc	120
tgcgctgcca	gtggcttcac	tttcagcgat	tacaatatgg	cctgggtgcg	ccaggcccc	180
ggcaagggtc	tggagtgggt	gccacaatt	acctatgagg	gcagaaacac	ttattaccgg	240
gattcagtga	aagggcgatt	taccatcagc	agggataatg	caaagaacag	tctgtacctg	300
cagatgaact	ctctgagagc	tgaggacacc	gctgtctact	attgtgcaag	cccacccag	360
tactatgagg	gctcaatcta	cagattgtgg	tttgcattt	ggggccaggg	aacactggtg	420
accgtctcg	gcgcttctac	aaaggcccc	tcggcttcc	ccctggcacc	ctccctccaag	480
agcacctctg	ggggcacagc	ggccctggc	tgcctggta	aggactactt	cccccgaaccg	540
gtgacggtgt	cgttgaactc	aggcgccctg	accagcggcg	tgcacaccc	ccggctgtc	600
ctacagtcc	caggactcta	ctccctcagc	agcgtggta	ccgtgcctc	cagcagctt	660
ggcacccaga	cctacatctg	caacgtgaat	cacaagccc	gcaacaccaa	ggtcgacaag	720
aaagttgagc	ccaaatctt	tgacaaaact	cacacatgcc	caccgtgccc	agcacctgaa	780
ctcctgggg	gaccgtcagt	cttccttcc	ccccaaaac	ccaaggacac	cctcatgatc	840
tcccgaccc	ctgaggtcac	atgcgtgg	gtggacgtga	gccacgaaga	ccctgagg	900
aagttcaact	ggtacgtgga	cggcgtggag	gtgcataatg	ccaagacaaa	gccgcggag	960
gagcagtaca	acagcacgta	ccgtgtggc	agcgtctca	ccgtcctgca	ccaggactgg	1020
ctgaatggca	aggagtacaa	gtgcaagg	tccaaacaaag	ccctccc	ccccatcgag	1080
aaaaccatct	ccaaagccaa	agcgcagccc	cgagaaccac	aggtgtacac	cctgccccca	1140
tcccgatg	agctgaccaa	gaaccagg	agcctgac	gcctggtaa	aggcttctat	1200
cccagcgaca	tcgcccgtg	gtggagagc	aatggcagc	cggagaacaa	ctacaagacc	1260
acgcctcccg	tgctggactc	cgacggctcc	ttcttcc	acagcaagct	caccgtggac	1320
aagagcaggt	ggcagcagg	gaacgttcc	tcatgctcc	tgtatgcatg	ggctctgcac	1380
aaccactaca	cgcagaagag	cctccctg	tctccggta	aa		1422

&lt;210&gt; 27

&lt;211&gt; 132

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

Gly Ile Thr Ile Pro Arg Asn Pro Gly Cys Pro Asn Ser Glu Asp Lys

1 5 eol f-seql 10 15

Asn Phe Pro Arg Thr Val Met Val Asn Leu Asn Ile His Asn Arg Asn  
20 25 30

Thr Asn Thr Asn Pro Lys Arg Ser Ser Asp Tyr Tyr Asn Arg Ser Thr  
35 40 45

Ser Pro Trp Asn Leu His Arg Asn Glu Asp Pro Glu Arg Tyr Pro Ser  
50 55 60

Val Ile Trp Glu Ala Lys Cys Arg His Leu Gly Cys Ile Asn Ala Asp  
65 70 75 80

Gly Asn Val Asp Tyr His Met Asn Ser Val Pro Ile Gln Gln Glu Ile  
85 90 95

Leu Val Leu Arg Arg Glu Pro Pro His Cys Pro Asn Ser Phe Arg Leu  
100 105 110

Gl u Lys Ile Leu Val Ser Val Gly Cys Thr Cys Val Thr Pro Ile Val  
115 120 125

His His Val Ala  
130

<210> 28  
<211> 133  
<212> PRT  
<213> Homo sapiens

<400> 28

Arg Lys Ile Pro Lys Val Gly His Thr Phe Phe Gln Lys Pro Glu Ser  
1 5 10 15

Cys Pro Pro Val Pro Gly Gly Ser Met Lys Leu Asp Ile Gly Ile Ile  
20 25 30

Asn Glu Asn Gln Arg Val Ser Met Ser Arg Asn Ile Glu Ser Arg Ser  
35 40 45

Thr Ser Pro Trp Asn Tyr Thr Val Thr Trp Asp Pro Asn Arg Tyr Pro  
50 55 60

Ser Glu Val Val Gln Ala Gln Cys Arg Asn Leu Gly Cys Ile Asn Ala  
65 70 75 80

Gln Gly Lys Glu Asp Ile Ser Met Asn Ser Val Pro Ile Gln Gln Glu  
85 90 95

Thr Leu Val Val Arg Arg Lys His Gln Gly Cys Ser Val Ser Phe Gln  
100 105 110

eol f-seql

Leu Glu Lys Val Leu Val Thr Val Glu Cys Thr Cys Val Thr Pro Val  
115 120 125

Ile His His Val Glu  
130